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splenic granulocytes, inflammatory monocytes and T helper 17 (Th17) cells, increased plasma levels of
iNOS, and increased mRNA levels of kynurenine pathway enzymes in the liver. Moreover, microglia acti-
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Summary 
Stressful life events have been recognized as key proximal risk factors for depression, and exposure 
to stress is associated with altered immune function. Moreover, depression correlates with higher 
levels of inflammatory markers, at least in a subpopulation of patients. There is evidence that 
decreased dopamine (DA) neurotransmission in the mesocorticolimbic pathways leads to impaired 
reward and aversion processing and could underlie major psychopathologies, including motivational 
impairments that are common in depression. The psycho-neuro-immune hypothesis for depression 
presented here postulates that the inhibitory effects of stress-induced inflammatory signalling on DA 
neurotransmission represent a link between exposure to stressful environments and the emergence 
of depression-relevant behavioural abnormalities. Previous experiments have demonstrated that 
exposure to a chronic uncontrollable stressor – namely chronic social defeat (CSD) – increases fear 
learning-memory, helplessness and fatigue, and increases plasma levels of the pro-inflammatory 
cytokine TNF, in C57BL/6 young-adult male mice.  
 In this thesis I provide evidence that exposure to CSD activates the innate and adaptive 
immune system, alters DA transmission, and disrupts reward and punishment processing. 
Specifically, CSD led to increased splenic granulocytes, inflammatory monocytes and T helper 17 
(Th17) cells, increased plasma levels of iNOS, and increased mRNA levels of kynurenine pathway 
enzymes in the liver. Moreover, microglia activation was evident in the ventral tegmental area (VTA). 
From the VTA, DA neurons project to different brain areas, including the nucleus accumbens (NAcc).  
In the NAcc, CSD mice showed decreased dopamine turnover (DOPAC/DA). CSD mice exhibited an 
attenuated hyper-locomotion response to a potent, selective DA transporter inhibitor. Behaviourally, 
CSD led to decreased operant responding for reward on a fixed-ratio schedule of reinforcement, and 
to reduced operant responses to an ambiguous reward stimulus in the learned non-reward (LNR) 
test, a behavioural assay for flexibility in the face of changing response-reinforcement contingencies.  
 To directly investigate the contribution of the DA mesolimbic system to the reward- and 
punishment-directed behaviours that are disrupted by CSD, I investigated the effects of 6-
hydroxydopamine-induced DA depletion specific to the nucleus accumbens (NAcc) on mouse 
behaviour in the following test battery: reward motivation in a progressive ratio schedule (PRS) 
operant test, approach-avoid responding in a learned non-reward (LNR) operant test, footshock 
escape behaviour in a learned helplessness (LH) operant test, footshock avoid-escape behaviour in a 
treadmill operant test, and freezing behaviour in a Pavlovian fear conditioning test. NAcc DA 
depletion led to reduced responding: (i) for gustatory reward under effortful conditions in the PRS 
test; (ii) to a stimulus recently associated with gustatory non-reward in the LNR test; (iii) to footshock 
recently experienced as uncontrollable in the LH test; and (iv) to footshock that could only be 
avoided-escaped by physical effort in the treadmill test. Monoamine depletion was specific to DA 
and whereas 6-OHDA infusion into NAcc also led to a moderate DA reduction in prefrontal cortex, 
direct and specific DA depletion in the latter region did not impact on behaviour in the test battery 
used. Taken together, these novel mouse findings add significantly to the evidence that NAcc DA is a 
major regulator of motivational processing of both reward and aversion. They indicate the need for 
translational study of the targeting of pathophysiological DA function for the treatment of 
motivational psychopathologies in various psychiatric disorders. 
 In terms of antidepressant treatment, evidence indicates that the recently developed 
antidepressant agomelatine (Valdoxan), a melatonin receptor 1/2 agonist and serotonin receptor 2C 
antagonist, exhibits increased therapeutic efficacy relative to placebo in moderate-severe 
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depression. Moreover, agomelatine (AGO) exhibits greater efficacy in treating interest-pleasure 
deficits relative to venlafaxine. I investigated AGO effects on mouse CSD-induced disruption of 
reward-directed behaviour in a progressive ratio schedule (PRS) test, a probabilistic reversal learning 
(PRL) test, and in terms of home cage reward wanting and consumption. Oral administration of AGO 
led to moderate brain exposure to the compound at 1 h. In the PRS test, CSD decreased reward 
motivation and sub-chronic per os AGO led to a non-significant reversal of this effect. In the PRL test, 
CSD decreased reward-stay probability and the number of reversals achieved, and AGO reduced the 
latter effect. In the home cage, CSD mice exhibited decreased operant responding for saccharin 
reward and water; in terms of consumption, CSD mice exhibited decreased saccharin drinking during 
the active period whereas they increased water drinking during the inactive period. Sub-chronic per 
os AGO was without effect on each of these CSD changes in reward-directed and homeostatic 
behaviours. With respect to the AGO effects in the PRS and PRL tests, it is noteworthy that, via 5-HT2C 
antagonism, AGO increases DA release in prefrontal cortex.  
By combining environmental, neurochemical and pharmacological manipulations and 
investigating their effects on immune, neurochemical, cellular, molecular and behavioural readouts, 
this thesis provides mouse model evidence for the importance of stress-immune system-dopamine 
interactions in the aetiopathophysiology of the disrupted motivational processing that is common in 
psychiatric and immune disorders. 
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Zusammenfassung 
Umfangreiche Studien haben gezeigt, dass Stress das Risiko einer Depression massgeblich erhöht. 
Stress übt einen modulatorischen Einfluss auf unser Immunsystem aus und auch eine Depression ist 
oftmals mit Zeichen einer Immunaktivierung assoziiert. Kernsymptome einer Depression sind eine 
beeinträchtigte Verarbeitung positiver und negativer Ereignisse und eine langanhaltende 
Lustlosigkeit, welche höchstwahrscheinlich auf eine Störung des dopaminergen Systems 
zurückzuführen sind. Das mesokortikolimbische dopaminerge System ist an der Steuerung des 
Belohnungs- und Motivationszentrums beteiligt. Gemäss der Psycho-Neuro-Immun-Hypothese übt 
die durch Stress ausgelöste Immunantwort einen inhibitorischen Einfluss auf das dopaminerge 
System aus und ist dadurch massgeblich an der Entstehung von Symptomen beteiligt, die auf eine 
Depression hinweisen. Chronischer Stress in C57BL/6 Mäusen, insbesondere sozialer Stress, führte zu 
verstärktem Angstlernen/-gedächtnis, Hoffnungslosigkeit und Erschöpfung. Zudem konnten erhöhte 
Plasmalevel des entzündungsfördernden Zytokins, TNF,  in den Mäusen festgestellt werden.  
 Im Rahmen dieser Thesis möchte ich aufzeigen, dass chronisch sozialer Stress (CSD) sowohl 
eine angeborene als auch eine erworbene Immunantwort auslöst, die dopaminerge Transmission 
beeinflusst sowie zu einer beeinträchtigten Verarbeitung positiver und negativer Reize führt. Zeichen 
für eine Immunaktivierung in CSD-Mäusen sind eine erhöhte Anzahl inflammatorischer Monozyten 
und Typ17-T-Helferzellen, ein erhöhter Plasma-iNOS-Spiegel und ein Anstieg der mRNA der 
Kynurenin-Enzyme in der Leber. Zudem lässt sich eine Mikrogliaaktivierung in dem ventralen 
Tegmentum (VT) nachweisen. Neurone im VT projiezieren unter anderem zum Nucleus accumbens 
(NAcc). Der Dopaminumsatz im NAcc chronisch gestresster Mäuse (CSD) ist im Vergleich zu 
Kontrollmäusen deutlich reduziert. Des Weiteren dämpft CSD die Steigerung der Lokomotion in Folge 
einer einmaligen Gabe eines selektiven Dopamin-Wiederaufnahmehemmer. Verhaltenstechnisch 
führt CSD im „learned non-reward“-Test mit einem fixen Intervall zu einem beeinträchtigten 
Belohnungslernen für einen positiven als auch für einen nicht eindeutig positiven Verstärker.  
 Um den direkten Zusammenhang zwischen dem mesokortikolimbischen dopaminergen 
System und den veränderten Verhaltensmuster von CSD-Mäusen zu erforschen, untersuchte ich den 
Einfluss einer Dopamindepletion des NAcc mittels Hyrdoxydopamin auf das Verhalten der Mäuse 
anhand folgender Testbatterien: Einem operanten „progressive ratio schedule“-Test (PRS) für die 
Motivation, einem  operanten „learned non-reward“-Test (LRN) für das Annäherungs-Vermeidungs-
Verhalten, einem operanten „learned helplessness“-Test (LH) für das Fluchtverhalten in Folge eines 
Fussschocks, einem operanten Aktivitätstest für das Fluchtverhalten in Folge eines Fussschocks und 
einem Pawlowschen Angstkonditionierungstest.   
Durch die Dopamindepletion im NAcc waren die CSD-Mäuse im PRS-Test weniger motiviert 
einen Aufwand für eine Belohnung in Form von Nahrung zu erbringen. Dies traf ebenfalls für einen 
Reiz zu, welchen die Mäuse mit einer nicht präferierten Nahrung assoziierten. Des Weiteren zeigten 
CSD Mäuse ein beeinträchtigtes Fluchtverhalten für einen unkontrollierbaren Fussschock im LH-Test 
als auch für einen, durch körperliche Leistung, kontrollierbaren Fussschock im  operanten 
Aktivitätstest auf dem Laufrad. Die Dopamindepletion hatte keine Auswirkungen auf andere 
monoaminerge Neurotransmittersysteme, bewirkte jedoch eine leichte Abnahme der 
Dopaminfreisetzung im präfrontalen Kortex. Eine direkte Hydroxydopamininjektion in den 
präfrontalen Kortex hatte jedoch keinen Einfluss auf das Verhalten der Mäuse. Daraus lässt sich 
folgern, dass das dopaminerge System im NAcc massgeblich an der Regulation der Belohnungs- und 
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Bestrafungsverarbeitung beteiligt ist. Translationale Studien sind nun erforderlich, um die patho-
physiologische Bedeutung von Dopamin in verschiedenen psychiatrischen Krankheiten zu verstehen. 
Das erst kürzlich entwickelte Antidepressiva Agomelatine (Valdoxan) ist ein Melatonin-
Rezeptor-Agonist und ein Serotonin-Rezeptor-2C-Antagonist und zeigt eine effiziente Wirkung in 
mittelschweren und schweren Fällen von Depression. Zudem ist Agomelatine (AGO) wirkungsvoller 
für die Behandlung der Anhedonie verglichen mit Venlafaxine. Im Rahmen meiner Thesis untersuchte 
ich die Wirkung von AGO auf das dysregulierte Motivations- und Belohnungsverhalten in CSD-
Mäusen mit Hilfe eines „progressive ratio schedule“-Test (PRS) und einem „probabilistic reversal 
learning“-Test (PRL), als auch mit der Erfassung des Belohnungsstreben im Heimkäfig. Agomelatine 
wurde oral verabreicht. CSD reduzierte das motivationale Handeln von Mäusen im PRS- und PRL-
Test. AGO war in der Lage diese Beeinträchtigung des Belohnungssystems zu normalisieren. Im 
Heimkäfig zeigten CSD-Mäuse ein reduziertes Verlangen nach Saccharin während der aktiven Phase, 
tranken jedoch mehr Wasser während der inaktiven Phase. AGO hatte keinen Effekt  auf diese stress-
induzierten Verhaltensänderung. Im Hinblick auf denn normalisierenden Effekt von AGO im PRS- und 
PRL-Test lässt sich sagen, dass Agomelatine, aufgrund seiner 5-HT2C antagonistischen Eigenschaften, 
zu einem erhöhten Dopaminfreisetzung im präfrontalen Kortex  führt.  
Mit Hilfe von ökologischen, neurochemischen und pharmakologischen Manipulationen und 
deren Einflüsse auf immunologische, neurochemische, zelluläre, molekuläre und verhaltensbezogene  
Systeme im Mausmodel verdeutlicht diese Arbeit die Bedeutung der Interaktion zwischen Stress, 
dem Immunsystem und Dopamin hinsichtlich der zugrundeliegenden Aetiopathophysiologie 
motivationaler Störungen in zahlreichen psychiatrischen und Immunkrankheiten.  
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General introduction 
1. Translational approach to depression research 
Current clinical classifications systems (DSM-5, ICD-10) define major depressive disorder (MDD, 
hereon referred to as depression) as a mood disorder characterized by core symptoms of 1) 
depressed mood, with a focus on negative events and feelings of sadness and helplessness, 2) 
reduced interest-pleasure for daily life activities and 3) increased fatigability, as lack of energy and 
reduced activity. However, from a phenomenological point of view, depression is a very 
heterogeneous condition (Langenecker et al., 2014). Most likely, the observed phenotypical 
heterogeneity reflects the existence of multiple pathophysiological routes, targeting particular 
behavioural/cognitive domains (Webb et al., 2015). In support of this view, current psychiatric 
nosology has been accused to create “… an artificial grouping of heterogeneous syndromes with 
different pathophysiological mechanism into one disorder…” (Wong et al., 2010). To parse the clinical 
and pathophysiological heterogeneity of depression and develop rapid and effective treatment or 
prevention strategies for each individual patient, an experimental classification for mental disorders 
has been advocated (Insel, 2014; Wong et al., 2010).  
 
The realization of a basic research-based classification system and the overcoming of the “disease 
entity” model (Cuthbert, 2015) has been the objective of the National Institute of Mental Health 
(NIMH) Research Domain Criteria (RDoC) initiative. 
1.1 An RDoC-inspired framework for depression research 
The RDoC project 
The NIMH RDoC initiative was introduced in 2008 to “develop, for research purposes, new ways of 
classifying mental disorders based on behavioural dimensions and neurobiological measures” 
(Cuthbert, 2015). The RDoC project considers psychiatric diseases from a translational research 
perspective, supporting the development of a precision medicine approach for mental disorders 
(Cuthbert and Insel, 2013).  
Current psychiatric nosology is based almost exclusively on presenting signs and symptoms, with 
classification systems for mental disorders (i.e. DSM-5, ICD-10) looking at disorders as symptom 
complexes based on clinical descriptions (Cuthbert, 2015). RDoC reverses the classic approach of 
starting with clinical definitions of mental disorders and seeking for biological correlates or risk 
factors (Cuthbert, 2015). An inventory of basic behavioural/cognitive functions and the related brain 
circuits is created and psychopathology is considered in terms of disruptions of the normal-range 
operation of specific primary behavioural functions and of the neural systems implementing these 
functions (Cuthbert and Insel, 2013). By doing so, the RDoC initiative operationalizes a fully 
dimensional approach to mental disorders (Dillon et al., 2014). There is indeed an explicit focus on 
the full range of functioning from normal to abnormal (Cuthbert and Insel, 2013; Woody and Gibb, 
2015). 
The RDoC project created a ‘matrix’ (Table 1) (http://www.nimh.nih.gov/research-
priorities/rdoc/research-domain-criteria-matrix.shtml) comprising four major axes (Cuthbert, 2015). 
The first axis – the columns in the matrix – comprises behavioural domains and their constituent 
dimensions, as primary objects of study. Dimensions, or ‘constructs’, are grouped into five 
superordinate domains of function: Positive Valence Systems, Negative Valence Systems, Cognitive 
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Systems, Systems for Social Processes, and Arousal/Regulatory Systems. Each domain then includes 
several subordinate dimensions.  The second axis – the rows in the matrix – consists of variables of 
study that are used to assess the dimensions. They are grouped into units of analysis and include 
genes, molecules, cells, circuits, physiology, behaviour, and self-reports. The third and fourth axes 
are neurodevelopmental trajectories and environmental influences, respectively, and their 
interactions are also important. The integration of clinical signs and symptoms as well as 
neurobiological measures for depression into an RDoC-informed framework could well assist in 
parsing the heterogeneity of depression as a clinical entity, and link different pathophysiological 
pathways to particular behavioural disturbances. 
 
Table 1.  The research domain criteria and their dimensions 
Negative 
Valence Systems 
Positive Valence 
Systems 
Cognitive 
Systems 
Systems for Social 
Processes 
Arousal and 
Regulatory 
Systems 
Acute threat 
(“fear”) 
Approach 
motivation 
Attention 
Affiliation and 
attachment 
Arousal 
Potential threat 
(“anxiety”) 
Initial 
responsiveness 
to reward 
Perception Social Communication 
Circadian 
Rhythms 
Sustained threat 
Sustained 
responsiveness 
to reward 
Declarative 
memory 
Perception and 
Understanding of Self 
Sleep and 
wakefulness 
Loss Reward learning 
Language 
behaviour 
Perception and 
Understanding of 
Others 
  
Frustrative 
nonreward 
Habit 
Cognitive 
(effortful) 
control 
    
    
Working 
memory 
    
Adapted from Cuthbert and Insel (2013) and Cuthbert (2015) 
Clinical and biological findings for depression need to be integrated into the RDoC classification 
system. The Positive Valence System and the Negative Valence System include core constructs for 
depression, and are the most heavily studied in depression research (Langenecker et al., 2014). 
Nonetheless, dimensions within Cognitive Systems, Systems for Social Processes, Arousal and 
Regulatory Systems are also relevant to depression. 
Positive Valence System in depression 
The Positive Valence System (PVS) includes approach motivation, initial responsiveness to reward, 
sustained responsiveness to reward, reward learning and habit, as major dimensions (Cuthbert and 
Insel, 2013). Diminished interest or pleasure is one of two symptoms required for a diagnosis of 
depression, along with depressed mood (DSM-5). Depressed individuals exhibit blunted responses to 
rewarding information, possibly representing a deficit in the approach-related or appetitive system 
(Bylsma et al., 2008). From these findings stems the hypothesis that depression is characterized by 
hyposensitivity to reward (Eshel and Roiser, 2010). 
Indeed, blunted encoding of reward-related stimuli, reward-related decision making and 
reinforcement learning are core facets of depression (Pizzagalli, 2014). Current clinical diagnosis does 
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not discriminate between a decrease in motivation towards rewarding stimuli and a reduction in 
experienced pleasure (Treadway and Zald, 2011). To overcome this symptom heterogeneity, a 
refined definition of anhedonia has been proposed (Treadway and Zald, 2011), which takes into 
account the distinction between a diminished hedonic response to rewards (consummatory 
anhedonia) and a reduced motivation to pursue them (motivational anhedonia). Depressed 
individuals do not show impaired consummatory pleasure as measured by the Sweet Taste Test 
(Dichter et al., 2010), while they are less likely to mobilize high effort to obtain desirable outcomes 
(Sherdell et al., 2012). 
Anhedonic individuals also show a deficit in adapting their behaviour as a function of previous 
reinforcements (Dillon et al., 2014). Indeed, depressed subjects  fail to integrate reinforcement 
history into decision making (Dillon et al., 2014) when assessed in a probabilistic reward task 
(Pizzagalli et al., 2008). This suggests that reward learning is also impaired in depression (Pizzagalli et 
al., 2005). Thus, regarding the PVS, depression is characterized by reduced approach motivation 
(Sherdell et al., 2012) and reward learning (Pizzagalli et al., 2005) while initial responsiveness to 
reward lies in the normal range of functioning (Dichter et al., 2010). 
Negative Valence System in depression 
The Negative Valence System (NVS) includes dimensions responsible for responses to aversive 
situations or context, such as acute threat (“fear”), potential threat (“anxiety”), sustained threat, loss 
and frustrative nonreward (Cuthbert and Insel, 2013).  
The NVS dimension, perceived sustained threat, also interfaces with behavioural dimensions that are 
dysfunctional in depression (Eshel and Roiser, 2010). Altered reactivity to aversive stimuli, including 
motivation to respond, contributes to the core depression symptoms of low mood and high fatigue, 
and involves various states that are common in depression (Eshel and Roiser, 2010). For example, 
experiencing lack of control of aversive stimuli can lead to helplessness, including reduced motivation 
to attempt control (Pryce et al., 2011b; Treadway and Zald, 2011); lack of control of an aversive 
stimulus can lead to increased fear conditioning to stimuli that predict the aversive stimulus (Nissen 
et al., 2010). Increased emotional reactivity to and decreased motivation to control aversive stimuli 
both contribute to high fatigue (Demyttenaere et al., 2005). Moreover, several lines of evidence 
point towards the presence of behavioural abnormalities related to the construct of loss in 
depression (Woody and Gibb, 2015). Behavioural alterations pertaining to loss include self-reports of 
hopelessness, rumination, psychomotor retardation and attentional bias to negative valenced 
information. Regarding the latter, in depressed subjects there is evidence for mood-congruent 
memory biases towards negative events (Gotlib et al., 2004; Watkins et al., 1992) and difficulties in 
classifying emotional content of facial stimuli (Langenecker et al., 2005). Thus, regarding the NVS, 
constructs of loss and sustained threat are central to depression, as evidence by the presence of 
memory/attentional biases (Gotlib et al., 2004; Watkins et al., 1992), sense of helplessness (Pryce et 
al., 2011b), increased punishment sensitivity (Eshel and Roiser, 2010), and psychomotor retardation 
and fatigue (Demyttenaere et al., 2005; Singh et al., 2013). 
Therefore, depression can be considered in terms of a dysregulation or dysfunction of 
behavioural/cognitive dimensions spanning both the PVS and the NVS (Langenecker et al., 2014). 
Deconstructing the heterogeneity of depression symptomatology and the respective 
pathophysiological pathways is the route to identification of efficacious dimension-specific anti-
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depressant strategies and the emergence of a precision medicine approach in psychiatry (Insel, 
2014).  
1.2 Depression-relevant behavioural readouts in rodents 
Basic research and animal models are fundamental for the identification of genetic, molecular and 
neural substrates for defined behavioural dimensions as well as for the identification of specific 
etiopathophysiological pathways influencing behavioural disorders (Cuthbert and Insel, 2013). To 
enable increased understanding of reward and aversion processing and the changes that underlie 
depression, neuropsychological paradigms are required that 1) enable the quantitative measurement 
of these neuropsychological processes and their responses to genetic, environmental and 
pharmacological manipulations; 2) can be applied in depressed patients, healthy humans, and 
laboratory animals (Pryce and Seifritz, 2011). In this section, translational tests for the assessment of 
reward and punishment-related behaviours that are relevant for depression symptoms will be 
described. The tests presented were used throughout Study A, B and C. 
Testing reward sensitivity in mice: relevance for PVS 
As presented in section 1.1, reward involves several psychological components: liking (reactions to 
hedonic stimuli), wanting (motivation process of incentive salience), Pavlovian stimulus-stimulus 
learning and goal-directed learning (instrumental learning with cognitive representations) (Berridge, 
2003; Berridge and Kringelbach, 2015). Reward consumption has been investigated in rodents using 
sucrose preference tests (Vialou et al., 2010; Wilkinson et al., 2011). Motivational components of 
reward have been assessed using operant behaviour tasks, e.g. progressive ratio schedule (Hamill et 
al., 1999; Ishiwari et al., 2004) and the concurrent fixed ratio/chow feeding choice task (Nunes et al., 
2014; Nunes et al., 2013a). Paradigms for reward-related learning in mice include Pavlovian 
conditioned place preference (Pena et al., 2014), and the goal-directed test of probabilistic reversal 
learning (Ineichen et al., 2012) and learned non-reward (Nilsson et al., 2012). 
Progressive ratio schedule test and operant sucrose-preference test 
The progressive ratio schedule or reinforcement (PRS) test is used to assess subjects’ motivation to 
obtain rewarding stimuli under effortful conditions (Hamill et al., 1999; Ishiwari et al., 2004). The PRS 
test is based on operant (response-outcome) learning, with mice first learning that a specific operant 
action (e.g. nose-poke into a stimulus hole) is followed by delivery of a reward-goal (e.g. sucrose 
pellets). Training for the PRS test is conducted on a fixed ratio (FR) 1 schedule; that is, one nose-poke 
leads to the delivery of one sucrose pellet. Within the course of a single PRS session, the requirement 
in terms of number of responses to access reward increases across trials. The animal initially emits a 
predetermined number of responses to obtain a reward (e.g., 1 response, start ratio = 1). Following 
reinforcer delivery, the subsequent response requirement increases by some increment (e.g., 
another 3 responses) such that in the next trial the animal is required to complete more responses 
than in previous trials (e.g., 4 responses before reward delivery) (Ineichen et al., 2012; Roane, 2008). 
The session can be terminated after a maximum session duration or a long time interval without 
response emission (break-point). 
Assessment of willingness to exert an effort in order to obtain a reward has been conducted also in 
humans, using the effort expenditure for rewards task (EEfRT) (Barch et al., 2014). Using the EEfRT, 
(Treadway et al., 2012) reported that depressed individuals are less willing to exert physical effort to 
obtain potentially larger rewards compared with healthy probands. 
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The sucrose preference test is commonly used in rodents to measure  reward consumption (Papp et 
al., 1991). In the sucrose preference test, animals are confronted with a two-bottle choice situation, 
with one bottle containing water and the other a sweet-tasting solution (e.g. saccharine); absolute 
values of water and saccharine consumption and percent saccharin preference are measured 
(Cathomas et al., 2015a).  However, depressed patients do not show blunted hedonic impact in a 
human sweet taste test (for review see Treadway and Zald, 2011). To assess rodent motivation for 
gustatory rewarding stimuli that is continuously available in the home cage, an operant form of the 
classical sucrose preference test can be used (Cathomas et al., 2015a), namely the IntelliCage 
operant choice test. In an Intellicage (Krackow et al., 2010) equipped with operant doors that control 
access to water and sucrose-filled bottles, mice have to make an operant response (e.g. nose-poke) 
to open the door and access the bottles. 
Both the PRS test and the IntelliCage operant choice test provide readouts for mouse motivation to 
obtain gustatory reward under effortful conditions. 
Learned non-reward test 
Adjusting behaviour in accordance to altered response-reward contingencies can be assessed in 
reinforcement-based paradigms, including reversal learning (Nilsson et al., 2012). Successful learning 
of such schedules is based on two main mechanisms: learned non-reward (LNR) – also referred to as 
the learned irrelevance – and perseveration. Perseveration refers to the tendency to continue to 
respond to a stimulus associated with negative feedback. Conversely LNR refers to reduced attention 
directed at a stimulus or a stimulus dimension that proves to be task irrelevant (Maes et al., 2006). 
The LNR test assesses the subject’s behaviour in a two-choice discrimination test where the stimulus 
previously associated with punishment and is now associated with reward and a second stimulus is 
novel and associated with punishment. Behavioural performance in this test reflects the subject’s 
sensitivity to punishment (negative feedback), measured in terms of ability to learn that a stimulus-
punishment association has changed to a stimulus-reward association (Maes et al., 2011). Recently, 
(Nilsson et al., 2012) established a LNR test in mice. In the mouse LNR test, animals first learn a two-
choice spatial discrimination (SD) task where a response in the correct nosepoke stimulus leads to 
the delivery of a single sucrose pellet and a response in the incorrect nosepoke stimulus does not. 
When the subject attains criterion at the SD stage, it enters the LNR stage: the previously correct 
nosepoke stimulus is removed, the previously incorrect nosepoke stimulus becomes correct, and a 
third, novel nosepoke stimulus, not available at the SD stage, is introduced as the new incorrect 
nosepoke stimulus. To learn correct responding, the subject must unlearn the stimulus-punishment 
association and learn that the same stimulus is now associated with reward. Healthy human 
probands commit more errors in a learned non-reward test than they do in a perseverance test 
(Maes et al., 2006). Interestingly, depressed humans commit more errors in an extra-dimensional 
shift test, which assesses both learned non-reward and perseverance, than do healthy subjects 
(Michopoulos et al., 2006). Thus, the LNR test represents an important translational tool to assess 
subjects’ flexibility to changing response-reward contingencies. 
Probabilistic reversal learning test 
The probabilistic reversal learning task (PRL) test is based on two-way reversal learning: in two-way 
reversal learning, subjects are required to exhibit continuous responding to the operant stimulus that 
is associated with reward (win-stay responses), including after predictable reversals in the operant 
stimulus associated with reward (lose-shift responses). In PRL, a proportion of correct responses is 
not reinforced i.e. on such trials responding to the correct stimulus is punished in terms of omission 
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of reward plus a delay to the next trial. This allows for assessment of the subject’s negative feedback 
sensitivity: the more frequently the subject chooses the incorrect stimulus (lose-shift) on the trial 
after unexpected negative feedback, the greater the subject’s negative feedback sensitivity (NFS). 
NFS was increased in depressed patients relative to controls (Taylor Tavares et al., 2008) and in 
healthy volunteers following acute tryptophan depletion to reduce central 5-HT (Cools et al., 2008). It 
has been proposed that increased PRL-NFS in depression is due to high-amplitude transient-phasic 5-
HT signalling of aversion (Cools et al., 2008). A study using a PRL test in rat has been published (Bari 
et al., 2010), and we have validated and studied 5-HT involvement in a PRL test in mouse (Ineichen et 
al., 2012). 
Testing aversion sensitivity in mice: relevance for NVS 
Fear conditioned freezing  
Classical fear conditioning is a form of associative learning in which an animal acquires a defence 
response to a neutral conditioned stimulus (CS,  e.g. light, tone) that is paired to an innately aversive 
unconditioned stimulus (US, e.g. painful foot electroshocks) (Blair et al., 2001). In rodents, fear can 
be measured as freezing behaviour to inescapable aversion. Fear acquisition leads to a progressive 
increase in the freezing behaviour. Associative fear learning and memory can then be tested by 
assessing the expression of freezing behaviour in response to the CS when the animal is subsequently 
exposed to it in the absence of the US (Blair et al., 2001). This form of fear conditioning and 
expression is associated with the synaptic plasticity changes in pathways of the lateral amygdala 
(AMYG) (Blair et al., 2001).  
The human version of the fear conditioning paradigm uses visual or tone CS and electroshock US, and 
skin conductance, which increases due to sweating induced by activation of the sympathetic 
autonomic nervous system, to measure emotional responsiveness to the CS (Nissen et al., 2010). 
Interestingly, Nissen et al. (2010) showed enhanced fear conditioning in depressed patients 
compared with healthy control subjects. Classical fear conditioning is a behavioural assay that can be 
used to measure generalized increased emotionality in response to aversive stimuli both in humans 
and in rodents (Azzinnari et al., 2014).  
Learned helplessness  
Generalized learned helplessness (LH) comprises the experiencing of an uncontrollable stressor 
leading to a generalized perception of aversive events as being uncontrollable, even if they are not 
(Pryce et al., 2012). The concept of LH was initially introduced in rodent behavioural research 
(Anisman and Merali, 2001). Animals receive either controllable aversive stimuli, e.g. electroshocks 
that can be terminated by an operant response, or uncontrollable aversive stimuli of the same 
intensity and duration. Then, both groups are tested and compared with controllable aversive 
stimuli, e.g. in the two-way shuttle arena where moving to the opposite site of the arena and 
avoiding or escaping electroshock is the control response (Pryce et al., 2012). The animals that 
experienced uncontrollable electroshocks, compared to those that experienced controllable 
electroshocks, exhibit a deficit in escapes in the test phase (Pryce et al., 2012; Pryce and Seifritz, 
2011).  
Human LH tests have been adapted from the animal paradigms and typically also use inescapable 
versus escapable electroshocks. LH has been proposed to be a major aetiological process influencing 
vulnerability to and onset of depression (Abramson et al., 1978; Pryce et al., 2011b). Moreover, LH 
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has been proposed as a major psychopathological mechanism in maintenance of depression (Pryce et 
al., 2011b). Interestingly, increased helplessness during and after exposure to uncontrollable aversive 
stimuli has been shown in depressed patients relative to healthy controls (Diener et al., 2009; Strigo 
et al., 2008). Thus, LH is a behavioural assay to measure generalized impaired cognitive control and 
decreased motivation to react to aversive stimuli that can be applied both in humans and in rodents 
(Azzinnari et al., 2014).  
Physical fatigue in an aversive environment (Treadmill test) 
The state of fatigue is a core symptom of depression, which is at the interface of somatic, emotional 
and cognitive pathologies (Pryce and Seifritz, 2011). Fatigue can be divided into components of 
psychomotor retardation, physical tiredness and mental fatigue (Demyttenaere et al., 2005). In 
rodents, fatigue has been tested by measuring activity on a running wheel (Ifuku et al., 2014) or 
running to avoid-escape an escapable footshock on a treadmill (Azzinnari et al., 2014). In the 
treadmill test mice are first assessed in their ability to run away from an escapable footshock at a 
lower speed; on the following day avoid-escape capability is tested under more effortful conditions 
(Azzinnari et al., 2014).  
In humans, the physical tiredness component of fatigue has been measured using the measurement 
of grip strength on a dynamometer (Shiratori et al., 2014). Interestingly, depressed patients exhibit 
rapid reduction of the grip strength of the right forelimb across trials of maximum grip strength 
(Emerson et al., 2001). Human fatigue is commensurate with decreased motivation and perceived 
ability to maintain a level of physical or mental effort (Hossain et al., 2003; Keller et al., 2007; 
Weinstein et al., 2010). Thus, fatigue tests can be used to assess motivation and exertion of effort 
towards rewards or away from aversive stimuli. 
1.3 The role of stress in depression                   
Stressful life events have been recognized as key proximal risk factors for depression (Kendler et al., 
1999; Slavich et al., 2009) influencing the development, expression and exacerbation of the disease 
(Brown and Harris, 1978; Lora and Fava, 1992). When stressful events are associated with 
depression, they typically occurred within 3-6 months prior to depression onset (Kendler et al., 
1998). Moreover, chronic life stressors are associated with higher probability of relapse occurrence 
(Lethbridge and Allen, 2008), more severe depressive symptoms (Leskela et al., 2006) and higher 
treatment resistance (Amital et al., 2008). 
Several authors have investigated whether some classes of life events are more likely to induce 
depression (for review see Hammen, 2005). Among chronic psychosocial stressors, experiences that 
are characterized by perceived lack of control of the aversive situation, interpersonal loss (e.g. loss of 
status, humiliation) and induce “psychobiological programmes of defeat and submission” (Gilbert, 
1992) have high depressogenic capabilities (Kendler et al., 2003). Uncontrollability is certainly a 
major characteristic of each of these life-event dimensions (Pryce et al., 2011b). Emphasis on the 
uncontrollability of stressors is consistent with reports showing that perceived control over stressful 
events is a key modulator of physiological stress responses, with uncontrollable stressors being 
associated with larger cortisol changes (Dickerson and Kemeny, 2004). 
Although stressors influence the occurrence of the first episodes of depression, they are less linked 
to recurrences (Daley et al., 2000; Kendler et al., 2000). These findings support the 
kindling/sensitization hypothesis in depression (Post, 1992), which postulates that stress and 
16 
 
previous depressive episodes can sensitize affected subjects, thus increasing the risk for future 
depressive episodes, even in the absence of stressors. 
Effects of stress on PVS and NVS behaviours in rodents 
As stated in section 1.2, animal research is fundamental for further understanding of depression 
aetiopathophysiology.  The establishment of valid animal models for depression not only requires 
behavioural assays of relevance to depression neuropsychopathology but also the use of genetic 
and/or environmental manipulation(s) of aetiological relevance to depression (Pryce and Seifritz, 
2011). 
Given the role of environmental stressors as risk factors in depression aetiology, various forms of 
chronic stressors, involving repeated applications of an uncontrollable and unpredictable stress, have 
been used as a manipulation to induce depression-relevant behavioural states in rodents, primarily in 
mice (Krishnan and Nestler, 2011). These stressors include social isolation (Schiavone et al., 2012), 
social instability in the form of alternate phases of isolation and crowding (Herzog et al., 2009), 
chronic unpredictable mild stress (CUMS) (Jayatissa et al., 2008; Papp et al., 2003), repeated social 
disruption (Wohleb et al., 2012), and chronic social defeat (CSD) (Azzinnari et al., 2014; Krishnan et 
al., 2007). Findings of preclinical studies using the stress models presented here show that exposure 
to chronic stressors induces dysfunctions in behavioural domains that pertain to both the PVS and 
NVS.  
Regarding the effects of stress on reward-related behaviours, it has been shown that prolonged 
social isolation during adulthood results in reduced sucrose drinking and alterations in sexual reward 
behaviour (Wallace et al., 2009), and that social instability, CUMS and CSD reduce sucrose intake 
(Herzog et al., 2009; Krishnan et al., 2007; Papp et al., 2003) and place-preference conditioning i.e. 
reduced approach to a place previously paired with a reward (Papp et al., 1991). However, the 
findings of reduced preference for palatable stimuli after stress exposure – usually referred to as 
anhedonia-like behaviours – points towards a deficit in the behavioural domain of initial 
responsiveness to reward rather than of reward motivation and learning. Given that depression is 
characterized by impaired reward motivation (Sherdell et al., 2012) and learning (Pizzagalli et al., 
2005), while initial responsiveness to reward lies in the normal range of functioning (Dichter et al., 
2010), stress models assessing reward-directed effort expenditure and reward learning are 
advocated. In rats, Jaisinghani and Rosenkranz (2015) showed that stress does not affect operant 
responding for rewards under a fixed ratio (FR) 4 schedule, and higher ratios or PR schedules have 
not been tested. Interestingly, when rats were assessed in a PRS test, stress reduced operant 
responding for rewards (Jaisinghani and Rosenkranz, 2015). 
The effects of stress on 1) reward-directed motivation and 2) cognitive flexibility to changing 
response-reward contingency will be addressed in Study B and C, respectively. 
Regarding the effects of stress on punishment-related behaviours, it has been shown that chronic 
psychosocial stress in mice increases contextual and cued fear conditioning (Yu et al., 2011) and 
induces a negative response bias (Papciak et al., 2013), suggesting increased expectation of aversive 
events (Enkel et al., 2010). Moreover, early life stressors increase sensitivity to conditioned place 
aversion (Ventura et al., 2013). Our laboratory recently showed that CSD in mice induces increased 
fear acquisition, decreased 2-way avoid-escape responding (increased helplessness) and increased 
fatigue (Azzinnari et al., 2014) 
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2. Neurobiology of NVS and PVS 
The psychological-behavioural processes that constitute NVS and PVS and mediate individuals’ 
responses to aversive and rewarding stimuli, respectively, share a common neural substrate: the 
mesocorticolimbic dopamine (DA) system (for review see Bromberg-Martin et al., 2010; Salamone 
and Correa, 2012).  
2.1 The Dopamine system: Neuroanatomy and Neurochemistry 
Dopaminergic pathways 
Most dopamine (DA)-synthesizing neurons in the brain are located in either the midbrain substantia 
nigra pars compacta (SNpc) or the ventral tegmental area (VTA) (Sesack and Grace, 2010). Projection 
axons arising from the SNpc and VTA follow defined pathways via the medial forebrain bundle (MFB) 
to innervate specific subcortical and cortical structures (Hattori, 1993). The nigrostriatal pathway 
projects from the SNpc to the dorsal striatum and has a prominent role in execution and planning of 
movement (Gepshtein et al., 2014) and in motor flexibility (Bestmann et al., 2015). Moreover, the 
nigrostriatal pathway plays an important role in non-motor functions (McClure et al., 2003), with 
striatal tonic DA release coordinating processes including working memory, implicit learning, decision 
making and planning (Brooks, 2006). 
The mesocortical pathway arises in the VTA and projects to frontal and temporal corticies, 
specifically the anterior cingulate and prefrontal cortex (Ford and Williams, 2008). This pathway is 
important for executive functions such as working memory (Floresco, 2013). The mesolimbic 
pathway also arises in the VTA and projects to the ventral striatum (including the nucleus 
accumbens, NAcc), bed nucleus of the stria terminalis, hippocampus, amygdala, and septum (Ford 
and Williams, 2008; Sesack and Grace, 2010). It is particularly important for the regulation of reward 
motivation (Salamone and Correa, 2012; Salamone et al., 2007). The NAcc is part of the ventral 
striatum and has extensive connectivity with other brain regions. It receives excitatory inputs from 
the PFC and the amygdala, and inhibitory afferents from the ventral pallidum (VP). Major projection 
regions of the NAcc include the VP and, reciprocally, the VTA (Sesack and Grace, 2010). 
Dopamine signaling 
In DAergic neurons, the amino acid tyrosine is converted into DA by tyrosine hydroxylase (TH). TH is 
the rate-limiting enzyme for the biosynthesis of the catecholamines dopamine, noradrenaline, and 
adrenaline (Dickson and Briggs, 2013). After synthesis, DA is transported into synaptic vesicles 
through the vesicular monoamine transporter type 2 (VMAT2) (Narendran et al., 2015). 
Dopamine exerts its effects on postsynaptic neurons by binding with DA receptors. DA receptors are 
divided into 2 classes: the DA 1 (D1) family (comprising the D1 and D5 subtypes) and the DA 2 (D2) 
family (comprising the D2, D3, and D4 subtypes) (Dalley and Everitt, 2009). Both classes are G-
protein-coupled receptors and are distinguishable by an opposite modulation of adenylate cyclase. 
The DA D1-like receptor family positively regulate adenylate cyclase activity to increase intracellular 
cyclic AMP (cAMP), while the D2-like class of receptors is negatively coupled to adenylate cyclase and 
inhibits the synthesis of cAMP (Dalley and Everitt, 2009). These opposite effects on cAMP result in an 
opposite regulation of protein kinase A (PKA) activity by D1 and D2 receptors. After release into the 
extracellular space, DA is cleared from the synaptic cleft by uptake into presynaptic nerve terminals 
by the dopamine transporter (DAT). 
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Biological effects of DA on target neurons depend on the post-synaptic signaling elicited by DA 
receptors. One major molecular target for the actions of DA is the DA- and cAMP-regulated 
phosphoprotein, Mr 32kDa (DARPP-32) (Fienberg et al., 1998; Zachariou et al., 2006). DARPP-32 is 
enriched in dopaminoceptive neurons (Zachariou et al., 2006) and is a crucial mediator of the 
biochemical, electrophysiological, transcriptional, and behavioural effects of DA (Svenningsson et al., 
2004). Upon PKA phosphorylation at Thr-34, DARPP-32 behaves as a potent inhibitor of protein 
phosphatase 1 (PP1) (Hemmings et al., 1984). Conversely, phosphorylation of DARPP-32 at Thr-75 by 
cyclin-dependent kinase-5 (Cdk5) converts it into an inhibitor of PKA (Bibb et al., 1999). Thus, both 
D1 and D2 intracellular signal transduction pathways converge on DARPP-32 (Tretter and Gebicke-
Haerter, 2012), that acts as an integrator for DA transmission (Svenningsson et al., 2004). 
2.2 Contribution of the DAergic mesocorticolimbic system to behavioural regulation 
The mesocorticolimbic DA system has been shown to modulate behavioural responses to both 
rewarding and aversive stimuli (Salamone and Correa, 2012). Dopamine neurons in the VTA that 
project to the NAcc are integral to these functions, with NAcc DA signalling serving to modulate the 
responsiveness of NAcc neurons to excitatory and inhibitory inputs, and thereby to modulate 
behavioural activation and inhibition by environmental stimuli (Alexander et al., 1990). 
DA system and sensitivity to rewards 
Much of the evidence for DA function in NAcc is derived from loss-of-function studies using 
pharmacological DA depletion or antagonism. Regarding the former, infusion of the monoamine 
neurotoxin 6-hydroxydopamine (6-OHDA) into the NAcc, leading to specific degeneration of DA 
axons efferent to NAcc and also DA cell body death in VTA, is a well-established method (Aberman 
and Salamone, 1999). It is known that NAcc DA depletion does not affect food consumption (Cousins 
et al., 1994) and that NAcc DA signaling does not regulate emotional “liking” reactivity to rewards 
(Smith et al., 2011). However, DA depletion in rat NAcc impairs acquisition of and rate of responding 
on operant schedules of reward reinforcement, particularly under conditions requiring high effort 
(Aberman and Salamone, 1999), including  PRS tests (Hamill et al., 1999). Moreover, NAcc DA 
depletion delays development of sucrose preference (Martinez-Hernandez et al., 2012). These 
findings indicate that NAcc DA directly regulates motivation for rewarding stimuli (Nunes et al., 
2013b). In addition to the importance of NAcc DA in regulating reward motivation, as characterised 
in rat, there is also increasing interest in the involvement of DA in the modulation of behavioural 
flexibility under conditions of changing reward contingency (Cools et al., 2011; van Schouwenburg et 
al., 2010). Studies in nonhuman primates showed that NAcc DA is responsible for encoding the 
incentive properties of stimuli and Pavlovian reward prediction error (Schultz, 1998). Consistent with 
animal data, human functional magnetic resonance imaging (fMRI) studies have described robust 
activation in the ventral striatum (NAcc) in response to rewards (O'Doherty, 2004) and this neural 
activation is stronger during the anticipation, rather than the consumption, of rewards (Dillon et al., 
2008). Accordingly, the ventral striatum has been strongly implicated in encoding reward prediction 
error and the hedonic value of outcomes, and it is robustly recruited during reward anticipation 
(Pizzagalli, 2014).  
DA system and sensitivity to aversive stimuli 
Mesocorticolimbic DA also modulates punishment-related behaviour. Indeed, DA is acutely released 
in the NAcc in response to painful stimuli (Young et al., 1993) and social stress (Cabib and Puglisi-
Allegra, 2012). Mesocorticolimbic DA also modulates the acquisition and expression of Pavlovian 
conditioned fear (Pezze and Feldon, 2004) and of punishment active avoidance (Wenzel et al., 2015). 
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For example, in rats, depletion of NAcc DA leads to a deficit in operant lever pressing to avoid-escape 
electric footshocks (McCullough et al., 1993), and in DA-deficient mice where DA expression could be 
reactivated region-specifically, only restoration of DA signalling to both the entire striatum and the 
amygdala enabled mice to learn two-way active avoidance (Darvas et al., 2011). In rats, midbrain DA 
depletion increases sensitivity to inescapable footshocks, i.e. reduces responding in a lever-press 
escape test (learned helplessness) (Winter et al., 2007). Moreover, electrophysiology studies in rats 
and rhesus macaques have demonstrated that DA neurons respond to punishment and its 
anticipation (Bromberg-Martin et al., 2010). Interestingly, a recent pharmacological fMRI study 
performed in healthy humans showed that the DA synthesis enhancer levodopa increased striatal 
activation by punishing stimuli (Wittmann and D’Esposito, 2015), supporting the hypothesis that DA 
contributes to punishment processing. 
2.3 DA system dysfunction in depression 
As stated above, the DA mesocorticolimbic system controls a number of psychological processes 
pertaining to both the NVS and the PVS.  These include reward-directed motivation and reward-
directed effort expenditure, reward learning, reactivity to and control of aversive environments, and 
fatigue. Concomitantly, depression can be interpreted as a dysfunction of the same behavioural 
domains that are influenced by the mesocorticolimbic DA system. DA dysfunction might, therefore, 
be important in the pathophysiology of depression (Dunlop and Nemeroff, 2007; Pizzagalli, 2014).  
One of the first indications for reduced DA transmission in depression was reports showing that the 
levels of homovanillic acid (HVA), one of the major metabolites of DA, are reduced in the plasma and 
cerebrospinal fluid of depressed subjects (Mitani et al., 2006; Roy et al., 1985). Lambert et al. (2000) 
directly measured CNS HVA levels in the internal jugular vein using catheters. Reduced levels of HVA 
were found, providing a strong indication for reduced DA metabolites in depression. Moreover, post-
mortem studies have provided evidence for reduced levels of the DA metabolite 
dihydroxyphenylacetic acid (DOPAC) in the caudate nucleus (Bowden et al., 1997), and reduced DAT 
levels in striatal regions (caudate, putamen, NAcc) of depressed subjects (Klimek et al., 2002). 
Consistent with reduced DAT levels, using positron emission tomography (PET), (Martinot et al., 
2001) showed reduced striatal (18F)-fluorodopa uptake in depressed patients with psychomotor 
retardation, providing a link between dopamine hypofunction and psychomotor retardation in 
depression.  
Transient catecholamine depletion has been used in humans to assess a potential causal link 
between reduced DA levels and depression (Pizzagalli, 2014). Administration of a tyrosine 
hydroxylase inhibitor (α-methylparatyrosine, AMPT) can induce relapse of depressive symptoms in 
subjects with a history of depression (Berman et al., 2002; Hasler et al., 2004; Miller, 1996). PET 
studies have shown that AMPT-induced DA depletion affects reward-related brain regions receiving 
strong catecholamine innervations, including the OFC (Bremner et al., 2003). Stimulation of DA 
release with psychostimulants (e.g. dextroamphetamine) has been used to probe the DA system in 
depression. Depressed patients display reduced activation in reward-related brain regions (OFC, 
caudate, putamen) in response to pleasant stimuli, after receiving dextroamphetamine (Tremblay et 
al., 2005). These fMRI findings support the hypothesis of a hypofunctional DAergic reward system in 
depression (Tremblay et al., 2005). 
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The effects of stress on the DA system 
On the basis of the observation that chronic stressors increase vulnerability to depression in humans 
(Kendler et al., 2000), preclinical research in animal models of depression investigated the 
neurobiological effects of prolonged exposure to stressors (Pizzagalli, 2014). Given the hypothesis 
that depression might stem from a hypofunctional DAergic system, a number of studies have 
explored the effects of stress on DA signaling. It has been show that exposure to chronic unavoidable 
stressors leads to DA system dysfunctions that include down-regulation of mesolimbic DA pathways 
(Cabib and Puglisi-Allegra, 2012), reduced DAT levels (Brake et al., 2004), and sensitization of 
mesocortical DA responses to subsequent stressors (Cuadra et al., 1999). 
Exposure of rats to CUMS leads to increased threshold (reduced sensitivity) for operant self-
stimulation of the VTA (Moreau et al., 1992), facilitates a DA response to aversive stimuli while 
blunting the DA response to rewarding stimuli (Di Chiara et al., 1999), and reduces basal striatal DA 
activity (Bekris et al., 2005). Interestingly, CUMS-induced DA blunting can be reversed by treatment 
with the antidepressant imipramine (Bekris et al., 2005). Moreover, other forms of inescapable 
chronic stressors (e.g. footshocks) can reduce the number of spontaneously active VTA DA neurons 
(Moore, 2001) and suppress basal and cocaine-induced DA NAcc transmission (Gambarana et al., 
1999; Mangiavacchi et al., 2001). A biological marker indicative of blunted mesolimbic DA release is 
the decreased DAT levels in efferent regions of the mesocorticolimbic DA pathway. In rats, reduced 
DAT levels have been observed in the striatum (including the NAcc) after exposure to early life stress 
(Brake et al., 2004), chronic psychosocial stress (Lucas et al., 2004) and immobilization stress (Lucas 
et al., 2007). Moreover, rats bred selectively for reduced motivation for reward also showed reduced 
DAT (Jiao et al., 2003). Interestingly, reduced DAT levels have been reported in depressed patients 
(Klimek et al., 2002; Martinot et al., 2001). As mentioned in section 2.1, DARPP-32 is a crucial 
mediator of the behavioural effects of DA signaling (Svenningsson et al., 2004; Zachariou et al., 
2006). Jin et al. (2015) have shown that CSD in mice increased expression of total DARPP-32, p-Thr34 
DARPP-32, and p-Thr75 DARPP-32 in the PFC or AMYG. Potentiated/sensitized mPFC DA release in 
response to a novel stressor has been demonstrated in rats previously exposed to chronic stress 
(Chrapusta et al., 1997; Cuadra et al., 1999). Since one proposed effect of activation of mesocortical 
DA neurons is hypothesized to be their inhibition of NAcc and its activation by DA (King and Finlay, 
1997), the stress-induced sensitization of mesocortical DA neurons might contribute to the 
maintenance of the depressive state. A sensitized mesocortical DAergic system could serve as a 
neurobiological correlate of the behavioural sensitization hypothesis for depression formulated by 
Post (1992). 
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3. The psycho-neuro-immune hypothesis for depression 
A number of studies indicate that immune and inflammatory processes contribute importantly to the 
aetiopathophysiology of brain diseases, including neurodegenerative disorders, mood and anxiety 
disorders and schizophrenia (Haroon et al., 2012; Miller et al., 2013). With regards to depression, 
several lines of evidence indicate that inflammation is important at least in a significant sub-
population of affected subjects (Haroon et al., 2012). The psycho-neuro-immune hypothesis for 
depression presented here postulates that activation of the immune system upon exposure to 
stressful environmental conditions impairs mesolimbic DA transmission, affecting the neural circuits 
that modulate behavioural responses to rewarding and aversive stimuli. 
3.1 Immune system activation in depression 
The first findings showing that depression is characterized by inflammation and monocytic and T cell 
activation were provided by Maes et al. (1990). This evidence for increased inflammatory biomarkers 
in depression, including increases in the production of inflammatory cytokines and increased cellular 
markers of immune activation (Maes et al., 1992), laid the foundation for a novel hypothesis that 
inflammation and cell-mediated immune activation are key factors in depression 
aetiopathophysiology (Maes, 2011). A substantial literature has reproduced and confirmed these 
findings, and meta-analytical studies have revealed that some of the most reliable peripheral 
biomarkers of increased inflammation in depression are increases in the pro-inflammatory cytokines 
interleukin (IL)-6, tumor necrosis factor (TNF)-α, and the acute-phase reactant, c-reactive protein 
(CRP), in the peripheral blood and the cerebrospinal fluid (CSF) (Haroon et al., 2012; Miller et al., 
2009a). Activation of nuclear factor kappa B (NF-κB), a primary transcription factor in the initiation of 
the inflammatory response, has also been demonstrated in depressed patients (Lukic et al., 2014). 
Although much of the interest in inflammation and depression has been focused on the innate 
immune response, findings of altered lymphocyte activation markers (Euteneuer et al., 2012; Grosse 
et al., 2015; Miller, 2010) in depressed patients led to the hypothesis that both acquired (e.g., T and 
B cell) and innate (e.g., macrophage) immune responses may be involved (Miller, 2010; Miller et al., 
2009a). Increased peripheral levels of inflammatory markers have been reported to correlate with 
the severity of depression-relevant symptoms, including fatigue, cognitive dysfunction, and impaired 
sleep (Bower et al., 2002; Meyers et al., 2005; Motivala et al., 2005). A complex interaction exists 
between peripheral inflammation and antidepressant treatment. Thus, whereas increased 
inflammatory markers normalize in depressed patients following successful antidepressant 
treatment (Miller et al., 2009a), depressed subjects that do not respond to antidepressant therapy 
also have increased inflammatory markers (Fitzgerald et al., 2006). The findings of reduced treatment 
response in patients with increased baseline inflammatory markers suggest a relationship between 
inflammation and treatment resistance (Fitzgerald et al., 2006; Lanquillon, 2000). 
Several studies have investigated whether depression is associated with markers of 
neuroinflammation. As the primary resident immune cells in the brain, microglial cells would be the 
first-line candidate mediators of abnormal immune-brain dialogue. Accumulating evidence suggests 
that glial pathology is a prominent feature of depression, and that microglia alterations participate in 
the neuropathology of depression (Jo et al., 2015). Microglial cells are proficient phagocytes and 
regarded as CNS-resident immune cells (Prinz and Priller, 2014). They are the primary sentinels 
patrolling the CNS, alert to any potential harmful event including pathogen invasion (Ransohoff and 
Perry, 2009). Moreover, their role is also extended to debris clearance, trophic support to neurons, 
and synaptic pruning during neurogenesis (Blank and Prinz, 2013). Human post-mortem studies in 
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depressives who committed suicide and control subjects identified higher microglial activation in 
different brain regions, including the anterior cingulate cortex (ACC), the pre-frontal cortex (PFC) and 
the hippocampus, in the former group (Steiner et al., 2008; Torres-Platas et al., 2014). Moreover, the 
levels of the neurotoxic molecule quinolinic acid (QA), which is synthesized in microglia, were also 
found to be dysregulated in different brain regions: microglial QA expression was elevated in the 
cingulate cortex, and was decreased or unchanged in the hippocampus (Busse et al., 2015; Steiner et 
al., 2008). Shelton et al. (2011), using gene expression analysis, observed up-regulation of local 
inflammatory, apoptotic, and oxidative stress pathways in the PFC from depressed subjects (Shelton 
et al., 2011). Interestingly, increased binding of translocator protein (TSPO), a marker of 
neuroinflammation mainly expressed by microglia cells, has been observed in vivo in the PFC, ACC, 
and insula of currently depressed patients using PET imaging (Setiawan et al., 2015). 
Another indication that inflammatory processes are intimately related to depression is the 
observation of increased prevalence of depression comorbid with a number of conditions (e.g. aging 
and obesity) and diseases (e.g. atherosclerosis, multiple sclerosis and rheumatoid arthritis), all of 
which are characterized by a chronic inflammatory component (Halaris, 2013; Maes, 2011). 
The findings of increased peripheral and central inflammatory markers in depression cannot answer 
the question of whether inflammation has a causal role in determining depressive state or is actually 
determined by depression itself. Interestingly, administration of inflammatory cytokines or cytokine 
inducers can promote depressive-like behaviours in both laboratory animals and humans (Haroon et 
al., 2012). These data support the notion that inflammation may have a role in the 
aetiopathophysiology of depression. 
3.2 Stimulation of the immune system impacts on sickness and depression-relevant behaviours 
Activation of peripheral inflammation and the systemic release of inflammatory cytokines can exert 
profound effects on brain and behaviour as a result of communication between the periphery and 
brain (Haroon et al., 2012). It is known that infectious diseases are associated with profound 
behavioural disturbances. These are collectively termed sickness behaviour and include malaise, 
fatigue, depressed mood, anorexia, sleep disturbances, decreased physical and social activities, and 
cognitive impairments (Dantzer et al., 2008). Sickness behaviour can be interpreted as an adaptive 
response of the host’s homoeostatic and behavioural priorities to facilitate an immune response and 
cope better with an infection, rather than simply a detrimental consequence of infection per se 
(Brydon et al., 2008; Hart, 1988). In experimental settings, administration of endotoxin 
(lipopolysaccharide, LPS) to humans induces a number of behavioural changes, including depressed 
mood, fatigue, and cognitive dysfunction (Hannestad et al., 2011b; Reichenberg et al., 2001). Several 
studies have investigated the behavioural effects of peripheral administration of the inflammatory 
cytokine interferon-α (IFN-α), a common treatment for infectious diseases including chronic hepatitis 
C (Raison et al., 2009). Chronic administration of IFN-α induces high rates of behavioural disturbance, 
including depression, in 30%-50% of patients treated with IFN-α (Schaefer et al., 2002). Compared to 
medically healthy patients with depression, patients with IFN-α-induced depression show increased 
psychomotor retardation and weight loss and less severe feelings of guilt (Capuron et al., 2009). 
Interestingly, pre-administration of the antidepressant paroxetine is an effective strategy for 
minimizing depressive symptoms induced by IFN-α therapy (Musselman et al., 2001). Experimental 
endotoxemia (i.e. LPS administration) in healthy humans decreases mood, increases prefrontal 
activation during the presentation of emotionally aversive stimuli (Kullmann et al., 2013), and 
enhances activity within the ACC during emotional face processing (Harrison et al., 2009), suggesting 
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a common pathophysiological basis for depression and sickness-associated mood change (Harrison et 
al., 2009). 
Using preclinical models of inflammation-induced behavioural alterations, it has been shown that 
depression-relevant behaviours occur against a background of sickness behaviours (Moreau et al., 
2008; Walker et al., 2013). Crucial points include whether or not the mechanisms underlying post-
sickness depression-relevant behaviours are the same as or different from those underlying sickness, 
and whether or not they are the same as or different from those underlying stress-induced 
depression-relevant behaviour (Walker et al., 2013). For example, in mice, LPS-induced peripheral 
inflammation reduces incentive motivation in an operant test for reward by affecting willingness to 
exert effort for reward and not by reducing consumption of freely-available reward (Vichaya et al., 
2014). Another relevant example is the effects of inflammation versus psychosocial stress on 
processing of aversive stimuli: peripheral administration of cytokine inducers such as LPS (Pugh et al., 
1998) or CD40 agonist antibody (Cathomas et al., 2015a) decrease Pavlovian fear conditioning, 
whereas psychosocial stress increases Pavlovian fear conditioning (Azzinnari et al., 2014; Yu et al., 
2011). 
One shared candidate for the initiation of aetiopathophysiological pathways for sickness behaviour 
and depression is the increased brain levels of the pro-inflammatory cytokines IL-1β and TNF-α which 
follow peripheral immune system activation (for review see Dantzer et al., 2008). A second candidate 
pathway is altered metabolism of tryptophan (TRP) (Dantzer et al., 2008; Schwarcz et al., 2012). The 
pro-inflammatory cytokines IFN-γ, TNF-α, IL-1, and IL-6 induce expression of indoleamine 2,3-
dioxygenase (IDO) (Campbell et al., 2014; Lestage et al., 2002), an enzyme expressed in various 
immune cells throughout the body, including dendritic cells, peripheral macrophages and microglia. 
IDO metabolizes TRP into kynurenine (KYN) along the KYN pathway (Haroon et al., 2012; Schwarcz et 
al., 2012). A second rate-limiting enzyme in the KYN pathway, also responsible for TRP-KYN 
conversion, is tryptophan-2,3-dioxygenase (TDO). TDO is mainly induced by corticosteroids and 
glucagon (Campbell et al., 2014), and inflammatory stimuli (Urata et al., 2014; Walker et al., 2013). In 
the periphery and brain, KYN catabolism results in increased levels of 3-OH-kynurenine (3-HK), 
quinolinic acid (QA) and/or kynurenic acid (KYNA) (Campbell et al., 2014). Tryptophan, KYN and 3-HK 
are readily transported across the blood-brain-barrier (BBB), while QA has to be produced in the 
brain from microglia cells (Schwarcz et al., 2012). In mice, IDO brain expression is increased at 24–48 
h after LPS administration and correlates with LPS-induced behavioural effects (O'Connor et al., 
2009). KYN pathway activation can result in excitotoxicity and oxidative stress in various brain 
regions and cell types, mediated by and impacting on various neurotransmitter systems, including 
glutamate, serotonin and dopamine (Cathomas et al., 2015a; Felger and Miller, 2012; Haroon et al., 
2012). Effects of inflammation and of KYN pathway activation on DA system will be discussed in 
section 3.4. 
3.3 The effects of stress on inflammation 
As presented in section 1.3, chronic psychosocial stressors are key proximal risk factors for 
depression (Kendler et al., 1999; Slavich et al., 2009). Thus, data showing that acute and chronic 
stressors can activate an immune response represent a fundamental step linking stress and 
depression as it relates to the immune system (Haroon et al., 2012). 
One of the earliest findings demonstrating that social stress can activate the immune system, 
obtained in humans, was that exposure to the Trier Social Stress Test (TSST), a public speaking and 
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mental arithmetic stressor, is associated with a rapid activation of NF-kB signaling in peripheral blood 
mononuclear cells (PBMCs) (Bierhaus et al., 2003). Interestingly, depressed subjects with an early life 
stress history exhibit an enhanced inflammatory responsiveness to the TSST, as indicated by higher 
IL-6 levels and NF-kB activation compared to healthy controls (Pace et al., 2006). Cohen et al. (2012) 
showed that stressful life experiences associated with long-term threat are associated with 
proinflammatory leukocytic phenotypes that are unresponsive to the anti-inflammatory actions of 
glucocorticoids (GCs). In accordance with these findings, chronic social stress in humans is associated 
with an increased representation of the immature proinflammatory monocyte transcriptome in 
PBMCs (Powell et al., 2013), and with functional resistance to glucocorticoids in monocytes, which 
enables activation of pro-inflammatory transcription control pathways (Miller et al., 2008a). 
Preclinical research has investigated the effects of stress on the immune system, both in the 
periphery and in the CNS. One very well described murine stress paradigm is repeated social defeat 
(RSD) (for review see Reader et al., 2015). RSD causes immune changes both in the periphery (i.e. 
bone marrow, circulation, spleen) and in the brain. RSD induces splenomegaly that correlates with 
increasing accumulation of splenic CD11b+ monocytes and granulocytes (Wohleb et al., 2012). 
Furthermore, social defeat induces GC resistance in splenocytes (Avitsur et al., 2002; Engler et al., 
2008). Accumulation of neutrophils and monocytes in the circulation and in the spleen is associated 
with increased cell mobilization and myelopoiesis in the bone marrow (Engler et al., 2004). RSD 
stimulates the release into the circulation of the pro-inflammatory cytokine IL-6 (Wohleb et al., 
2011). Regarding the effects of RSD on neuroinflammation, RSD leads to region-specific microglial 
activation and to increased inflammatory profile of microglia (Wohleb et al., 2011). Moreover, RSD 
increases monocyte/macrophage trafficking to the brain (Wohleb et al., 2013). These effects of 
region-specific microglial activation and monocyte trafficking associated with chronic stress have 
been observed in other paradigms of repeated stress (for review: Reader et al., 2015; Walker et al., 
2014), including restraint stress (Hinwood et al., 2012; Hinwood et al., 2013; Kopp et al., 2013), 
footshocks (Ataka et al., 2013), CUMS (Couch et al., 2013; Pan et al., 2014). Besides being region-
specific, microglia response to stress is also time-dependent. Kreisel et al. (2014) show a dynamic 
microglia response to CUMS in mice: hippocampal microglia cells were increased after 2 days of 
stress, but there was no change or even a reduction of microglia cells after 4 days or at the end of the 
4-week stress protocol. Likewise, restraint stress increases the number of microglia only at day 4 of a 
6-days stress protocol (Nair and Bonneau, 2006). Our laboratory has recently shown that CSD in mice 
leads to increased levels of the pro-inflammatory cytokines IL-6 and TNF-α, splenomegaly, and brain 
region-specific dysregulation of the inflammatory transcriptional signature (Azzinnari et al., 2014). 
Specifically, in the ventral hippocampus (HIPP), for 11 of the 54 genes with altered expression in CSD 
mice, the pro-inflammatory cytokines TNF, IL-6 and IL-3 were major upstream regulators of 
expression. The up-regulated genes included the TNF-receptor superfamily gene Tnfrsf25 (Azzinnari 
et al., 2014). In AMYG, CSD led to dysregulation of genes related to canonical pathways of “T cell 
receptor signalling” and “CCR5 signalling in macrophages”, suggesting that CSD initiated changes in 
immune-inflammation transcription processes in this brain area (Azzinnari et al., 2014). In mPFC, de-
regulated canonical pathways were immune-inflammatory, namely “IL-12 signalling and production 
of macrophages” and “production of nitric oxide and reactive oxygen species in macrophages” 
(Azzinnari et al., 2014). 
As presented in section 3.2, the KYN pathway can be activated by inflammatory signaling and it 
regulates immune system-mediated behavioural changes (Dantzer et al., 2008; Schwarcz et al., 
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2012), possibly via its action on neurotransmitters systems (Felger and Miller, 2012). Interestingly, 
stress-induced inflammation has also been found to activate the KYN pathway. CUMS in mice 
increases plasma KYN levels and brain 3-HK content (Agudelo et al., 2014), while restraint stress 
increases TDO mRNA expression and enzymatic activity in the liver (Gibney et al., 2014). Chronic 
stress in mice up-regulates Ido mRNA expression in the dorsal raphe (Couch et al., 2013). Our lab has 
recently shown CSD activation of the kynurenine pathway in periphery and brain regions: in blood, 
KYN and 3-HK were increased in CSD versus CON mice. Co-occurring with these increased plasma 
levels of TRP metabolites, CSD mice had increased brain levels of KYN and 3-HK in AMYG and HIPP. 
Interestingly, CSD-induced KYN pathway activation and increased conditioned fear were reversed by 
pharmacological KYN pathway antagonism (i.e. IDO inhibitor) (Fuertig et al., in prep). 
In terms of the mechanisms by which stress activates the inflammatory response, attention has been 
focused on the sympathetic nervous system (SNS) (Haroon et al., 2012), with the hypothesis that 
stress-induced increased sympathetic tone leads to the release of pro-inflammatory cytokines in the 
periphery (Elenkov et al., 2000; Powell et al., 2013; Rasouli et al., 2011). Indeed, catecholamines 
acting through α- and β-adrenergic receptors have been shown to increase cytokine expression in 
both the brain and the periphery of rats exposed to uncontrollable stressors (Johnson et al., 2005). 
More specifically, Powell et al. (2013) have shown that social stressors up-regulate bone marrow 
production of Ly6Chi proinflammatory monocytes and that these effects are mediated by β-
adrenergic receptors. Pharmacological β-adrenergic antagonism (i.e. propranolol) has been shown to 
reduce stress-induced inflammation (Johnson et al., 2005), up-regulation of bone marrow 
myelopoiesis (Powell et al., 2013), microglia activation, and behavioural changes (Wohleb et al., 
2011). 
3.4 The DA system: a converging node for stress-induced inflammation 
Several hypotheses have been proposed to account for the association of depression with increased 
inflammatory biomarkers and the capacity of (stress-induced) inflammatory stimuli to induce 
depressive symptoms (Haroon et al., 2012). These include the effects of stress and inflammation on 
neural plasticity, neuroendocrine function, and neurotransmitter metabolism (Haroon et al., 2012). 
The latter mechanism has received considerable attention in numerous human and rodent studies. 
Several neurotransmitter systems are affected by inflammation, including serotonin (Maes et al., 
2012; Miller et al., 2013), dopamine (de Pablos et al., 2014; Miller et al., 2013), and glutamate 
(Dantzer and Walker, 2014; Steiner et al., 2012). In the psycho-neuro-immune hypothesis for 
depression presented here it is hypothesized that stress-induced inflammation targets basal ganglia 
and DA pathways, thus influencing the emergence of depression symptoms (Felger and Miller, 2012). 
Various lines of experimental evidence indicate that inflammation can affect DA signaling. In rat, 
peripheral administration of LPS increases extracellular levels of DA metabolites (DOPAC and HVA) in 
the NAcc via increased DAT activity (van Heesch et al., 2014). Peripheral TNF-α can also increase HVA 
NAcc levels (van Heesch et al., 2013). Moreover, high doses of peripheral LPS lead to a decrease in 
tyrosine hydroxylase (TH)-expressing neurons in the SN (Qin et al., 2007); an effect that is partially 
mediated by LPS-induced microglia activation and the subsequent induction of oxidative stress in DA 
cells (Gao et al., 2002; Qin et al., 2013). In Parkinson’s disease, oxidative stress-mediated death of DA 
neurons has been proposed as a mechanism for DA cell degeneration (Kannarkat et al., 2013; Miller 
et al., 2009b). Human studies with endotoxin challenge have shown greater increases in self-reported 
and observer-rated depressed mood over time, as well as significant reductions in ventral striatum 
activity to monetary reward cues (Eisenberger et al., 2010). Moreover, peripheral inflammation 
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following typhoid vaccination is associated with altered SN activity and psychomotor slowing (Brydon 
et al., 2008), and with mood deterioration and reduced sACC-NAcc functional connectivity during 
emotional stimuli processing (Harrison et al., 2009). 
Rodent studies have investigated the link between inflammation and DA function using a model for 
multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). It has been shown that 
EAE-mediated neuroinflammation impairs striatal DA neurotransmission, as indicated by reduced DA 
metabolism (i.e. reduced DA turnover) (Balkowiec-Iskra et al., 2007) and reduced DA release (Gentile 
et al., 2015). Given the high comorbidity of depression with multiple sclerosis (Maes, 2011), findings 
of EAE-induced DA dysfunction might be relevant for the identification of shared (inflammatory) 
pathophysiological routes (Feinstein et al., 2014; Gold and Irwin, 2006). 
As presented in section 3.2, IFN-α therapy induces depression-relevant behaviours in humans and 
laboratory animals. These behavioural effects co-occur with mesolimbic DA dysfunction. Capuron et 
al. (2007) showed basal ganglia hyper-metabolism and symptoms of fatigue during IFN-α therapy. 
Increased basal ganglia glucose metabolism has been demonstrated in PD patients and might reflect 
the degeneration of inhibitory circuits, consequent to the loss of DA cells in the SNpc (Capuron et al., 
2007; Wichmann and DeLong, 2003). 
Given the effects of inflammatory signaling on DA transmission, it can also be hypothesized that 
stress-induced immune system activation might exert detrimental effects on the DA system. de 
Pablos et al. (2014) showed that in rats chronic stress exacerbates microglial activation after injection 
of a pro-inflammatory stimulus such as LPS in the ventral mesencephalon, leading to an increase in 
the death of DAergic neurons in the SN. Moreover, psychosocial stress (CSD) in mice activates 
microglia, increases COX-1 microglia expression in the VTA, and COX-1-dependent prostaglandin E2 
(PGE2) increase attenuates mesocortical DA signaling (Tanaka et al., 2012).  
Interestingly, Savitz et al. (2015a) have shown that in depressed subjects the KYN pathway is 
activated and that the KYN/TRP ratio is inversely associated with striatal volumes in the depression 
sample, suggesting that activation of the KYN pathway might affect striatal volume in depressed 
patients to an extent that has clinical significance (Savitz et al., 2015a). 
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4. Aims of the thesis 
Aims of Study A: Chronic depletion of nucleus accumbens dopamine in mice leads to impaired 
reward and aversion processing relevant to motivation pathologies 
There is evidence that decreased DA neurotransmission in the mesocorticolimbic pathways leads to 
impaired reward and aversion processing and could underlie major psychopathologies, including 
motivational impairments that are common in depression. 6-OHDA NAcc injection is a well-
established method to achieve chronic VTA-NAcc DA depletion and investigate its effects on 
behaviour. Loss-of-function studies have been conducted primarily with rat and reward processing. 
Equivalent mouse studies are rare, and the aim of Study A was to investigate the effects of 6-OHDA-
induced chronic NAcc DA depletion on mouse behaviour using the following test battery: reward 
motivation in a progressive ratio schedule (PRS) operant test, approach-avoid responding in a 
learned non-reward (LNR) operant test, footshock escape behaviour in a learned helplessness (LH) 
operant test, footshock avoid-escape behaviour in a treadmill operant test, and freezing behaviour in 
a Pavlovian fear conditioning test. A further rationale of Study A was to facilitate understanding of 
DA contribution to the disrupted behaviours induced by environmental stress in mice; for example, 
chronic social defeat (CSD) impairs animals’ reward seeking and active attempts to control aversive 
stimuli, and impacts on VTA-NAcc DA function (see Study B and C). Therefore, each mouse 
behavioural test included in Study A is relevant to dimensions of reward or aversion processing often 
disrupted in psychiatric disorders, and studied also in Study B or C. 
Aims of Study B: Mouse chronic social stress induces peripheral-CNS inflammation, dopamine 
deregulation and disrupted processing of rewarding stimuli 
Depression is often preceded by stressful life events and correlates with high levels of inflammatory 
markers, at least in a subpopulation of patients. Moreover, experimental findings suggest the 
involvement of DAergic dysfunction in depressive symptoms. The psycho-neuro-immune hypothesis 
for depression postulates that the inhibitory effects of stress-induced inflammatory signaling on DA 
neurotransmission represent a link between exposure to stressful environments and the emergence 
of depression-relevant behavioural abnormalities. Thus, the first aim of Study B was to investigate 
the effects of CSD on reward motivation using consummatory and appetitive-operant tests and on 
cognitive flexibility in the face of changing response-reward contingency using a learned non-reward 
(LNR) test. Secondly, we aimed to extend the understanding of the inflammatory response that is 
elicited by CSD, characterizing the activation of the innate and adaptive immune system and of the 
kynurenine pathway, with focus on the mesolimbic DA system. Lastly, we assessed the effects of CSD 
on the mesolimbic DA system, with a focus on DA signaling in the mesocorticolimbic pathway. 
Aims of Study C: Mouse chronic social stress disrupts reward motivation and cognitive flexibility 
and certain of these effects are responsive to the antidepressant agomelatine 
Depression is characterized by reduced motivation for reward and impaired reward learning, while 
responsiveness to reward lies in the normal range of functioning. In humans, these behavioural 
domains have been tested using the effort expenditure for rewards task (EEfRT), the probabilistic 
reversal learning (PRL) and the sweet taste test, respectively. In Study C, the effects of CSD on 
reward-directed motivation and reward learning were assessed using a progressive ratio schedule 
(PRS) test and an Intellicage operant sucrose test, and the PRL test, respectively. The second major 
aim of Study C was to investigate the effects of the newly developed antidepressant agomelatine 
(Valdoxan), particularly in terms of its efficacy in reversing CSD-induced deficits in reward processing. 
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Abstract 
Experimental reduction of dopamine (DA) neurotransmission in the mesocorticolimbic pathways 
leads to impaired reward and aversion processing, and could underlie the motivational impairments 
that are common in depression and schizophrenia. The ventral tegmental area-nucleus accumbens 
(VTA-NAcc) DA projection is fundamental to these effects. Injection of the neurotoxin 6-
hydroxydopamine (6-OHDA) in the NAcc is a well-established method for chronic NAcc DA depletion. 
Whilst stress-model and molecular-genetic studies of DA function focus on mice, 6-OHDA NAcc 
studies have been conducted primarily with rat. The aim of the current study was to investigate 
effects of 6-OHDA-induced NAcc DA depletion on C57BL/6 mouse behaviour using the following test 
battery: reward motivation in a progressive ratio schedule (PRS) operant test, approach-avoidance 
responding in a learned non-reward (LNR) operant test, footshock escape behaviour in a learned 
helplessness (LH) operant test, footshock avoid-escape behaviour in a treadmill operant test, and 
freezing behaviour in a Pavlovian fear conditioning test. Relative to vehicle controls, NAcc DA-
depleted mice exhibited reduced responding: (i) for gustatory reward under effortful conditions in 
the PRS test; (ii) to a stimulus recently associated with gustatory non-reward in the LNR test; (iii) to 
footshock recently experienced as uncontrollable in the LH test; and (iv) to footshock that could only 
be avoided-escaped by physical effort in the treadmill test. Taken together, these findings add 
significantly to the comparative evidence that NAcc DA is a major regulator of motivational 
processing of both reward and aversion. They indicate the need for translational study of the 
targetting of pathophysiological DA function for the treatment of motivational psychopathologies in 
various psychiatric disorders, and the suitability of mouse, in addition to rat, models for this research.      
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Introduction 
Dopamine (DA) neurons residing in the ventral tegmental area (VTA) innervate several brain regions, 
and primary among these are the hippocampus, amygdala, prefrontal cortex (PFC) and nucleus 
accumbens (NAcc) (Lammel et al., 2008; Sesack and Grace, 2010). The NAcc is part of the ventral 
striatum and has extensive connectivity with other brain regions: it receives excitatory inputs from 
the PFC and the amygdala, and inhibitory afferents from the ventral pallidum (VP); major projection 
regions of the NAcc include the VP and, reciprocally, the VTA (Sesack and Grace, 2010). Nucleus 
accumbens DA signalling modulates behavioural responsiveness to stimuli, in terms of stimulus-
stimulus learning, response-outcome learning, and the motivation underlying behaviour directed at 
positive stimuli and negative stimuli (Salamone and Correa, 2012; Wise, 2004). The motivation 
functions of NAcc DA is the focus of the present study, and a major rationale for the study is that 
pathologies in motivation towards positive-valence and negative-valence stimuli are characteristic of 
various psychiatric disorders including depression and schizophrenia (Eshel and Roiser, 2010; Wang 
et al., 2015). Reduced DA function has been hypothesized as a major pathophysiological factor in 
depression (Dunlop and Nemeroff, 2007) and negative symptomatology in schizophrenia (Whitton et 
al., 2015). There is evidence for altered DA neurotransmission in each of these disorders (Bowden et 
al., 1997; Mitani et al., 2006; Rice et al., 2014). 
Much of the definitive evidence for the importance of NAcc-DA function in the modulation of 
goal-directed behaviour has been obtained in loss-of-function experiments conducted in rats. 
Infusion of the monoamine neurotoxin 6-hydroxydopamine (6-OHDA) into the NAcc, leading to 
specific degeneration of DA fibre terminals (Stott and Barker, 2014), is the most well-established 
method (Aberman and Salamone, 1999), and has primarily been applied to study the importance of 
NAcc DA in the regulation of  gustatory stimulus processing. In rat, in free-choice situations, NAcc DA 
depletion delays development of preference for sucrose solution relative to water (Martinez-
Hernandez et al., 2012), NAcc DA depletion impairs both the operant acquisition of response-
outcome learning and the motivation to respond, with the latter effect being most pronounced 
under conditions of high effort (Aberman and Salamone, 1999). Such findings demonstrate that NAcc 
DA regulates the motivation for - the “wanting” of - sweet-tasting stimuli (Nunes et al., 2013b). In 
contrast, NAcc DA does not regulate appetite for homeostatic dietary need (Cousins and Salamone, 
1994),  or hedonic responding to - the “liking” of - sweet stimuli (Smith et al., 2011). In addition to 
the evidence that NAcc DA regulates reward learning and motivation, there is interest in the 
involvement of DA in regulation of the behavioural flexibility required under conditions of changing 
response-outcome contingency. For example, VTA DA projections to the prefrontal cortex (PFC) have 
been proposed to actively maintain goal-directed behaviour in the face of distraction (Cools et al., 
2011; van Schouwenburg et al., 2010). Reversal learning involves inhibition of a previously reinforced 
response i.e. inhibition of perseveration, and activation of a previously non-reinforced response i.e. 
suppression of learned irrelevance/learned non-reward. Serotonin within the PFC has been 
demonstrated to suppress perseveration, in common marmoset (Clarke, 2004), and glutamate within 
the orbital PFC has been demonstrated to suppress learned irrelevance, using a reversal-learning test 
that separated perseveration and learned non-reward, in rat (Tait and Brown, 2007). Recently, a 
mouse test for learned non-reward (LNR) was described (Nilsson et al., 2012), and can be used to 
study the involvement of NAcc DA or PFC DA in the regulation of this form of behavioural flexibility. 
The first aims of the present study were to investigate the effects of 6-OHDA depletion of NAcc DA in 
mice on their motivation for sucrose-reinforcer using a progressive ratio schedule test; and of 6-
OHDA depletion of NAcc DA or medial PFC (mPFC) DA on their flexibility in the face of changing 
response-outcome contingency using the LNR test. 
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Nucleus accumbens DA also modulates goal-directed behaviour relative to negative stimuli. 
Dopamine is released acutely in the NAcc in response to unconditioned aversive stimuli e.g. electric 
footshock (Young et al., 1993) and social stress (Cabib and Puglisi-Allegra, 2012). In the case of 
inescapable/uncontrollable stimuli, the initial increase in NAcc DA is followed by a decrease below 
pre-stress tonic levels (Cabib and Puglisi-Allegra, 2012). As with positive stimuli, NAcc DA appears to 
modulate learning and motivational aspects of behaviour directed at aversive stimuli. In rat, 
depletion of NAcc DA leads to a deficit in operant lever pressing or two-way shuttling, to avoid-
escape footshock (McCullough et al., 1993; Wenzel et al., 2015). In DA-deficient mice in which DA 
expression could be reactivated region-specifically, restoration of DA signalling to both entire 
striatum and amygdala was necessary and sufficient to enable mice to learn two-way active 
avoidance (Darvas et al., 2011). Also in mice, DA depletion in VTA and substantia nigra pars compacta 
led to increased sensitivity to inescapable footshocks expressed as a subsequent response deficit in a 
lever-press escape test i.e. learned helplessness (Winter et al., 2007). With respect to aversive 
stimulus-stimulus learning, studied primarily using Pavlovian fear conditioning, conditioned stimuli 
(CS), e.g. tone, that predict footshock, increase DA release in the NAcc (Pezze and Feldon, 2004; 
Wenzel et al., 2015). Whether NAcc DA depletion affects CS fear conditioning or expression remains 
to be investigated (Pezze and Feldon, 2004). To increase understanding of the involvement of NAcc 
DA in aversive stimulus processing, particularly in terms of motivation to respond adaptively to them, 
the second aims of the present study were to investigate the effects of 6-OHDA depletion of NAcc DA 
in mice on their active escape of footshock in a learned helplessness (LH) test (Pryce et al., 2012), and 
their active avoidance-escape of footshock in a treadmill running test (Azzinnari et al., 2014). Given 
that the mPFC is critical to the processing of stimulus un/controllability in the rat (Amat et al., 2008), 
the effects of mPFC DA depletion were also studied in the LH test. The third aim was to study effects 
of NAcc DA depletion in the Pavlovian fear conditioning test.  
Animal models are essential to understanding the contributions of NAcc DA and mPFC DA to 
adaptive and disrupted motivational processing of rewarding and aversive stimuli. Reduced 
motivation to engage with reward underlies the core depression symptom of loss of interest and 
core negative symptoms in schizophrenia, and is prominent in the mental health research domain 
criterion (RDoC), Positive valence systems (Cuthbert and Insel, 2013). Altered reactivity to aversive 
stimuli is a major construct in the RDoC, Negative valence (Cuthbert and Insel, 2013). Altered 
reactivity to and motivation to cope with aversive stimuli could well contribute to the core 
depression symptoms of low mood and high fatigue (Eshel and Roiser, 2010). For example, perceived 
absence of control of aversive stimuli can lead to helplessness, including reduced motivation to 
attempt control (Nunes et al., 2013b; Pryce et al., 2011a; Treadway and Zald, 2011), and increased 
emotional reactivity to and decreased motivation to control aversive stimuli both contribute to high 
fatigue (Demyttenaere et al., 2005). As described above, it is rat studies that have contributed most 
to current understanding of mesolimbic DA regulation of motivation and cognition relative to 
positive and negative stimuli. Currently, the 6-OHDA DA depletion approach has rarely been applied 
in mouse, but there is nonetheless increasing emphasis on applying environmental manipulations 
and molecular-genetic tools in mice to study DA function and dysfunction. For example, chronic 
social defeat stress in mice has been shown to impair reward-directed behaviour (Chaudhury et al., 
2013; Lammel et al., 2014) and active attempts to control aversive stimuli (Azzinnari et al., 2014), and 
optogenetic methodology has been applied to stimulate VTA DA neurons and reverse some of these 
effects (Chaudhury et al., 2013; Lammel et al., 2014; Tanaka et al., 2012). We aimed to investigate 
whether 6-OHDA NAcc, and in some tests mPFC, DA depletion impacted on mouse reward and 
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aversion processing in a similar manner to that described for rat, and were particularly interested in 
its motivational effects, given the importance of motivation pathologies in psychiatry.  
Materials and methods 
Animals 
The study was conducted with male C57BL/6J mice (Janvier Labs, Saint-Berthevin, France) aged 10 
weeks and weighting 26.1  2.0 g at the time of surgery. Mice were maintained in pairs in type 2L 
cages and on a reversed 12:12 h light-dark cycle (lights off at 07:00 h) in an individually-ventilated 
caging system, with temperature at 20-22°C and humidity at 50-60%. The standard diet was 
complete pellet (Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water, both available continuously 
and ad libitum unless stated otherwise below for experimental reasons. All procedures were 
conducted under a permit for animal experimentation (No. 170/2012) issued by the Veterinary 
Office, Zurich, Switzerland, in accordance with the Animal Protection Act (1978) Switzerland.  
 
Injection of 6-hydroxydopamine (6-OHDA) 
At 30 min prior to injection of 6-OHDA or vehicle, mice received i.p. injections of desipramine 
hydrochloride (Sigma-Aldrich, 50 and 35 mg/kg for NAcc and mPFC lesion, respectively) and 
escitalopram oxalate (H. Lundbeck A/S, Valby, Denmark, 5 mg/kg), in order to block 6-OHDA uptake 
by noradrenaline and serotonin neurons, respectively. Mice were anaesthetised with a cocktail of 
fentanyl 0.04 mg/ kg, midazolam 4 mg/kg and medetomidine 0.4 mg/kg, i.p.. Using a stereotaxic 
frame (WPI, Berlin, Germany) and 10 µl syringe (NanoFil, WPI) equipped with a 33G needle (WPI), 
mice received bilateral injections of 6-OHDA hydrochloride (Sigma-Aldrich) or vehicle in the NAcc or 
mPFC. 6-hydroxydopamine was dissolved in 0.9% saline containing 0.02% ascorbic acid (AA). 
Coordinates, established using a mouse brain atlas (Franklin and Paxinos, 2008) and pilot injections 
of methylene blue, were, relative to bregma, for NAcc, AP +2.0, ML ±0.7, DV -4.6 mm, and for mPFC, 
AP +2.4, ML ±0.3, DV -2.4 mm. Injection parameters for 6-OHDA were, for NAcc, 1.5 µg or 2 µg/0.5 
µl/2.5 min, and for mPFC, 1.5 µg/0.2 µL/2 min, and the same volume and rate were used for vehicle 
injections (Veh: 0.02 % AA in saline). The needle was left in place for a further 3 min to allow tissue 
diffusion, before being retracted slowly. A period of 10-12 days, sufficient for mouse post-surgery 
recovery and for degeneration of DA fibres (Stott and Barker, 2014), was allowed between injection 
and behavioural testing. Body weight was measured on days 1-10 post-surgery.  
 
Behavioural testing 
Operant tests using gustatory positive reinforcement 
 Apparatus. For the progressive ratio schedule (PRS) and learned non-reward (LNR) 
experiments, training and testing were conducted using operant boxes (TSE Systems GmbH, Bad 
Homburg, Germany), details of which are given elsewhere (Ineichen et al., 2012). Briefly, nose-poke 
ports detected mouse nose poke responses via an infra-red beam, and port position and number 
changed according to the test (PRS or LNR). Sugar pellets (14 mg, Dustless Precision Pellets, TSE 
Systems GmbH) were delivered singly into the feeder port, which was situated adjacent to the single 
nose-poke port in the PRS test and in the wall opposite the two nose-poke ports in the LNR test. 
Pellet delivery was signalled by a tone from a speaker. Pellet retrieval was detected via infra-red 
beam. 
 Restricted feeding protocol. For 5 days, mouse daily body weight and daily food intake were 
measured to obtain mean baseline values. Beginning one week before and continuing during the 
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operant training phases of the PRS and LNR experiments, mice were food restricted and kept at 90% 
of their free-feeding (baseline) body weight, to ensure motivation for operant training.  
 
Progressive ratio schedule (PRS) test 
 Naive mice (N=24) were initially trained to nosepoke into a single port to obtain a sucrose 
pellet under a fixed ratio 1 (FR1) schedule. Mice required 8-12 sessions to acquire the defined 
criterion for operant learning, which was 2 consecutive sessions at which ≥ 30 pellets were earned at 
FR1. For PRS testing, mice were returned to 100 % baseline body weight; this was to reduce their 
appetite and thereby to increase test sensitivity to detecting motivation for the sweet taste of 
sucrose pellets rather than their calorific content. Mice were then given 3 sessions of PRS testing and 
the mean score of the last two sessions was used to counter-balance subject allocation to 
experimental (NAcc Veh vs 6-OHDA) groups. The PRS test parameters were: start ratio (required 
number of nose-pokes on first trial) = 1, repetition factor (number of consecutive trials for which the 
ratio remained constant) = 5, and step-wise linear fixed ratio increase (number of nose-pokes by 
which the ratio increased per increment) = 3, e.g. reward ratio on trials 1-5 = 1 response, on trials 6-
10 = 4 responses, on trials 11-15 = 7 responses, and on trial 16-20 = 10 responses, and so on. The 
break point, i.e. minimum time without at least 1 response that signalled end of the session, was 600 
s, and maximum session duration was 40 min. After surgery + 10-12 days, mice, weighing 100 % 
baseline body weight (104  3 %) were given the PRS test. The measures of interest were: cumulative 
number of pellets earned and ratio attained at 10, 20, 30 and 40 min after test onset, overall mean 
time between collection of pellet n and the first operant response for pellet n+1 (post-reinforcement 
pause, PRP), and absolute peak response rate (PRR) calculated as the highest overall response rate 
within a ratio and expressed as responses/min (Bezzina et al., 2008). 
 
Learned non-reward (LNR) test 
 The LNR test was based on that described by Nilsson et al. (2012). Naive mice (N=19 in NAcc 
experiment, N=25 in mPFC experiment) were kept at 90-95% baseline body weight throughout LNR 
testing. Details of operant training for this test are given in Supplementary Information. Briefly, mice 
were trained to initiate each trial by one operant nosepoke into the feeder port, which illuminated a 
stimulus nose-poke port in the opposite, stimulus wall; one response in the stimulus port activated 
signalled delivery of a sucrose pellet into the feeder port, which the mouse returned to and retrieved 
the pellet. The criterion for completion of training was 2 consecutive sessions at which ≥ 49 pellets 
were earned. There were three spatial locations (left, middle, right) in the stimulus wall. The first 
stage of the test was a two-choice spatial discrimination (SD): following trial initiation, the subject 
had to choose between two stimulus nose-poke ports whilst a blank panel occupied the third 
location. A response in the correct stimulus port led to delivery of a sucrose pellet in the feeder port 
and an incorrect response led to a 5 s timeout. Mice were allowed 10 s to initiate a trial and 6 s to 
make a choice response. The SD stage consisted of 70 trials divided into seven 10-trial blocks; SD 
learning criterion was nine correct responses within any 10-trial block, and if the subject did not 
attain criterion the SD stage was repeated on the next day. On the day after attaining SD criterion, 
the second stage, learned non-reward (LNR), was presented: the incorrect stimulus port location at 
SD became the correct port, the previously correct stimulus port was removed and replaced by the 
blank panel, and the blank panel was replaced by a stimulus port and this became the new location 
for the incorrect port. Number of trials, learning criterion, and times allowed for trial initiation and 
choice responding, were all identical to those at the SD stage. At the LNR stage, the subject must 
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overcome nonreinforcement-avoid behaviour and acquire reinforcement-approach behaviour at the 
same stimulus port, in the absence of the possibility to perseverate in responding at the previously 
correct port (Nilsson et al., 2012).  Measures of interest for SD and LNR were: omissions to initiate a 
trial (OIT), omissions to make a choice response (OR), incorrect choice response (IR), the sum of OIT, 
OR and IR, referred to as total errors (TE), and correct choice responses (CR). Prior to 6-OHDA 
infusion, mice were tested on three stages of SD+LNR so that the effects of DA depletion could be 
assessed against a stable baseline of SD and LNR behaviour. Between the completion of LNR and the 
subsequent SD stage, mice were given one session with only the central stimulus port available. Total 
errors in the third LNR stage were used to counter-balance subject allocation to experimental (Veh vs 
6-OHDA) groups. After surgery + 10-12 days, mice, weighing 90-95 % (92  4 %, NAcc Expt; 93  5 %, 
mPFC Expt) baseline body weight were tested on the fourth stage of SD+LNR. 
 
Operant tests using footshock negative reinforcement 
Learned helplessness (LH) test 
 The LH test was conducted using a fully-automated apparatus (Multi Conditioning System, 
TSE Systems GmbH, Bad-Homburg, Germany), details of which are given in (Pryce et al., 2012). 
Briefly, an arena was positioned on an electrifiable grid and contained a central divider with an 
opening (“gate”) via which mice could transfer from one side of the arena to the other. The test was 
based on the evidence that pre-exposure of mice to inescapable (uncontrollable) footshocks in this 
context leads to a subsequent deficit in two-way escape behaviour to the same stimulus in the same 
context, relative to mice pre-exposed to the same amount of escapable (controllable) footshock and 
to mice naive of footshock pre-exposure i.e. a validated specific LH effect (Pryce et al., 2012). In the 
present experiment, only the inescapable condition was used, to assess whether NAcc or mPFC DA 
depletion affected responses to inescapable footshock, and whether it affected responses to the shift 
from inescapable to escapable footshock (whether DA depletion effects were specific to pre-
exposure to inescapable stimuli or also altered responses to pre-exposure to escapable stimuli was 
not tested). Naive mice were allocated randomly to 6-OHDA and Veh groups, N=27 in the NAcc 
experiment and N=24 in the mPFC experiment. After surgery + 10-12 days, day 1, mice were placed 
in the arena for 15-min without footshock to habituate them to the two-way arena and assess their 
locomotor activity. On days 2-4 (Inescapable footshock exposure) mice were exposed to 24 
inescapable footshock (IS) trials/day, at 0.15 mA; footshock duration was variable, with a mean of 3.5 
s, 2.7 s and 3.3 s on days 2, 3 and 4, respectively (maximum per trial footshock duration was 5 s on 
each day), and using a variable inter-trial interval (ITI) of 50 ± 40 s. On day 5 (Escape test) mice were 
exposed to 30 escapable footshock (ES) trials at 0.20 mA and with constant maximum footshock 
duration of 5 s/trial. The following measures were calculated for the escape test: total escape 
failures, mean escape latency, mean locomotor activity during ITI (arbitrary units/min, a.u./min), 
mean % time spent freezing during ITI (freezing defined as zero a.u. moved for at least 2 s), and 
distance moved during footshock (footshock reactivity, a.u./s). 
 At day 1 specifically, 6-OHDA mice exhibited decreased locomotion (see Results). In order to 
investigate whether this was associated with increased anxiety in a novel environment, an additional 
experiment was conducted in which mice were first given a 15-min habituation session in the two-
way arena, on the following day received NAcc 6-OHDA (N=10) or Veh (N=10) infusion, and then 
given further activity tests in the same arena at 14 and 15 days post-surgery. 
 
Treadmill test 
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 The same mice as those used in the study of NAcc DA depletion effects in the LH test were 
used for this experiment, with an interval of 2 days. The treadmill test requires the mouse to run on 
an inclined (5°) plane to avoid or escape an electrified grid; it has been used to demonstrate a deficit 
in running at fast speed specifically in mice exposed to chronic psychosocial stress (Azzinnari et al., 
2014). The test is suitable to detect effects of manipulations on two states (although not 
concurrently): the absolute level of effort the subject exerts to avoid-escape punishment - if this level 
is exceeded by the treadmill speed the subject will receive the maximum footshock amount shortly 
after test onset; the cumulative level of effort the subject exerts to avoid-escape punishment - the 
maximum footshock amount will accumulate gradually and exponentially and the mouse will 
approach the maximum test duration. On experimental day 1 (training), mice were placed on the 
treadmill for 2 min at a speed of 0 cm/s, 5 min at 15-20 cm/s at 1 min increments, and 5 min at 20 
cm/s. Total number and duration of footshocks were scored automatically; the cumulative maximum 
duration of footshock any mouse could receive was 20 s, and the training session was terminated if 
this was reached. On day 2, a pre-test session consisted of 2 min at 0 cm/s and 5 min at 20 cm/s. This 
was followed immediately by the test session, which consisted of 20 min at 23 cm/s (or less if 
cumulative total footshock duration reached 10 s). Test measures were running time at 23 cm/s 
(maximum 20 min) and total cumulative footshock duration (maximum 10 sec). 
 
Pavlovian CS-footshock fear conditioning test 
 For this test of aversive stimulus-stimulus conditioning the same apparatus was used as for 
the LH test. Naive mice (N=19) were allocated randomly to NAcc 6-OHDA and Veh groups. After 
surgery + 10-12 days (day 1), mice were placed on the grid in the arena (without central gate) for 15 
min without footshocks to assess their locomotor activity and habituate them to the two-way arena 
(context). On day 2 (Conditioning), mice were placed back in the arena and exposed to 6 trials of 20 s 
tone (5 kHz, 85 dB, conditioned stimulus, CS) the final 2 s of which were contiguous with an 
inescapable footshock of 0.20 mA (unconditioned stimulus, US), and with inter-trial intervals (ITI) of 
120 s. On day 3 (Expression test), mice were returned to the arena for a 20-min context test (20 x 1-
min bins), followed immediately by a CS test in the same context comprising 12 x 30 s CS separated 
by ITI of 90 s. The test measure was % time spent freezing during CS or ITI trials (Cathomas et al., 
2015c). 
 
Hot plate pain test 
As an independent assessment of effects of NAcc DA depletion on pain sensitivity, a hot plate 
test was conducted in mice studied in the LH + Treadmill experiment and in mice studied in the fear 
conditioning experiment, with an inter-test interval of 1 day. The hot plate test was conducted using 
a programmable thermoelectric heating plate (Teca, Chicago IL, USA) set at 50°C (Pryce et al., 2012). 
The latency (s) until first occurrence of one of the following behaviours was scored: licking a forepaw, 
licking a hind paw, lifting a hind paw, jumping. The maximum test duration was 60 s. 
 
Ex vivo determination of brain tissue monoamine levels 
At 1-2 days after completion of a behavioural experiment, the fresh brain was collected, frozen on 
powdered dry-ice and stored at -80°C. Frozen brains were sectioned coronally at 1.0 mm intervals 
using a stainless-steel brain matrix (Plastics One, model MMCS-1, Roanoke VA, USA) (Azzinnari et al., 
2014). The NAcc, mPFC, caudate-putamen (CPu) and amygdala (Amyg) were identified using a mouse 
brain atlas (Franklin and Paxinos, 2008) and micro-dissected bilaterally using a brain punch ( = 1- 
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mm, Stoelting Europe, Dublin, Ireland) (Azzinnari et al., 2014) and the two punches per region and 
mouse were processed together. Mean total tissue weights per region were: NAcc 1.7 mg, mPFC 1.3 
mg, CPu 1.3 mg, Amyg 1.6 mg.  
HPLC-ED for DA and 5-HT. For tissue homogenization, 100 µl (mPFC, Amyg), 250 µl (NAcc) or 
300 µl (CPu) ice-cooled perchloric acid (0.4 M) was added to each sample. Ultrasonication was 
conducted for 5 s at 30% power (VibraCell, VCX130PB, Sonics and Materials, Inc., Newtown CT, USA), 
followed by centrifugation at 16,000×g for 10 min at 4°C (CT15RE, VWR/Hitamachi, Lutterworth, UK). 
The supernatant was passed through a 0.22 µm filter (Minisart RC4, Sartorius AG, Göttingen, 
Germany) and kept on ice until analysis. High performamce liquid chromatography (HPLC) and 
electrochemical detection (ED) were conducted for DA and 5-HT and their respective major 
metabolites, dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA), according 
to Oeckl et al. (2012). Briefly, isocratic separation of DA and 5-HT was carried out with a reversed-
phase C18 column (YMC-Pack ODS-AQ, 100×2.1 mm, S-3 μm, YMC Europe GmbH, Dinslaken, 
Germany). The mobile phase consisted of 1.7 mM 1-octanesulfonic acid sodium salt, 1.0 mM 
Na2EDTA × 2H2O, 8.0 mM NaCl, 100 mM NaH2PO4× 2H2O (pH 3.80), mixed with 9.3% acetonitrile, and 
was delivered at a flow rate of 0.4 ml/min. For ED an electrochemical cell with a glassy carbon 
electrode and an ISAAC Ag/AgCl reference electrode (VT-03, Antec, Zoeterwoude, Netherlands) was 
used. Homogenates (20 µl) were injected onto the HPLC system using an autosampler (ASI-100T). 
Concentrations of monoamines and metabolites were calculated using an external standard 
calibration and expressed as ng/mg brain tissue. 
 Radioenzymatic assay for noradrenaline. Following tissue homogenization (see above) PFC, 
NAcc and Amyg samples were further diluted (1:1, 1:10 and 1:5, respectively) in artificial 
cerebrospinal fluid (aCSF). For NA quantification, a radioenzymatic assay was used as described 
previously.(Lu et al., 2008) This assay involves COMT-catalyzed O-methylation using [3H]S-
adenosylmethionine as methyl donor and separation of the resulting [3H]normetanephrine by thin-
layer chromatography (TLC).  
 
Immunohistochemistry for tyrosine hydroxylase 
In addition to quantification of DA tissue levels using HPLC-ED, 6-OHDA depletion of DA fibre 
terminals in NAcc (and surrounding regions) was also assessed qualitatively using tyrosine 
hydroxylase (TH) immunohistochemistry. In an additional cohort of mice, following NAcc 6-OHDA 
(N=3) or Veh (N=3) infusion + 12 days, mice were deeply anaesthetized with pentobarbital and 
transcardially perfused with phosphate-buffered saline (PBS, pH 7.4) and fixative (4% 
paraformaldehyde (PFA) in PBS). Brains were post-fixed over-night in 4% PFA, and cryoprotected in 
30% sucrose for 48h. Brains were frozen on powdered dry ice and cut at 40 µm with a microtome 
(Zeiss). Brain sections were collected in antifreeze solution and stored at -20°C until analysis. Free-
floating sections were washed with PBS, quenched with 3% H2O2 for 15 min, blocked with normal 
goat serum and incubated o/n at 4°C with a mouse anti-TH antibody (1:1000; Santa Cruz 
Biotechnology), followed by 2 h RT incubation with a biotinylated goat anti-mouse secondary 
antibody (1:500; Millipore). Sections were then incubated with 1% avidin-biotin peroxidase complex 
(Vectastain ABC kit, Vector) for 30 min at RT. Staining was visualized using diaminobenzidine (DAB) 
solution. NAcc was identified using the mouse brain atlas (Franklin and Paxinos, 2008). Images were 
acquired using a brightfield microscope (Zeiss, Axiovert). 
 
Statistical analysis 
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Statistical analysis of 6-OHDA lesion effects on behaviour and brain monoamine content was 
conducted using SPSS (version 20, SPSS Inc., Chicago IL, USA). In most cases an unpaired t-test was 
conducted. Prior to conducting a t-test, Levene’s test for equality of variances was conducted; in case 
of non-equal variances the corresponding t-test was used and degrees of freedom adjusted 
accordingly. Analysis of variance (ANOVA) was conducted in cases of repeated measures, with a 
between-subject factor of group (6-OHDA, Vehicle) and a within-subject factor of test phase (e.g. PRS 
test, LH test, fear conditioning test). Where appropriate, ANOVA post hoc testing was conducted 
using the Bonferroni procedure. Statistical significance was set at p≤0.05. Where an estimate of 
variance is given this is the standard deviation (SD). 
Results 
Efficacy and specificity of 6-OHDA dopamine depletion 
Four experiments were conducted investigating the behavioural effects of 6-OHDA lesion targeting 
the NAcc. The findings of ex vivo assessments of DA and 5-HT tissue levels in NAcc, CPu, mPFC and 
Amyg are presented in Table 1. Mice injected with 6-OHDA exhibited a marked (74-87%) and 
consistent reduction in NAcc DA in each experiment: PRS test, t(14) = 5.1, p<0.0005; LNR test, t(16) = 
6.8, p<0.0005; LH test and treadmill test, t(25) = 10.2, p<0.0005; fear conditioning test, t(17) = 10.6, 
p<0.0005. We also assessed for effects of NAcc 6-OHDA on DA tissue levels in off-target regions, 
either as a specificity control or because DA function in that region could be relevant to the 
behavioural processes under study. Caudate-putamen was studied in each of the four NAcc 
experiments: there was no effect of NAcc 6-OHDA on CPu DA levels in two experiments, an increase 
in the PRS experiment (t(14) = -3.8, p<0.005), and a decrease in the LH test + treadmill test experiment 
(t(24) = 3.5, p<0.005). There was no effect on Amyg DA levels, as measured in two experiments. For 
mPFC DA, firstly it is important to note that baseline (Veh) levels were markedly lower than in NAcc, 
CPu and Amyg (Table 1). NAcc 6-OHDA lesions led to reduced mPFC DA levels in each of the four 
experiments: In the PRS and LNR experiments, DA levels were below detection in 6-OHDA mice 
specifically; there was a moderate-high reduction in mPFC DA in the LH test + treadmill test (t(24) = 
2.8, p<0.01), and in the fear conditioning test (t(17) = 4.3, p<0.0005). To investigate whether this off-
target effect could itself recapitulate the behavioural effects of NAcc DA depletion (see below), the 
effects of mPFC 6-OHDA lesion were studied directly in the LNR test and LH test. There was a marked 
(67-86%) and consistent reduction of mPFC DA: LNR test, t(28) = 2.5, p<0.02; LH test, t(22) = 3.6, 
p<0.002 (Table 1). Furthermore this was specific to mPFC with no impact on DA levels in NAcc, CPu or 
Amyg. With regard to 5-HT, in no experiment was there a reduction in 5-HT tissue levels (Table S1). 
To assess the effect of NAcc or mPFC 6-OHDA lesion on noradrenaline (NA) levels in NAcc, mPFC, CPu 
and Amyg, additional experiments were conducted and radioenzymatic assay used for NA 
measurements (Table S2). NAcc 6-OHDA lesion did not affect NA levels in any region; mPFC 6-OHDA 
lesion led to increased NA in the mPFC (t(9) = -4.6, p<0.002) and decreased NA in the NAcc (t(9) = 2.4, 
p<0.05). 
 Nucleus accumbens 6-OHDA efficacy and specificity was also assessed qualitatively using TH 
staining for DA fibre terminals. Representative 6-OHDA and Veh sections are given in Figure S3. The 
TH stain was markedly reduced in the NAcc core and NAcc shell of 6-OHDA mice. One additional 
region that exhibited reduced stain in 6-OHDA mice was the extreme medial CPu.    
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Table 1. Effects of NAcc or mPFC 6-OHDA infusion on tissue dopamine in brain regions of interest 
     
Dopamine (ng/mg tissue) 
     
            NAcc CPu mPFC Amygdala 
Target region Behavioural test     Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA 
NAcc 
 
Progressive ratio schedule X 3.31 0.86c 15.70 22.47c 0.29 
n.d. 
    
  
(N=8 Veh, 8 6-OHDA) SD 1.19 0.64c  1.57 4.82c 0.41     
      
    
 
          
NAcc 
 
Learned non-reward X 4.92 1.04c 19.09 20.88 0.25 
n.d. 
    
  
(N=10, 9) SD 1.64 0.52c 4.73 4.44 0.24     
      
                
NAcc 
 
Learned helplessness & X 6.89 0.90c 19.37 15.3b 0.12 0.05b 1.89 2.10 
  
Treadmill  (N=13, 14) SD 2.04 0.79c 3.13 2.78c 0.08 0.04c  1.44 1.33 
      
                
NAcc 
 
Fear conditioned freezing X 6.45 1.43c 14.61 13.66 0.14 0.02c 1.06 0.97 
  
(N=11, 11) 
 
SD 1.29 0.36c 2.02 2.61 0.07 0.04c 0.39 0.35 
      
                
mPFC 
 
Learned non-reward X 6.08 7.28 13.20 14.55 0.24 0.08a     
  
(N=13, 12) SD 1.63 1.77 3.77 4.31 0.22 0.11 c     
      
                
mPFC 
 
Learned helplessness X 7.16 8.59 13.71 14.98 0.07 0.01b 2.31 2.20 
  
(N=12, 12) SD 1.48 2.66 2.79 5.21 0.06 0.01 c 1.54 1.19 
                            
6-OHDA dose was 2 µg per hemisphere for NAcc and 1.5 µg per hemisphere for mPFC.  
Scores are mean  SD.  
a p<0.05, b p<0.01, c p<0.001 in t-tests. 
 
 
Physical effects of 6-OHDA dopamine depletion 
Effects of NAcc and mPFC 6-OHDA on body weight (BW) were measured for days 1 to 10 after 
surgery. ANOVA was conducted for post-surgery BW expressed as a percentage of pre-surgery 
baseline (= 100%). Data for the NAcc LH + Treadmill experiment are presented as a representative 
example (Figure S1): There was a Group X Day (baseline, post-surgery days 1-10) interaction (F(10, 
271)=4.3, p<0.0005); post hoc analysis revealed that Veh mice recovered to baseline BW by day 4 
whereas 6-OHDA mice recovered by day 8, and that % BW was lower in 6-OHDA compared to Veh 
mice on days 1-5. For the mPFC 6-OHDA LH experiment, there was a main effect of Day (F(10, 220)=8.8, 
p<0.0005) but no effect involving Group (p = 0.56); post hoc analysis revealed that both groups 
recovered baseline BW by day 4 (data not shown). 
 
Operant tests using gustatory positive reinforcement 
Progressive ratio schedule (PRS) test 
The PRS test was used to investigate effects of NAcc DA depletion with 1.5 or 2.0 µg 6-OHDA on 
motivation for sucrose pellets in non-food deprived mice under effortful conditions. Following 
operant training and prior to surgery, mice were given three PRS tests, and for group allocation were 
counter-balanced on total number of pellets earned (Veh: 47.9 ± 0.3, 1.5 µg: 45.8 ± 0.3, 2 µg:  46.2 ± 
0.8 (p=0.48)) and final ratio attained (Veh: 28.4 ± 0.4, 1.5 µg: 27.4 ± 0.4, 2 µg:  27.4 ± 1.0 (p=0.62)). 
For analysis of 6-OHDA effects on cumulative number of pellets earned and PR ratio attained, the PRS 
test was divided into four 10-min blocks and ANOVA was conducted for Dose X Time-block. For 
cumulative pellets earned there was a main effect of Dose (F(2, 21)=4.20, p<0.03; Fig. 1A); post hoc 
analysis revealed that mice injected with 2 µg 6-OHDA earned less pellets than Veh mice (p<0.04).  
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There was also a main effect of Dose for PR ratio attained (F(2, 21)=3.9, p<0.04; Fig. 1B); 2 µg 6-OHDA 
mice attained a lower ratio than Veh mice (p<0.04). The reduced motivation of NAcc DA-depleted 
mice was also evident in mean post-reinforcement pause (PRP) (F(2, 21)=15.4, p<0.0005; Fig. 1C) with 
both 1.5 µg and 2 µg 6-OHDA mice exhibiting higher mean PRP than Veh mice, and in peak response 
rate (PRR) (F(2, 21)=3.5, p<0.05; Fig. 1D) which was lower (and occurred at a lower ratio) in 2 µg 6-
OHDA mice than in Veh mice. 
 Behavioural effects of DA depletion in all other tests were studied using 2 µg 6-OHDA, 
specifically. 
 
 
Figure 1. Effects of NAcc DA decrease (Veh, 1.5 µg, 2 µg 6-OHDA) on behavioural measures in the progressive 
ratio schedule (PRS) test. A) Mean  SD cumulative scores for number of pellets earned at 10, 20, 30 and 40 
min. B) Mean+/-SD cumulative scores for ratio attained at 10, 20, 30 and 40 min. For each measure there was a 
main effect of dose in 2-way ANOVA, and *indicates p<0.05 for 2ug 6-OHDA vs Veh in post hoc Bonferroni test. 
C) Scatterplot and mean for post-reinforcement pause (PRP, seconds (s)). D) Absolute peak response rate 
(PRR). Values in parentheses indicate the ratio at which the PRR was achieved. For each measure there was a 
dose effect in 1-way ANOVA, and * p<0.05, ** p<0.001, *** p<0.005 in post hoc Bonferroni tests. 
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Learned non-reward (LNR) test 
 The LNR test was used to investigate effects of NAcc or mPFC DA depletion on cognitive 
reward-directed behaviour. Mice were tested on three consecutive stages of both simple 
discrimination (SD) and learned non-reward (LNR) (SD+LNR 1-3) prior to DA depletion, and therefore 
any effects of the latter were unlikely to be due to impaired task acquisition. That mice acquired the 
task was indicated by improved performance across successive stages. For example, for total errors 
there was a main effect of Stage for both simple discrimination (F(2, 54) = 3.7, p<0.04) and learned non-
reward (F(2, 38) = 4.0, p<0.03) (Fig. 2A); the decrease in total errors across stages indicated that mice 
learned rule-switching (Nilsson et al., 2012; Tait and Brown, 2007). The total error scores at LNR3 
were used to counterbalance allocation of mice to NAcc 6-OHDA and Veh groups. At the post-DA 
depletion simple discrimination stage (SD4), there was no effect of NAcc DA depletion on any 
measure, e.g. total errors (p=0.37, Fig. 2B). In contrast, NAcc DA depletion did impair learned non-
reward behaviour at LNR4 (Fig. 2B), in the form of increased omissions to initiate a trial (t(9.5) = -2.3, 
p<0.05), increased incorrect choice responses (t(17) = -3.2, p<0.005) and increased total errors (t(12.3) = 
-2.8, p<0.02). There was no effect on omissions to make a choice response (p<0.2) or correct choice 
responses (p<0.6). 
 In the mPFC experiment, as for the NAcc, performance improved across successive stages, 
e.g. total errors decreased across stages of simple discrimination (F(2, 29) = 17.8, p<0.0005) and 
learned non-reward (F(2, 29) = 6.9, p<0.01). At the post-DA depletion simple discrimination stage (SD4) 
there was no effect on any measure, e.g. total errors: Veh 16.7 ± 25.5, 6-OHDA 17.8 ± 18.1 (p=0.90). 
In contrast to the NAcc experiment, there was also no effect of mPFC DA depletion on learned non-
reward behaviour at LNR4, e.g. total errors: Veh 69.6 ± 43.6, 6-OHDA 89.7 ± 59.7 (p=0.34). 
    
 
Figure 2. Effects of NAcc DA decrease (Veh, 2 µg 6-OHDA) on behavioural measures in the spatial discrimination 
(SD) and learned non-reward (LNR) stages of the LNR test. A) Pre-lesion training: mean+SD scores for total 
errors in stages SD1-3 and stages LNR1-3 prior to NAcc 6-OHDA lesion; mice were allocated to Veh and 6-OHDA 
groups by counter-balancing on LNR3 total-error scores. For both SD and LNR there was a stage effect in 1-way 
ANOVA and * indicates p<0.05 for stage 3 vs Stage 1 in post hoc Bonferroni tests. B) Post-NAcc 6-OHDA lesion 
testing: mean+SD scores in SD4 and LNR4 tests for omissions to initiate a trial (OIT), incorrect choice responses 
(IR) and total errors (TE). In the LNR test specifically there was an effect of NAcc DA depletion in t-tests, * 
p<0.05, ** p<0.01. 
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Learned helplessness (LH) test 
 The LH test was used to investigate effects of NAcc or mPFC DA depletion on learning, 
motivation and emotion in mice exposed to inescapable and subsequently escapable footshock 
stimuli. A habituation session, three inescapable footshock pre-exposure sessions, and an escape 
test, were conducted on consecutive days. In the NAcc experiment, in the habituation session, DA 
depletion led to a decrease in locomotor activity (t(25) = 3.7, p<0.001, Fig. 3A) and an increase in % 
time freezing (Veh: 3.2  1.5 %, 6-OHDA 6.3  2.5 %, t(25) = -3.8, p<0.001). Mice were then exposed to 
three daily sessions of inescapable footshock. During the final session, there was no effect of DA 
depletion on locomotor activity (Veh: 4617  1148 a.u./min, 6-OHDA 3717  1291 a.u./min, p=0.08), 
but DA depleted mice did exhibit increased mean % time freezing relative to Veh mice (Veh: 10.8  
5.3 %, 6-OHDA 18.7  12.0 %, t(25) = 3.4, p<0.03). In the Escape test conducted on the following day, 
there was no effect of DA depletion on locomotor activity (p=0.46, Fig. 3B), or % time freezing (Veh: 
11.8  5.3 %, 6-OHDA 13.6  7.9 %, p=0.49). Dopamine depletion resulted in increased mean latency 
to escape (t(17.8) = -2.1, p<0.05, Fig. 3C) and increased failure to escape (t(25) = -2.2, p<0.05, Fig. 3D). 
Escape failures were also analysed in blocks of 10 trials to investigate for DA-depletion learning 
effects: there was a main effect of group (F(1, 25) = 4.6, p<0.05) and also of trial block (F(1, 50) = 4.4, 
p<0.02); whilst both 6-OHDA and Veh mice exhibited increased escape responses in trials 21-30 
versus 1-10, indicating learning, the relative deficit in DA-depleted mice persisted (Fig. 3E). The 
escape deficit in DA-depleted mice co-occured with decreased footshock reactivity (t(23) = 2.5, p<0.05, 
Fig. 3F, one outlier per group was removed for analysis).  We further investigated the finding that 
locomotor activity was reduced by NAcc DA depletion in the habituation session (Fig. 3A). This might 
have indicated a motor impairment (albeit temporary) or, given that the arena was novel to the mice 
during this session, increased anxiety/decreased motivation to explore the novel environment. An 
additional experiment was conducted in which mice underwent a habituation session prior to 6-
OHDA NAcc lesion, and were then re-tested in the familiar environment. Under these conditions 
there was no effect of NAcc DA depletion on locomotor activity (p=0.17, Fig. S2) thereby supporting 
the interpretation of increased anxiety/decreased motivation to explore the novel arena.  
 In the mPFC experiment, there was no effect of DA depletion on locomotor activity in the 
habituation session (Veh: 8583  1442 a.u./min, 6-OHDA 8856  1924 a.u./min, p=0.70) or on % time 
freezing (Veh: 2.0  1.6 %, 6-OHDA 2.7  2.1 %, p=0.36). During the final session of inescapable 
footshock, there was again no effect on locomotor activity (Veh: 4636  945 a.u./min, 6-OHDA: 4249 
 1111 a.u./min, p=0.37) or % time freezing (Veh: 6.2  3.5 %, 6-OHDA: 9.2  5.7 %, p=0.13). Also in 
the Escape test, mPFC DA depletion was without behavioural effects:  locomotor activity (Veh: 5653 
 1170 a.u./min, 6-OHDA: 5736  1436 a.u./min, p=0.88); mean % time freezing (Veh: 5.9  3.5 %, 6-
OHDA: 6.8  3.7 %, p=0.57); escape failures (Veh: 9.5  7.8, 6-OHDA: 13.1  9.9, p=0.34); mean 
escape latency (Veh: 3.2  1.0 s, 6-OHDA: 3.5  1.1 s, p=0.48); footshock reactivity (Veh: 163  49 
a.u./s, 6-OHDA: 149  57 a.u./s, p=0.53).. 
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Figure 3. Effects of NAcc DA decrease (Veh (N=13), 2 µg 6-OHDA (N=14)) on behavioural measures in the 
learned helplessness (LH) paradigm. A) Locomotor activity in the habituation session on day 1. B) Locomotor 
activity during intervals between footshocks in the escape test on day 5. C) Mean escape latency to 30 
footshocks in day 5 escape test (maximum footshock = 5 s). D) Total escape failures in day 5 escape test. E) 
Escape failures per 10-trial block of escape test. F) Footshock reactivity in terms of mean distance/s in day 5 
escape test. In A-D and F, * p<0.05, *** p<0.001 in t-tests. In E, there were significant main effects of group and 
block in 2-way ANOVA; * p<0.05 for group, and letters indicate pairwise block effects in post hoc Bonferroni 
tests. In F), a indicates outlier values (according to Grubbs' test) that were excluded for the t-test. 
 
Treadmill test 
 The treadmill test was used to investigate effects of NAcc DA depletion on effortful 
avoidance of and escape from an aversive stimulus. Mice are first exposed to the apparatus when it 
is stationary and then at walking speed so that they can acquire operant avoidance and escape 
responses. The NAcc DA depleted and Veh mice that were studied in the treadmill test had been 
tested 2 days previously in the LH paradigm. In the treadmill training session, there was no effect of 
DA depletion on total footshock time (p=0.44, Fig. 4A). The next day, during the 5-min pre-test 
session at a treadmill speed of 20 cm/s, there was a borderline non-significant increase in total 
footshock time in DA depleted mice (Veh: 5.8 ± 8.4 s, 6-OHDA: 12.0 ± 8.3 s, p=0.06). In the treadmill 
test, conducted at a speed of 23 cm/s, the running time achieved was decreased in DA depleted 
compared to Veh mice (t(25) = 3.7, p<0.001, Fig. 4B). Ten out of 13 Veh mice achieved the maximum 
running time of 20 min without accumulating 10 s of footshock, whereas this was the case in only 1 
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of 14 6-OHDA mice. Accordingly, total footshock time was higher in DA depleted mice (t(21.4) = -4.1, 
p<0.001, Fig. 4C). 
     
 
Figure 4. Effects of NAcc DA decrease (Veh (N=13), 2 µg 6-OHDA (N=14)) on measures at the training and test 
session of the treadmill test. Mice were the same as those studied in the learned helplessness test. A) Total 
duration of footshock received during the treadmill training session. B) Running time achieved during the test 
session with maximum duration of 20-min (1200 sec). C) Total duration of footshock received during the test 
session, with maximum cumulative duration of 10 sec. *** p<0.001, **** p<0.0001 in t-tests. 
 
 
Pavlovian fear conditioning test 
 Auditory tone-footshock conditioning, measured as % time spent freezing, was used to 
investigate effects of NAcc DA depletion on aversive stimulus-stimulus learning. During the CS-US 
conditioning session, there was a main effect of CS trial-block on % time freezing (F(2, 34) = 23.9, 
p<0.0005, Fig. 5A), with acquired freezing increasing continuously across trials. There was no main or 
trial interaction effect of DA depletion (p=0.54, Fig. 5A). On the following day, consecutive expression 
tests were conducted for contextual and CS fear-freezing. There was no effect of NAcc DA depletion 
on % time freezing in either the context test (p=0.32; Fig. 5B) or the CS test (p=0.51, Fig. 5C). 
 
 
Figure 5. Effects of NAcc DA decrease (Veh. 2 µg 6-OHDA) on % time spent freezing (mean±SD) in the CS-US 
fear conditioning paradigm. A) Freezing acquisition during CS-US conditioning, B) Freezing expression to 
context, and C) Freezing expression to the CS. There were no significant effects of NAcc DA depletion. 
 
Hot plate test 
 Nucleus accumbens DA depletion resulted in reduced active behavioural responsiveness to 
footshock in the LH test and the treadmill test. One possible explanation for these effects is 
analgesia. To investigate this, in mice that had been studied in the NAcc LH + Treadmill experiment or 
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the NAcc fear conditioning experiment, the hot plate test was carried out to assess thermal pain 
sensitivity. There was no effect of DA depletion in either mice studied previously in the LH test + 
Treadmill test (response latency: Veh: 28.4  11.8 s, 6-OHDA: 26.6  10.5 s, p=0.68), or in mice 
studied in the fear conditioning test (Veh: 33.1  11.0 s, 6-OHDA: 27.5  3.8 s, p=0.12). Also in mPFC 
DA depleted mice that had been studied in the LH test, there was no effect of DA depletion (Veh: 
24.8  7.3 s, 6-OHDA: 22.8  9.6 s, p=0.25). 
Discussion 
The aims of the present study were to investigate the effects of 6-OHDA-induced DA depletion in the 
nucleus accumbens on reward and punishment processing in a mouse test battery, to thereby 
establish: (1) whether the effects of this manipulation as demonstrated comprehensively in rat also 
apply in mouse; and (2) to what extent accumbens-dopamine modulation of motivational processes, 
in particular, underlie deficiencies in both positive- and negative-stimulus processing. Bilateral DA 
and DA fibre depletion in the nucleus accumbens resulted in reduced responding for gustatory 
reward on a progressively effortful operant schedule, and reduced responding to a rewarded operant 
stimulus that was previously non-rewarded. Furthermore, it decreased two-way escape responding 
to an aversive stimulus experienced as uncontrollable, and decreased one-way active avoidance-
escape responding to an aversive stimulus that was controllable by effort. Whilst NAcc 6-OHDA 
injection also resulted in a moderate level of chronic mPFC DA depletion, direct mPFC DA depletion 
did not recapitulate the behavioural effects of NAcc DA depletion, as demonstrated for the LNR test 
and LH test. There were also no/only minor effects of 6-OHDA on DA levels in caudate putamen and 
amygdala. Owing to co-administration of drugs blocking their respective transporter proteins, neither 
serotonin nor noradrenaline were depleted by NAcc 6-OHDA lesion, indicating that the observed 
effects were consequent to DA depletion. mPFC 6-OHDA lesion did lead to moderately increased NA 
in mPFC and decreased NA and increased 5-HT in the NAcc, and these effects call for some caution in 
accepting the evidence for no effect of mPFC DA depletion.  
 
Accumbens DA deficiency impairs reward motivation under effortful or ambiguous conditions 
The progressive ratio schedule with gustatory reward has been applied previously to study 
effects of NAcc DA depletion in rat: reduced motivation was demonstrated specifically for high-effort 
PR schedules (Assadi et al., 2009; Hamill et al., 1999). To our knowledge the present study provides 
the first demonstration that, also in mice, NAcc DA depletion reduces motivation for gustatory 
reward under the high-effort conditions of a PR schedule. These effects were to some extent 6-OHDA 
dose-dependent, and the higher, more efficacious dose of 2 µg/hemisphere was the specific dose 
used in all other experiments. Mice were maintained at 100% baseline body weight (BW) for the PRS 
test, with the aim of maximising the palatable incentive value of sucrose pellets relative to their 
calorific value; rat studies have also conducted PRS testing at or close to baseline BW (e.g. (Hamill et 
al., 1999)). Given that mice received extensive operant training and three pre-depletion PRS sessions, 
there is little likelihood that the deficits in DA-depleted mice were due to impairment in task 
acquisition. Our findings support the hypothesis that NAcc DA modulates specific motivational 
processes underlying behaviour directed towards palatable reward (and probably also other reward 
categories), including behavioural activation, exertion of effort, appetitive behaviour, and sustained 
task engagement (Salamone and Correa, 2012). Sucrose (vs. water)-preference studies in rats 
demonstrate that NAcc DA depletion does not decrease reward wanting under non-effortful 
conditions (Berridge and Robinson, 1998). In human depression, patients do not differ from healthy 
controls in their reports of the intensity and pleasantness of sucrose (Dichter et al., 2010). However, 
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using monetary reward, depressed patients exhibit reduced motivation to expend effort to obtain 
reward (Treadway et al., 2012). 
 The learned non-reward test deployed here was first described for mice relatively recently 
(Nilsson et al., 2012); the absolute and relative (LNR versus SD stages) number of trials and errors to 
attain learning criteria, and rate of learning-set across stages, were similar in the present study to 
those in the original report (Nilsson et al., 2012). Two-choice spatial discrimination (SD) requires 
acquisition of CS-reward and CS-non-reward associations, and the elicitation of appetitive and 
avoidance behaviours, respectively, by these two associations. The LNR contingency change requires 
relearning that the CS-non-reward association is now a CS-reward association and concomitant 
overcoming of avoidance due to learned non-reward (LNR). Accumbens DA depletion was without 
effect on both omission and commission errors during SD, indicating that the CS-US acquisitions and 
appropriate appetitive and avoidance behaviours were intact. At the LNR stage, NAcc DA depleted 
mice exhibited increases in omission of trial initiation and commission of incorrect responses, each of 
which we interpret as indicating an increased state of LNR. That is, in the absence of normal NAcc DA 
levels, motivation - e.g. behavioural activation, effort, approach - relative to a CS-US reward with a 
recent history of non-reward was decreased. Mice received extensive operant training and three pre-
depletion SD+LNR sessions, so the high LNR errors in DA-depleted mice were not due to impairment 
of task acquisition. In a rat study with a reversal learning (rather than LNR) test, DA depletion in 
dorsal striatum impaired reversal (Fanous et al., 2007). Also in a rat reversal learning study, NAcc 
injection of D1R or D2R antagonist or D1R agonist were each without effect, and a D2R agonist 
impaired reversal learning (Haluk and Floresco, 2009). Excitotoxic lesion of the NAcc, particularly the 
core region, has been demonstrated to impair reversal between strategies and stimulus dimensions, 
as well as reversal between stimuli within a dimension; however, the use of excitotoxic lesion means 
that the observed effects cannot be unequivocally attributed to DA deficiency (Reading and Dunnett, 
1991). In the original mouse LNR study, systemic serotonin 2C receptor (5-HT2CR) antagonism 
decreased LNR errors specifically (Nilsson et al., 2012). Given that 5-HT2CR antagonism increases 
mesocorticolimbic DA function (Di Matteo et al., 2001), this performance-enhancement effect is 
relevant to the current findings that NAcc DA depletion leads to performance deficiency. 
 A major projection region of the NAcc, and one which is also important in reversal learning 
and other forms of behavioural flexibility, is the PFC (Clarke, 2004). In rat, the orbital PFC is important 
in simple reversal learning and the medial PFC in reversal learning between stimulus dimensions 
(Brown and Bowman, 2002). In the present study, mPFC DA depletion was without effect on either 
SD or LNR. Blockade of D1R or D2R in mPFC in rat reduced behavioural flexibility; it acted primarily by 
increasing perseveration (Floresco et al., 2006), which is not tested in the LNR paradigm. It is thus 
possible that in reversal learning tasks, mPFC contributes mainly to overcoming perseveration rather 
than to LNR (Allen and Leri, 2014; Hsiao et al., 2013). Furthermore, neurotransmitters other than DA, 
in particular serotonin, may modulate mPFC-dependent cognitive flexibility (Clarke, 2004; van der 
Plasse and Feenstra, 2008). 
 
Accumbens DA deficiency impairs aversion-control motivation under previously uncontrollable or 
effortful conditions 
We established the learned helplessness effect paradigm for mice in order to have an 
objective test for aversive un/controllability in this species (Pryce et al., 2012). Following repeated 
sessions of matched escapable footshock (ES) or inescapable footshock (IS), when both groups are 
tested under ES conditions, the IS mice exhibit more escape failures. This deficit in escape behaviour 
is underlain by decreased motor reactivity to the footshock, which we have interpreted as a 
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motivational deficit, particularly given that pain sensitivity remains intact (Pryce et al., 2012). In the 
present study we restricted the experiment to the IS condition, and demonstrated that NAcc DA 
depletion resulted in increased escape failure concomitant with increased escape latency and 
decreased motor reactivity to the aversive US. In rat, 6-OHDA injection in the striatum led to 
increased operant escape failure in subjects exposed to IS, and the same effect was obtained when 6-
OHDA was injected into the substantia nigra pars compacta (SNC) (Winter et al., 2007). Also in rat, in 
the absence of prior IS, 6-OHDA NAcc DA depletion decreased operant (lever press) escape-avoid 
behaviour; furthermore, in intact subjects, performing this operant behaviour led to increased NAcc 
DA release (McCullough et al., 1993). Rats exposed to IS and exhibiting a high level of 2-way escape 
failure were characterised by a decrease in the proportion of active DA neurons in the VTA (Belujon 
and Grace, 2015). Therefore, in addition to chronic NAcc DA depletion impairing motivational 
processes that mediate engagement with reward, as evidenced in PRS and LNR tests, the current 
mouse LH findings add to the evidence that depleted NAcc DA also impairs murine motivational and 
learning processes mediating disengagement from punishment (Wenzel et al., 2015). Indeed, 
deficient motivation has been proposed to be one of the three major mediators of the LH effect 
(Maier and Seligman, 1976; Pryce et al., 2011b), and the current evidence indicates that decreased 
NAcc DA underlies this state. The other proposed major mediators of the LH effect are increased 
emotional responding to aversive stimuli perceived as uncontrollable, and decreased cognitive 
expectancy that stimuli will be controllable (Maier and Seligman, 1976; Pryce et al., 2011a). The 
proportion of time spent freezing provides a measure of emotionality in the LH paradigm: freezing 
was increased in NAcc DA depleted mice relative to control mice during IS pre-exposure but not 
during the escape test; freezing is also not increased in IS relative to ES intact mice (Pryce et al., 
2012). By separating the escape test session into blocks of trials, we were able to analyse for learning 
effects on escape performance; both Veh and NAcc DA depleted mice exhibited reduced escape 
failures across the session, indicating that impaired operant learning did not underlie the deficit in 
the latter group. In rat, the mPFC has been demonstrated to be critical to the learning of 
un/controllability and is probably a region in which the cognitive expectancy of stimulus control is 
processed: thus, GABA-mediated (picrotoxin) disinhibition of mPFC resulted in increased escape 
behaviour in subjects exposed to IS (Amat et al., 2008). In the present study, there were no effects of 
mPFC DA depletion on behaviour of mice in the LH test, suggesting that DA does not modulate mPFC-
mediated cognitive expectancy aspects of the LH effect.  
The footshock treadmill test allows for the assessment of active avoidance-escape from an 
aversive stimulus under effortful conditions. NAcc DA depletion resulted in a marked decrease in 
running time. The majority of DA-depleted mice ran for only 1-2 minutes of the test session until 
receiving the maximum footshock amount. These data suggest that NAcc DA depletion decreased the 
absolute level of effort mice are able to/are motivated to exert to actively avoid-escape footshock. 
The findings complement the evidence from the LH test that NAcc DA depletion decreased 
motivation to escape footshock following IS. Whilst it is important to note that the treadmill 
experiment was conducted with the same mice that were studied in the LH test, the majority of 
vehicle mice showed typical treadmill behaviour, i.e. they completed the 20-min test, indicating the 
absence of a major confounding effect from the LH test. Previous studies have used the footshock 
treadmill test to assess various factors, including physical exercise (Massett, 2005) and inflammation 
(Carmichael et al., 2006). It has been proposed as a readout test for fatigability, a core symptom of 
depression (ICD-10, DSM-5). As noted above, the current findings suggest that NAcc DA depletion 
acts more to reduce absolute level of effort rather than cumulative effort to avoid-escape aversion. 
Given the complexity of the psychopathological construct of fatigue, both of these states could be 
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components of it in depression. Thus, fatigue is proposed to comprise muscular, motivational, motor, 
emotional and cognitive components (Demyttenaere et al., 2005; Kluger et al., 2013). It has been 
proposed that deficient DA-ergic modulation of striatal and cortical regions is an important 
pathophysiological factor for fatigue (Demyttenaere et al., 2005; Salamone et al., 2007). 
The third test in which effects of NAcc DA depletion on responsiveness to aversive stimuli 
were studied was Pavlovian fear conditioning. In contrast to the operant tests, there was no effect on 
each of CS-US acquisition, context expression and CS expression, as measured using freezing 
behaviour. In rat, evidence for whether exposure to inescapable CS-US elicits increased extracellular 
DA in the NAcc is equivocal, with different findings being accommodated by proposing NAcc sub-
region specificity (Levita et al., 2002b; Wilkinson et al., 1998). Excitotoxic lesioning of the rat NAcc 
core was without effect on CS-US acquisition or expression or on context-US acquisition, but did 
reduce context expression of conditioned fear (Levita et al., 2002a). Therefore, the previous rat and 
current mouse findings indicate that the NAcc is not a major contributor to the mesolimbic DA 
regulation of Pavlovian fear conditioning, with the amygdala being a more likely region of DA action 
(Pezze and Feldon, 2004; Wenzel et al., 2015). Thus, of the three tests that exposed mice to 
footshock, in the two tests where active operant behaviour resulted in negative reinforcement, NAcc 
DA depletion led to a deficit in this behaviour, and in the test where behaviour was without 
consequence, NAcc DA depletion was without behavioural effect. 
Conclusion and Outlook 
The present study provides novel evidence for mice that reduced DA levels in NAcc lead to 
reduced responding to: stimuli that predict reward under effortful conditions, stimuli that now 
predict reward but with recent association with non-reward, an aversive stimulus recently 
experienced as uncontrollable, an aversive stimulus under effortful conditions. The findings obtained 
with the current operant test battery extend rat findings for NAcc DA function to mouse, and also 
add to the overall understanding of the importance of NAcc DA as an important modulator of 
motivational processes - including behavioural activation, exertion of effort, sustained task 
engagement - elicited by both rewarding and aversive stimuli (Bromberg-Martin et al., 2010; 
Salamone and Correa, 2012; Wenzel et al., 2015). This study also adds to the evidence that 
motivational and motor functions of DA, classically attributed to the VTA-mesolimbic and SNC-
nigrostriatal pathways, respectively, are intimately inter-related and can both be affected by NAcc 
DA deficiency (Haber, 2014; Sesack and Grace, 2010). Our rationale for establishing the present 
mouse test battery was to enable the integrated study of motivational processing of rewarding and 
aversive stimuli. It can then be applied to investigate whether specific manipulations induce deficits 
in one or more of these processes that are relevant to motivational domains in psychopathology. The 
evidence that NAcc DA deficiency impairs reward motivation under effortful or ambiguous conditions 
suggests its relevance to the RDoC of Positive valence systems, the core symptom of loss of interest-
pleasure in depression and the core negative symptoms in schizophrenia. The evidence that the 
same manipulation impairs aversion-control motivation under previously uncontrollable or effortful 
conditions suggests its relevance to the state of helplessness and the core symptom of fatigue, in 
depression. That the battery enables detection of effects of a single manipulation on motivational 
processing of both reward and aversion indicates that it will facilitate the study and understanding of 
how reward and aversion processing are inter-related. We readily acknowledge that 6-OHDA DA 
depletion is a severe manipulation with little aetiological validity. Nonetheless, mouse environmental 
manipulations with aetiological validity, such as the chronic social defeat stressor, do indeed impact 
on DA signalling (Azzinnari et al., 2014; Chaudhury et al., 2013; Lammel et al., 2014; Tanaka et al., 
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2012), and also lead to impaired aversion-control motivation in the two-way avoid-escape and the 
treadmill test (Azzinnari et al., 2014) and impaired reward motivation in the PRS test and LNR test 
(Bergamini et al., in prep-b). Future studies can combine aetiologically valid genetic and 
environmental manipulations with the reward-aversion test battery presented here, to identify the 
pathophysiological processes underlying motivational deficits, discover novel treatment targets, and 
screen the preclinical therapeutic efficacy of compounds developed for these targets. 
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Supplementary information 
 
Learned non-reward (LNR) test: Stages of training and testing  
Operant behaviour training for the LNR test was based on that described by Nilsson et al.(Nilsson et 
al., 2012) 
Nosepoke training. Only the central stimulus nose-poke port was used. Each trial started with 
switching on the houselight and the LED in the stimulus nose-poke port. A nosepoke led to the 
stimulus port LED switching off and delivery of a sucrose pellet into the feeder port at the opposite 
wall. Collection of the pellet initiated a 5 s timeout. Maximum number of rewards was 40, and 
criterion was ≥ 30 rewards in each of two consecutive sessions. 
Trial training. The mouse had to nosepoke in the feeder port to start each trial, activating the 
houselight and the central stimulus port LED. A nosepoke in the stimulus port led to the stimulus port 
LED switching off and delivery of a sucrose pellet into the feeder port. A limited response time was 
introduced at two stages of each trial: there was a limited hold of 10 s for a feeder port nosepoke to 
initiate each trial; once the trial was initiated, there was a limited hold of 6 s for a nosepoke in the 
stimulus port. Omission of either response led to termination of the trial and onset of the next 5 s 
timeout. To meet criterion, mice had to complete ≥ 49 correct nosepokes over a total of 70 trials. 
After attaining criterion on one session, two further sessions were given, one for the left and one for 
the right stimulus ports, with order counterbalanced across subjects.  
Spatial discrimination (SD).  The left and right stimulus ports were available in the testing apparatus 
and the central stimulus port was replaced by a blank panel. The correct stimulus port was the 
opposite to that which was used for the last session of trial training. A response in the correct 
stimulus port (correct choice responses, CR) led to switching off the LED in both stimulus ports, pellet 
delivery in the feeder port and onset of the 5 s timeout after pellet collection. A response in the 
incorrect stimulus port (incorrect choice response, IR) led to onset of the 5 s timeout. Failure to 
either self-initiate a trial within 10 s (omissions to initiate a trial, OIT) or to nosepoke in either of the 
two stimulus ports within 6 s (omissions to make a choice response, OR), led to termination of the 
trial and immediate onset of the timeout. Therefore, for each trial, the mouse response was either 
correct (CR), incorrect (IR) or an omission (OIT, OR). Each SD session comprised seven blocks of 10 
trials each. The session criterion for SD learning was nine correct responses in any 10-trial block. 
Learned non-reward (LNR). The incorrect stimulus port at SD was now correct, the correct stimulus 
port at SD was replaced by a black panel and a third stimulus port, not available during SD, became 
the incorrect stimulus port. Otherwise, conditions were as for SD.  
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Table S1. Effects of NAcc or mPFC 6-OHDA infusion on tissue serotonin in brain regions of interest 
     
Serotonin (ng/mg tissue) 
     
            NAcc CPu mPFC Amygdala 
Target region Behavioural test     Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA 
NAcc 
 
Progressive ratio schedule X 0.58 0.76 0.17 0.18 0.37 0.33     
  
(N=8 Veh, 8 6-OHDA) SD 0.25 0.31 0.08 0.08 0.32 0.23     
      
                
NAcc 
 
Learned non-reward X 0.56 0.57 0.29 0.35 0.09 0.05     
  
(N=10, 9) SD 0.22 0.13 0.09 0.17 0.05 0.02     
      
                
NAcc 
 
Learned helplessness & X 1.00 0.95 0.87 1.30 0.30 0.54 1.39 1.60 
  
Treadmill (N=13, 14) 
 
SD 0.39 0.27 0.45 1.92 0.11 0.38 0.24 0.60 
      
                
NAcc 
 
Fear conditioned freezing X 0.85 0.94 0.23 0.27 0.47 0.42 1.23 1.14 
  
(N=11, 11) 
  
SD 0.24 0.25 0.06 0.07 0.10 0.09 0.36 0.23 
      
                
mPFC 
 
Learned non-reward X 0.77 0.90 0.27 0.34 0.39 0.40     
  
(N=13, 12) 
  
SD 0.22 0.33 0.10 0.10 0.09 0.14     
      
                
mPFC 
 
Learned helplessness X 0.77 1.14 0.27 0.28 0.18 0.17 1.29 1.15 
  
(N=12, 12) 
  
SD 0.20 0.34 0.07 0.11 0.14 0.07 0.34 0.19 
                            
6-OHDA dose was 2 µg per hemisphere for NAcc and 1.5 µg per hemisphere for mPFC.  
Scores are mean  SD.  
a p<0.05, b p<0.01. 
 
Table S2. Effects of targeted 6-OHDA infusion on tissue noradrenaline in brain regions of interest 
  
Noradrenaline (pg/mg tissue) 
  
    
 
NAcc CPu mPFC Amygdala 
Target region  Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA Veh 6-OHDA 
NAcc 
 
X 13.22 15.65 2.60 3.58 15.81 11.53 20.19 18.23 
(N=5 Veh, 9 6-OHDA) SD 10.29 9.75 0.68 1.68 4.45 5.51 8.02 5.68 
   
                
mPFC 
 
X 6.96 4.65 4.72 5.34 8.73 19.63 15.77 15.88 
(N=5, 8) SD 2.22 0.87 1.11 1.52 2.48 4.77 8.20 6.41 
                      
6-OHDA dose was 2 µg per hemisphere for NAcc and 1.5 µg per hemisphere for mPFC.  
Scores are mean  SD. 
a p<0.05, b p<0.001. 
 
a 
b 
a b 
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Figure S1. Effect of NAcc DA decrease (Veh, 2 µg 6-OHDA) on post-surgery body weight expressed as 
a percentage of pre-surgery baseline (= 100%). Scores are % mean +/- SD scores. In 2-way ANOVA 
there was a group x day interaction, and a p<0.05, b p<0.001 for day-specific 6-OHDA vs Veh effects 
in post hoc Bonferroni tests. 
 
   Figure S2 
 
Figure S2. Lack of effect of NAcc DA decrease (Veh, 2 µg 6-OHDA) on post-surgery locomotion in a 
familiar arena. Day 0: locomotor activity was measured in a novel arena (same as that used for the 
learned helplessness test). Twelve days after 6-OHDA NAcc lesion or NAcc Veh, mice were re-tested 
for locomotor activity in the same arena, on two consecutive days (Day 1 and 2). Scores are mean +/- 
SD. 
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Figure S3 
 
 
Figure S3. Immunohistochemical staining for tyrosine hydroxylase to delineate the extent of the 
depletion of dopaminergic fibres following (A) Vehicle or (B) 6-OHDA injection in the nucleus 
accumbens. Brains were perfused at day 12 post-injection. Coronal images of mouse striata showing 
loss of TH+ fibers in the NAcc core and shell following injection of 6-OHDA. 
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Abstract 
Stressful life events are risk factors for depression. Stress induces, and depression is associated with, 
immune activation. Core depression symptoms, most notably decreased motivation, are proposed to 
stem from dopamine (DA) dysfunction. Whilst it is proposed that DA dysfunction can result from 
immune activation, the evidence for this is currently sparse. We have previously shown that 
exposure of mice to a chronic uncontrollable psychosocial stressor, chronic social defeat (CSD), 
increases fear conditioning, helplessness and fatigue, and induces peripheral immune activation. The 
aims of the present study were to investigate CSD effects on: (1) Immune function in periphery and 
brain at cellular and molecular levels, including the mesolimbic DA pathway. (2) Mesolimbic DA 
pathway function. (3) Reward-directed behaviour using operant tasks. Relative to controls, CSD mice 
exhibited increased spleen levels of granulocytes (CD11b+/SSChi/Ly6Cint), inflammatory monocytes 
(CD11b+/SSClo/Ly6Chi) and T helper 17 cells (CD4+/IL-17A+), increased plasma levels of iNOS, and 
increased liver expression levels of genes for kynurenine-pathway enzymes. In the ventral tegmental 
area, microglia activation (Iba1, Cd11b) was increased, and in nucleus accumbens (NAcc), dopamine 
turnover (DOPAC/DA) was decreased. When challenged with a DA reuptake inhibitor, CSD mice 
exhibited both attenuated hyper-locomotion and NAcc c-Fos activation. In operant tests with 
sucrose-pellet reinforcement, CSD mice exhibited decreased motivation under effortful conditions. 
This study provides some of the most robust evidence to-date in support of the hypothesis that 
stress-induced peripheral and brain inflammation co-occur with attenuated mesolimbic DA function 
including decreased interest in reward. 
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Introduction 
Major depressive disorder (MDD, hereon referred to as depression) is common and complex with 
respect to symptoms and aetio-pathophysiology (Nabeshima and Kim, 2013). Depression-related 
psychopathology includes marked deficits in reward-related behavioural domains (Russo and Nestler, 
2013). Indeed, in depressed patients, there is evidence for reduced appetitive motivation (Sherdell et 
al., 2012) and reward learning (Pizzagalli et al., 2005).  Moreover, reward-related deficits have been 
associated with reduced activation of striatal regions (Pizzagalli, 2014; Pizzagalli et al., 2009). It has 
been hypothesized that dysfunction of the mesolimbic DA system is a major pathophysiology 
underlying reduced interest in reward in depression (Dunlop and Nemeroff, 2007; Pizzagalli, 2014).  
Stressful life events are key proximal risk factors for depression (Kendler et al., 1999; Slavich 
et al., 2009). Psychosocial stressors that are uncontrollable, including interpersonal loss (e.g. of 
status), defeat and submission are particularly depressogenic (Gilbert, 1992; Kendler et al., 2003). 
Pre-clinical studies in rodents have investigated various stressors (Krishnan and Nestler, 2011), 
including social stress (Azzinnari et al., 2014; Krishnan et al., 2007). In chronic social defeat (CSD), 
mice are exposed continuously to aggressive dominant mice including short daily attack. Their 
submissive behaviour is ineffective in controlling attacks by a different aggressor mouse each day 
(Azzinnari et al., 2014; Kudryavtseva et al., 1991), such that CSD mice experience chronic exposure to 
uncontrollable social stressors. Mouse CSD induces a number of depression-relevant behaviours, 
including decreased sucrose preference and social interaction (Covington et al., 2009), and increased 
fear acquisition, helplessness and fatigue (Azzinnari et al., 2014). 
Clinical and preclinical studies have demonstrated stressor reactivity of the immune system. 
(Slavich and Irwin, 2014). In humans, psychosocial stress activates the sympathetic nervous system 
(SNS), and release of epinephrine and norepinephrine and binding by adrenergic receptors on 
immune cells promotes an inflammatory cascade (Bierhaus et al., 2003). Positive correlation 
between chronic social stressors and levels of C-reactive protein, interleukin (IL)-6 (Gruenewald et 
al., 2009) and soluble receptor for tumor necrosis factor-α, have been reported (Chiang et al., 2012). 
In mice, repeated social defeat induces brain trafficking of myeloid cells and microglial activation 
(Wohleb et al., 2011; Wohleb et al., 2013). In CSD mice, splenomegaly and increased plasma levels of 
the pro-inflammatory cytokines TNF-α and IL-6 have been reported (Azzinnari et al., 2014).   
There is growing interest in the hypothesis that stress-induced immune-inflammation 
contributes to depression pathophysiology (Beumer et al., 2012). Activation of the immune system in 
depression is certainly well-documented (Maes, 2011). Depressed patients show higher blood levels 
of the inflammatory markers CRP, IL-6, IL-1 and TNF-α (Muller, 2014). In brain, the 
neuroinflammatory marker translocator protein (TSPO) was increased in the anterior cingulate cortex 
(ACC) and correlated with depression severity (Setiawan et al., 2015).  Normalization of inflammatory 
markers after successful antidepressant treatment has been described (Hannestad et al., 2011a), as 
has treatment resistance in patients with increased inflammatory markers at treatment onset 
(O'Brien et al., 2007). One consequence of increased pro-inflammatory cytokine levels is the 
upregulation of the tryptophan enzyme indoleamine 2,3 dioxygenase (IDO) in macrophages, and 
synthesis of kynurenine pathway metabolites  (Campbell et al., 2014; Schwarcz et al., 2012). These 
include 3-hydroxykynurenine (3-HK), a free radical generator that promotes oxidative stress 
(Schwarcz et al., 2012), and the glutamate receptor agonist and neurotoxin quinolinic acid (QA) 
(Dantzer and Walker, 2014). There is evidence for activation of the kynurenine pathway in 
depression (Savitz et al., 2015b; Steiner et al., 2011). Furthermore, it has been proposed that 
kynurenine pathway over-activity can impact on DAergic function (Felger and Miller, 2012; Felger et 
al., 2013; Miller et al., 2013). Indeed, experimental stimulation of the immune system in healthy 
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humans induces reduced reward interest, fatigue, and psychomotor retardation, consistent with 
impaired DA function (Felger and Miller, 2012). Rodent studies have demonstrated the importance of 
the dopamine neurons located in the ventral tegmental area (VTA) and projecting to the nucleus 
accumbens (NAcc) in the modulation of reward learning and motivation (Russo and Nestler, 2013). 
Using neurotoxin to specifically deplete DA projections to the NAcc, we have demonstrated that 
decreased NAcc DA levels attenuate motivation for gustatory reward in a simple but effortful operant 
test and in a learned non-reward test requiring cognitive flexibility (Bergamini et al., Submitted 
manuscript).  
Against the above background, the overall aim of the present study was to apply the mouse 
CSD stressor to investigate for co-occurrence of: (1) activated immune-inflammatory responses in the 
periphery and brain, with a focus on VTA and NAcc in the latter. (2) Reduced DA function in the VTA-
NAcc pathway, including pharmacological challenge. (3) Reduced operant responding for 
reinforcement in tests that are sensitive to NAcc DA status. Demonstration that a psychosocial 
stressor impacts on the VTA-NAcc DA pathway at immune, neurobiological and behavioural levels 
would constitute some of the most robust evidence to date for the psycho-neuro-immune 
hypothesis of depression. 
Materials and methods 
Animals 
Breeding of C57BL/6J mice was conducted in-house. Male offspring were weaned at age 3 weeks and 
caged in groups of 2-3 littermates. Mice were aged 10-13 weeks and weighed 24.0-30.0 g at study 
onset. Male CD-1 mice (Janvier, Saint-Berthevin, France) were aged 8 months, were ex-breeders, and 
caged singly at study onset. Mice were maintained on a reversed 12:12 h light-dark cycle (lights off 
07:00-19:00 h) in an individually-ventilated caging system at 21-22°C and 50-60% humidity. 
Complete-pellet diet (Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water were available ad 
libitum, unless stated otherwise below for operant training and testing. In the week prior to CSD, all 
C57BL/6J mice were handled and weighed on five days. All procedures were conducted under a 
permit for animal experimentation (No. 170/2012) issued by the Veterinary Office, Zurich, 
Switzerland, in accordance with the Animal Protection Act (1978) Switzerland. 
Chronic social defeat 
Three days prior to onset of 15-day chronic social defeat (CSD), mice were tested in terms of 
locomotion in a 15-min activity test, and activity scores were used to counter-balance the allocation 
of mice to CSD and control (CON) groups. This, and the CSD procedure, was conducted as described 
previously (Azzinnari et al., 2014). Briefly, social defeat sessions were conducted under dim light on 
15 consecutive days. Cages contained a divider made from transparent Plexiglas and perforated with 
multiple holes for sensory interactions. On day 1, each CSD C57BL/6J mouse was removed from its 
home cage and placed in the home cage of a CD-1 mouse. Mice remained together until either a 
cumulative total of 60-s physical attack had occurred or 10 min had elapsed. The CSD mouse 
remained in the compartment in which it had been attacked and the CD-1 mouse was placed in the 
opposite compartment, allowing continuous olfactory, visual and auditory contact during the 
following 24 h. On day 2, the CSD mice x CD-1 mice pairings were rotated so that each CSD mouse 
was placed in the home cage of and confronted with a novel CD-1 mouse, and vice versa. To prevent 
bite wounds - an essential aspect of the method given that a major aim of the study was to 
investigate psychosocial stress-induced inflammation - the lower incisors of CD-1 mice were trimmed 
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at 3-day intervals using a rodent tooth-cutting forceps under brief isoflurane anaesthesia across CSD. 
Control (CON) mice remained in littermate pairs and were handled and weighed daily.  
Experimental design 
Eight separate experiments were conducted with the overall and integrative aim of studying the 
effects of CSD on peripheral and central inflammation, DA structure-function, and reward-directed 
behaviour (Figure 1). In the first experiment, CSD effects on spleen and whole brain immune-cell 
status at day 16 were assessed using flow cytometry. In the second experiment, day 16 liver levels of 
genes encoding enzymes important in the kynurenine pathway were measured using RT-PCR, and 
plasma levels of iNOS were measured by ELISA. Third, brains were perfused for 
immunohistochemistry of the microglia marker Iba1 in VTA and additional brain regions, at day 16. 
Fourth, gene expression of the microglia marker Cd11b and of genes central to DA synthesis and 
transport were measured in VTA tissue punches using RT-PCR. Fifth, the tissue level of DA and its 
major metabolite were measured in NAcc using HPLC-ED. In the sixth experiment, CSD effects on 
responsiveness to a DA reuptake inhibitor in terms of an activity-test (day 16) and home-cage activity 
(day 16-17) and NAcc immediate-early gene expression (day 17), were investigated. In the seventh 
experiment, mice were first given baseline testing in a two-bottle saccharin versus water test and 
then the effects of CSD were tested at day 16. In the final experiment, mice were first trained in an 
operant apparatus with sucrose-pellet reinforcement, exposed to CSD or CON, and then CSD effects 
were assessed on reward motivation at day 8 and on behaviour in a learned non-reward task at days 
16-29. 
 
 
Figure 1. Experimental designs. Eight experiments were conducted with mice exposed to chronic social defeat 
(CSD) or control handling (CON) on days 1-15. Mice were handled prior to experiments and body weights were 
measured daily. Experiment 1: brain and spleen samples (S) were collected on day 16. Immune cells were 
analysed using flow cytometry. Experiment 2: plasma liver samples were collected on day 16 for assessment of 
gene expression of kynurenine pathway (KP) enzymes. Experiment 3: brains were perfused on day 16 and 
processed for immunohistochemical analysis of Iba1 expression in several brain regions of interest (ROIs). 
Experiment 5: on day 16 brains were collected and NAcc punches were dissected for HPLC analysis of DA and 
metabolites. Experiments 6: on day 16 mice were injected with the DA reuptake inhibitor GBR 12909 or VEH, 
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and their locomotor activity (LA) was monitored for 2 hours. Afterwards, mice activity was monitored in the 
home cage (HC). On day 17 mice were injected with GBR 12909 or VEH and their brains were collected for qPCR 
analysis of immediate-early genes (IEGs). Experiment 7: saccharin preference test (SPT) was performed on day 
16. Experiments 8: an operant test on a fixed ratio 1 (FR1) schedule for sucrose reward was conducted on day 8 
and a learned non-reward (LNR) test was conducted on days 16 to 29. 
 
 
Isolation of splenocytes and brain mononuclear cells and flow cytometry 
For isolation of splenocytes, the spleen was minced in Roswell Park Memorial Institute (RPMI) 
medium (5% fetal calf serum) and digested for 20 min at RT in Hanks’ balanced salt solution (HBSS) 
containing 50 µg/ml DNase I and 100 µg/ml Collagenase/Dispase (Roche). The digestion was passed 
through a 100 µl nylon mesh (BD Biosciences), followed by lysis of erythrocytes in Ammonium-
Chloride-Potassium (ACK) buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2). After a final 
resuspension in HBSS, cells were counted and 5 x 106 were used for antibody staining. Mononuclear 
cells (MNCs) from entire brain were isolated as described previously (Moransard et al., 2010; Suter et 
al., 2003). Briefly, mice were perfused transcardially with HBSS, the brain dissected out, chopped 
with a scalpel, and digested for 30 min at 37°C in HBSS containing 50 µg/ml DNase I and 100 µg/ml 
Collagenase/Dispase. The digestion was passed through a 100 µl nylon mesh and re-suspended in 
30% Percoll (Sigma). The gradient was centrifuged at 29,000 g for 30 min at 4°C. The interphase 
containing mononuclear cells was collected and washed with HBSS. For both spleen and brain cells, 
each sample was divided into two halves. One was used for extracellular staining and the other for 
extracellular+intracellular staining. Intracellular staining of cytokines was performed after a 4 h 
incubation with phorbol 12-myristate 13-acetate (PMA, 50 ng/ml) and Ionomycin (500 ng/ml) 
(Sigma), to allow accumulation of cytokines within cells. 
 For flow cytometry of splenocytes and brain MNCs, cells were re-suspended in FACS buffer 
comprising 2% FCS, 5 mM EDTA and 0.01% NaN3 in PBS. Fc receptors were blocked by incubation 
with anti-mouse CD16/32 (Fc-block, BD Pharmingen). The LIVE/DEAD® Fixable Aqua Dead Cell Stain 
Kit (Molecular Probes) was used to exclude non-viable cells. For extracellular staining, the antibodies 
used were: PE-Cy5.5 CD45 (BD Pharmingen), PE-Cy7 CD11b (BD Pharmingen), FITC Ly6c (BioLegend) 
and PE MHC II (BD Pharmingen). For extra- and intracellular staining, the antibodies used were: PE-
Cy5.5 CD45 (BD Pharmingen), PE-Cy7 CD11b (BD Pharmingen), APC-Cy7 CD4 (BD Pharmingen), PE-
Cy5 Foxp3 (eBioscience), PE IL-17A (BD Pharmingen), Alexa 700 CD8 (eBioscience), APC Ki67 (BD 
Pharmingen), FITC TNF (BD Pharmingen) and eF450 IFNγ (eBioscience). To assess the activation 
status of immune cells the proinflammatory cytokines TNF and IFNγ and the major histocompatibility 
complex (MHC) class II were used. Cell proliferation was assessed using the marker Ki-67. For brain 
MNCs, absolute cell counts were achieved using fluorescent Counting Beads (Molecular probes).  
Expression levels of proteins were estimated using the geometric mean of fluorescence intensity 
(MFI). Flow cytometry was conducted with a LSR II Fortessa (BD Biosciences). FlowJo software (Tree 
Star Inc.) was used for flow cytometry data analysis. 
 
Plasma iNOS ELISA 
Mice were decapitated and trunk blood was collected in EDTA-coated tubes (Microvette 500 K3E, 
Sarstedt) and placed on ice. Tubes were centrifuged at 3000 rpm for 15 min at 4°C and plasma 
aliquots were transferred to cryotubes (Protein LoBind tubes, Eppendorf) and stored at -80°C. Plasma 
iNOS was measured in duplicate using a commercial ELISA kit according to the manufacturer’s 
instructions (Mouse Inducible nitric oxide synthase ELISA Kit, MyBioSource). 
 
60 
 
Real time PCR assays  
Mice were decapitated and brain, spleen and liver, depending on experiment, were dissected out 
and frozen on dry-ice. Frozen brains were sectioned coronally at 1.0 mm intervals using a stainless-
steel brain matrix, and regions of interest, identified with reference to a mouse brain atlas (Franklin 
and Paxinos, 2008), were micro-dissected bilaterally using a brain punch ( = 1.0 mm)  (Azzinnari et 
al., 2014). Brain punches were placed in 350 µl of lysis RLT buffer (Qiagen) (containing 1% β-
mercaptoethanol) and homogenized using a tissue lyser (Mixer-Mill 300, Qiagen) with stainless steel 
beads ( = 5 mm, Retsch). Total RNA was isolated using the RNeasy Plus Micro Kit (Qiagen). For 
spleen and liver, total RNA was isolated using Trizol (Ambion) according to the manufacturer`s 
instructions, and further digested with DNase I (Fermentas). The list of genes of interest and the 
respective primers used are given in Table S1. RNA was reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative gene expression analysis was 
performed using SYBR green (Applied Biosystems) and a 7900HT Fast Real-Time PCR System (Applied 
Biosystems). PRC cycle conditions were: 2 min at 50°C, 2 min at 95°C; 40 cycles: 15 s at 95°C, 30 s at 
60°C, 30 s at 72°C. A melting curve was run for each PCR plate. Threshold cycle (Ct) values of the 
target gene were normalized to the Ct values of the corresponding reference gene, using the ΔΔCt 
method described by (Pfaffl et al., 2002). For brain and spleen, Actb was used as the reference gene, 
and for liver the geometric mean of Ct values for Hprt1 and Tbp was used as normalization factor 
(NF). Relative expression values were log2-transformed for statistical analysis. 
HPLC-ED of NAcc tissue dopamine 
Mice were decapitated and the brain dissected out, frozen on powdered dry-ice and stored at -80°C. 
Frozen brains were sectioned coronally at 1.0 mm intervals and the NAcc was micro-dissected 
bilaterally using a brain punch ( = 1 mm) (see previous section for details). The two punches were 
weighed and homogenized together, using 250 µl ice-cooled perchloric acid (0.4 M). Ultra-sonication 
was conducted for 5 s at 30% power (VibraCell, VCX130PB, Sonics and Materials, Inc., Newtown CT, 
USA), followed by centrifugation at 16,000 g for 10 min at 4°C. The supernatant was passed through 
a 0.22 µm filter (Minisart RC4, Sartorius AG, Göttingen, Germany) and kept on ice until analysis. High 
performamce liquid chromatography (HPLC) and electrochemical detection (ED) were conducted for 
DA and its major metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 
according to (Oeckl et al., 2012). Briefly, isocratic separation of DA was carried out with a reversed-
phase C18 column (YMC-Pack ODS-AQ, 100×2.1 mm, S-3 μm, YMC Europe GmbH, Dinslaken, 
Germany). The mobile phase consisted of 1.7 mM 1-octanesulfonic acid sodium salt, 1.0 mM 
Na2EDTA × 2H2O, 8.0 mM NaCl, 100 mM NaH2PO4 × 2H2O (pH 3.80), mixed with 9.3% acetonitrile, and 
was delivered at a flow rate of 0.4 ml/min. For ED an electrochemical cell with a glassy carbon 
electrode and an ISAAC Ag/AgCl reference electrode (VT-03, Antec, Zoeterwoude, Netherlands) was 
used. Homogenates (20 µl) were injected onto the HPLC system using an autosampler (ASI-100T). 
Dopamine, DOPAC and HVA concentrations were calculated using an external standard calibration 
and expressed as ng/mg brain tissue. 
 
Iba1 immunohistochemistry 
Mice were deeply anesthetized with pentobarbital and perfused transcardially with phosphate-
buffered saline (PBS, pH 7.4) and fixative (4% paraformaldehyde (PFA) in PBS). Brains were dissected 
out, post-fixed over-night in 4% PFA and cryoprotected in 30% sucrose for 48h, frozen on powdered 
dry ice and stored at -80°C until sectioning. Brains were sectioned coronally at 40 µm using a 
microtome (Zeiss), with sections collected in antifreeze solution (15% glucose and 30% ethylene 
61 
 
glycol in 50 mM phosphate buffer, pH 7.4) and stored at -20°C. Free-floating sections were washed 
with PBS, quenched with 3% H2O2 for 15 min, blocked with 2% normal serum and incubated o/n at 
4°C with a rabbit anti-Iba1 antibody (1:1000; Wako Chemicals) followed by a 2 h RT incubation with a 
biotinylated goat anti-rabbit secondary antibody (1:500; Millipore). Sections were then incubated 
with 1% avidin-biotin peroxidase complex (Vectastain ABC kit, Vector) for 30 min at RT. Labeling was 
visualized by using diaminobenzidine (DAB) solution. The brain regions of interest (ROIs) were VTA, 
NAcc, amygdala and medial prefrontal cortex. Sections including these regions, 3-6 per mouse, were 
identified with the aid of a mouse brain atlas (Franklin and Paxinos, 2008). Images were acquired 
using a brightfield microscope (Axiovert, Zeiss). Digital image analysis (DIA) of Iba1 staining was 
performed blind with respect to mouse identity using the software ImageJ (NIH): the threshold for 
positive staining was determined and used to calculate the percentage of the area of each image that 
was Iba1-immunoreactive (IR) (Wohleb et al., 2011). 
 
Behavioural tests 
Baseline activity testing and effects of GBR 12909  
In each experiment, at 3 days prior to onset of CSD/CON, a 15-min activity test in a novel arena was 
conducted and total locomotor distance was used to allocate mice to CSD and CON groups in a 
counter-balanced manner. An automated test apparatus was used (Multi Conditioning System, TSE 
Systems GmbH, Bad-Homburg, Germany (Pryce et al., 2012)).  
 In the DA pharmacological challenge experiment, on day 16, CSD and CON mice were 
injected intra-peritoneally (i.p.) with either the dopamine transporter (DAT) inhibitor GBR 12909 
dihydrochloride (Sigma-Aldrich) at 6mg/10ml/kg in physiological saline vehicle or with vehicle only. 
After return to the home cage for 30 min, mice were placed into the same arena as used for baseline 
activity testing but now containing a central divider with an opening (“gate”) via which mice could 
transfer from one side of the arena to the other, to stimulate activity/exploration, for 2 h. The main 
measure of interest was total locomotor activity (arbitrary units) per 2 h. Mice were then returned to 
their home cage and activity was monitored continuously for 24 h using a passive infrared sensor 
located above the cage (MP Motion Sensor AMN12112, Panasonic) and connected to a RedLab 
recoding unit (1024HLS, Meilhaus Electronic). For this purpose, CON pairs were separated from each 
other using the same type of divider used to separate CSD from CD1 mice; they were habituated to 
the divider for 2 h per day on two days prior to this home cage activity measurement. On day 17, 
after completion of the home-cage activity monitoring, mice were injected with a second i.p. dose of 
GBR 12909 or vehicle and after 30 min were decapitated and the brains processed for NAcc RNA 
extraction (see Real time PCR assays). 
 
Two-bottle saccharin test 
For this experiment, mice were habituated to drinking from 15 ml screw-top polypropylene tubes 
from which the tip had been removed. Two such tubes were attached adjacently to the cage lid each 
day at 08:00 h and removed at 16:00 h. Amount drunk per tube in ml was calculated based on 
weight. On days 12 to 8 prior to onset of CSD/CON, the pairs of mice were presented with one tube 
containing water and one tube containing 0.15% (W/V) saccharin (as sodium salt hydrate, Sigma) 
solution, with the left-right positioning of the two tubes alternated across days (Cathomas et al., 
2015). On the final day of baseline measurements, average saccharin consumption per mouse was 
5.4  1.4 g, average water consumption was 0.15  0.10 g, and average saccharin preference was 
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98.7  0.5% (meanSD). The effects of CSD on saccharin and water drinking and saccharin preference 
were tested in a single test at day 16. 
  
Operant reward tests 
Operant apparatus 
Operant training and testing were conducted using operant boxes (TSE Systems GmbH, Bad 
Homburg, Germany) details of which are given elsewhere (Ineichen et al., 2012). Briefly, nose-poke 
ports detected mouse nose poke responses via an infra-red beam, and port position and number 
changed according to the test (see below). Sucrose pellets (14 mg, Dustless Precision Pellets, TSE 
Systems GmbH) were delivered singly into the feeder port, signalled by a tone from a speaker. Pellet 
retrieval was detected via infra-red beam. 
Feeding protocols 
Mice had ad libitum access to food until age 11 weeks. At age 11 weeks, for 5 days, daily body weight 
(BW) and daily food intake were measured to obtain mean free-feeding (baseline) values. Beginning 
the following week and continuing throughout operant training, mice were food restricted and kept 
at 90-95% of baseline BW, to ensure adequate motivation during operant training with sucrose pellet 
reinforcement. For one week prior to and during the 15-day CSD, mice were given sufficient normal 
diet to return to and maintain 100% baseline BW. In accordance with our previous observations, CSD 
mice required a greater amount of daily food to maintain this target BW than did CON mice (see 
Results). Mice were maintained at 95% baseline body weight throughout LNR testing, with CSD mice 
again requiring an increased amount of normal diet relative to CON mice.  
Fixed-ratio 1 schedule of reinforcement (FR1) test and learned non-reward (LNR) test 
The same operant training was required for the FR1 and LNR tests, and details are given in 
Supplementary information of Study A. Briefly, mice were trained to initiate each trial by one operant 
nosepoke into the feeder port, which resulted in illumination of a stimulus nose-poke port in the 
opposite, stimulus wall. One response in the stimulus port activated signalled delivery of a sucrose 
pellet into the feeder port, which the mouse returned to and retrieved the pellet. At 2.5 s after pellet 
retrieval, the next trial could be initiated. In the final stage of training, mice were allowed 10 s to 
initiate each trial with a single nosepoke in the feeder port and, if they did so, 6 s to make a single 
nosepoke in the stimulus port; omission of either response resulted in the onset of a 5 s timeout. The 
criterion for completion of training was 2 sessions of 70 trials at each of which ≥ 49 pellets were 
earned under the above conditions. When mice had attained training criterion on these two sessions 
they were tested in two further daily sessions. The mean number of pellets earned during these four 
sessions was used to counter-balance the allocation of mice to CSD and CON groups. 
 The FR1 test comprised the same conditions as used at the final stage of training (described 
above), and was conducted at CSD day 8 with mice maintained at 100% baseline BW. Measures of 
interest were: omissions to initiate trials at the feeder port, omissions to emit responses at the 
stimulus port in initiated trials, total pellets earned, and session duration. 
 The LNR test was based on that described by Nilsson et al. (2012). For this test there were 
three spatial locations (left, middle, right) for a nose-poke port in the stimulus wall. The first stage of 
the test was a two-choice spatial discrimination (SD): following trial initiation, the mouse had to 
choose between two stimulus nose-poke ports whilst a blank panel occupied the third location. A 
response in the correct stimulus port led to delivery of a sucrose pellet in the feeder port and an 
incorrect response led to a 5 s timeout. Mice were allowed 10 s to initiate a trial and 6 s to make a 
choice response. The SD stage consisted of 70 trials divided into seven 10-trial blocks; SD learning 
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criterion was nine correct responses within any 10-trial block, and if the subject did not attain 
criterion the SD stage was repeated on the next day. On the day after attaining SD criterion, the 
second stage, learned non-reward (LNR), was presented: the incorrect stimulus location at SD 
became the correct stimulus, the previously correct stimulus was removed and replaced by the blank 
panel, and the blank panel was replaced by a stimulus port and this became the new incorrect 
stimulus. Number of trials, learning criterion and times allowed for trial initiation and choice 
responding were all identical to those at the SD stage. At the LNR stage, the mouse must overcome 
non-reinforcement-avoid behaviour and acquire reinforcement-approach behaviour at the same 
stimulus, in the absence of the possibility to perseverate in responding at the previously correct 
stimulus (Nilsson et al., 2012). Measures of interest for SD and LNR were: omissions to initiate trials, 
omissions to emit choice responses, incorrect choice responses, total errors (i.e. the sum of the 
previous three error types)), and correct choice responses (CR). LNR testing began at day 16 and 
continued for 3-13 days depending on mouse-specific attainment of learning criteria for the SD and 
LNR stages. Testing was conducted 5 days/week. CSD mice were maintained in the same cage and 
next to the same CD1 mouse during this period. CSD sessions with maximum attack duration of 30 s 
were conducted on the other 2 days/week. 
  
Statistical analysis 
Statistical analysis of CSD effects was conducted using SPSS (version 20, SPSS Inc., Chicago IL, USA). In 
most cases an unpaired t-test or analysis of variance (ANOVA) was conducted. Where appropriate, 
ANOVA post hoc testing was conducted using the Bonferroni procedure. Analysis of covariance 
(ANCOVA) was used in Expt 8 (FR1 test). Statistical significance was set at p ≤ 0.05. Where an 
estimate of variance is given this is the standard deviation (SD). 
Results 
CSD validation 
We have previously shown that CSD leads to increased mean percent day-to-day body weight delta 
(Azzinnari et al., 2014). During the 15-day CSD, % daily body weight delta was calculated. For each 
experiment with ad libitum access to food (i.e. Expts 1-7, Fig. 1), CSD mice had higher day-to-day 
body weight delta than CON mice: for example, in Expt 1 (Fig. 1): CON 1.0 ± 0.3 %, CSD 2.1 ± 0.5 % (p 
< 0.0001). Given that one major aim was to investigate effects of psychosocial stress on the immune 
system, it is essential to minimise occurrence of skin wounds during CSD attacks. As reported 
previously, regular trimming of the lower incisor teeth of the CD-1 mice and timing the duration of 
daily physical attack to 1 min maximum, restricts wounding to surface abrasions and these occur 
rarely (Azzinnari et al., 2014). For example, in Expt. 1 (Fig. 1), during the 15-day CSD the median total 
number of surface skin wounds per mouse was 0 and the maximum was 3; there were no deep bite 
wounds throughout the study. 
 
CSD induces peripheral and brain inflammatory responses 
In the first experiment (Fig. 1), CSD effects on spleen and whole brain immune-cell status at day 16, 
were assessed. Spleens from CON and CSD mice were collected and splenocytes were analysed using 
flow cytometry. CSD decreased the number of lymphocytes (CD45+/CD11b-) (t(10)= 3.6, p < 0.005, Fig. 
2A, B), whereas the number of CD45+/CD11b+ myeloid cells was increased (t(10)= 2.4, p < 0.04, Fig. 2A, 
C). In this latter population, identification of granulocytes and inflammatory monocytes was based on 
SSC-A and Ly6C staining (Fig. 2D). SSChi/Ly6Cint granulocytes (t(10)= 2.4, p < 0.04, Fig. 1E) and 
SSClo/Ly6Chi inflammatory monocytes (t(10)= 4.3, p < 0.002, Fig. 1F) were both increased in the spleen 
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of CSD mice. Based on mean fluorescence intensity (MFI), the expression of TNF-α (t(9)= 3.0, p < 0.02, 
Fig. 3A), IFN-γ (t(9)= 4.0, p < 0.004, Fig. 3B) and Ki-67 (t(9)= -3.0, p < 0.02, Fig. 3C) on myeloid cells was 
increased in CSD mice, while the surface expression of MHC II on myeloid cells was decreased in 
these same CSD mice compared to their CON counterparts (t(10)= 3.6, p < 0.005, Fig. 3D).  
 
 
Figure 2. Effects of CSD on splenic leukocytes at day 16, as assessed using flow cytometry. Spleens were 
processed from 6 CSD and 6 CON mice. A) FACS dot plots for the percentage of total cells defined as 
lymphocytes and myeloid cells based on CD45/CD11b staining, in a representative CON mouse and CSD mouse. 
B) Cell counts for CD45
+
/CD11b
-
 lymphocytes in CON vs. CSD mice. C) Cell counts for CD45
+
/CD11b
+
 myeloid 
cells in CON vs. CSD mice. D) FACS dot plots for the percentage of total myeloid cells that were gated into 
different subsets, in a representative CON mouse and CSD mouse: CD11b
+
/SSC
hi
/Ly6C
int
 = granulocyte, 
CD11b
+
/SSC
lo
/Ly6C
hi
 = inflammatory monocyte. E) Cell counts for Ly6C
+
/SSC
hi
 granulocytes in CON vs. CSD mice.  
F) Cell counts for Ly6C
hi
/SSC
lo
 inflammatory monocytes in CON vs. CSD mice. p values were obtained in 
unpaired t-tests. 
 
 
 
Figure 3. Effects of CSD on expression levels of activation and proliferation markers in CD45
+
/CD11b
+ 
myeloid 
cells in the spleens obtained from 6 CON and 6 CSD mice at day 16 (same mice as in Fig. 2), as assessed using 
flow cytometry and the geometric mean of fluorescence intensity (MFI). A) TNF-α. B) IFN-γ. C) Ki-67. D) MHC II. 
p values were obtained in unpaired t-tests. In A), B) and C), the data point for one CSD mouse is missing 
because of a staining issue.  
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As stated above, CSD resulted in a decrease in the number of lymphocytes in the spleen. With 
respect to some specific T-cell types, CSD had no effect on the number of cytotoxic CD8+ T cells (p = 
0.73) or on the number of total CD4+ T cells (p = 0.28) (Fig. 4A-C). Within CD4+ T cells, there was no 
effect of CSD on counts for CD4+/IFN-γ+ Th1 cells (p = 0.51) or CD4+/Foxp3+T-reg cells (p = 0.85) (Fig. 
S1). However, CSD led to an increase in the number of CD4+/IL17A+ Th17 cells (t(9)= 3.1, p < 0.02) (Fig. 
4D, E). 
 
 
 
Figure 4. Effects of CSD on splenic T cells at day 16, as assessed using flow cytometry. Spleens were obtained 
from 6 CSD and 6 CON mice (same mice as in Fig. 2 and Fig. 3). A) FACS dot plots for the percentage of CD4
+ 
and 
CD8
+ 
T cells in a representative CON mouse and CSD mouse. B) Cell counts for CD4+ T cells in CON vs. CSD mice. 
C) Cell counts for CD8+ T cells in CON vs. CSD mice. D) FACS dot plots for the percentage of CD4
+ 
and CD8
+ 
T 
cells in a representative CON mouse and CSD mouse. E) Cell counts for Th17 T cells. The p value was obtained in 
an unpaired t-tests. In B), C) and E), the data point for one CSD mouse is absent because of a staining issue.  
In a separate experiment (Expt 2, Fig. 1), the effects of CSD on the expression of genes 
encoding enzymes of the KYN pathway (Fig. 5A) in the liver, one of the major organs of KYN-pathway 
activity, were investigated using qPCR. The liver from CSD mice exhibited increased levels of Ido2, 
Tdo2, Kmo, Kynu, and 3-Haao, with no significant increase in Tdo1 (Fig. 5B-G). Liver expression of 
Ido1 was barely detectable in CON and CSD mice (i.e. Ct > 36-37), in accordance with previous 
reports (Dai and Zhu, 2010). Given that activated myeloid cells and an activated KYN pathway are 
both associated with increased oxidative stress, we measured plasma levels of iNOS in these same 
mice. Plasma levels of iNOS were indeed increased in CSD compared to CON mice (t(10)= 2.6, p < 0.03) 
(Fig. 5H). 
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Figure 5. Effects of CSD on liver kynurenine-pathway enzyme gene expression and plasma iNOS levels at day 16. 
Livers and blood plasma were obtained from 6 CSD and 6 CON mice; liver data from one CON mouse are 
excluded because of unreliable RNA quantification.  A) The metabolic steps in the kynurenine (KYN) pathway 
for which the enzymes studied are responsible. The KYN pathway is initiated by metabolism of tryptophan to N-
formylkynurenine by indoleamine 2,3-dioxygenase 1 and 2 (IDO1, IDO2) and tryptophan 2,3-dioxygenase 1 and 
2 (TDO1, TDO2); N-formylkynurenine is degraded by formamidase to kynurenine (KYN). KYN conversion to 3-
hydroxykynurenine (3-HK) is catalysed by kynurenine 3-monooxygenase (KMO), and 3-HK to 3-
hydroxyanthranilic acid (3-HANA) by kynureninase (KYNU). 3-hydroxyanthranilic acid 3,4-dioxygenase (3-HAO) 
converts 3-HANA to 2-amino-3-carboxymuconic-6-semialdehyde, which then rearranges to form quinolinic acid 
(QA) (Schwarcz et al., 2012). Liver mRNA expression levels of the genes for each of these enzymes was 
measured using qPCR: B) Ido2, C) Tdo1, D) Tdo2, E) Kmo, F) Kynu, G) 3-HAO, H) Plasma iNOS concentration 
measured using ELISA. p values were obtained in unpaired t-tests. 
 
Moving to the analysis of CSD effects on immune status of the brain, in the same mice used 
to study spleen leukocytes (Expt 1, Fig. 1), we also isolated and analysed whole-brain mononuclear 
cells using flow cytometry. There was no CSD effect on the total numbers of brain lymphocytes 
(CD11b-/CD45+) (p = 0.13, Fig. 6A, B), macrophages (CD11b+/CD45hi) (p = 0.43, Fig. 6A, C), or microglia 
(CD11b+/CD45low) (p = 0.55, Fig. 6A, D). To assess brain region-specific effects of CSD on microglia, we 
conducted a separate experiment (Expt 3, Fig. 1) with the aim of measuring the microglia marker 
Iba1, in perfused brain sections using immunohistochemistry (IHC). In the VTA specifically, CSD led to 
an increase in the area that was Iba1-immunoreactive (IR) (t(13)= -2.8, p < 0.02, Fig. 6E, F). This effect 
was specific to the VTA, with there being no CSD effect on this measure in nucleus accumbens (p = 
0.83), medial prefrontal cortex (p = 0.23) or amygdala (p = 0.45) (data not shown). In a separate 
cohort of mice (Expt 4, Fig. 1), the VTA was punched and mRNA levels of another marker of microglia 
activation, Cd11b, were measured using qPCR; CSD mice exhibited increased Cd11b expression 
relative to CON mice (t(20)= -2.7, p < 0.02, Fig. 6G). 
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Figure 6.  Effects of CSD on brain measures of immune status at day 16. Data are derived from three separate 
experiments. A)-D). Fresh brains were obtained from 6 CSD and 6 CON mice (same mice as in Fig. 2-4): A) FACS 
dot plots for whole-brain mononuclear cells showing the percentage of lymphocytes (CD11b
-
/CD45
+
), 
macrophages (CD11b
+
/CD45
hi
) and microglia (CD11b
+
/CD45
lo
) in a representative CON mouse and CSD mouse. 
Cell counts for: B) Lymphocytes. (C) Macrophages. (D) Microglia. E)-F) Brains from 7 CSD and 8 CON mice were 
perfused for Iba1 immunohistochemistry: E) Representative images of Iba1
+
 staining in VTA from a CON mouse 
and a CSD mouse. F) Percentage area exhibiting Iba1
+
 staining in the VTA. G) Fresh brains were obtained from 
12 CSD and 10 CON mice: qPCR mRNA expression of CD11b mRNA in the VTA. p values were obtained in 
unpaired t-tests. 
 
CSD induces changes in the mesolimbic dopamine system 
In the same mice that exhibited increased expression of Cd11b in VTA, we also measured VTA (Fig. 
7A) expression of several genes essential to DA function, namely tyrosine hydroxylase (Th), vesicular 
monoamine transporter 2 (Vmat2), dopamine transporter (Dat) and dopamine receptor 2 (Drd2) 
(Expt 4, Fig. 1).  There was no effect of CSD on expression of Th (p = 0.14, Fig. 7B), CSD led to an 
increase in Vmat2 (t(20)= -2.1, p < 0.05, Fig. 7C), CSD was without effect on Dat (p = 0.29, Fig. 7D) and 
on Drd2 (p = 0.12, Fig. 7E).  In a separate cohort of mice (Expt 5, Fig. 1), the NAcc was investigated in 
terms of tissue levels of DA and its major metabolites DOPAC and HVA, using HPLC-ED. The ratio 
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DOPAC/DA, the major measure of DA turnover, was reduced in CSD relative to CON mice (t(19)= 2.2, p 
< 0.05, Fig. 7G). There was no effect of CSD on the ratio HVA/DA (p = 0.57, Fig. 7H). 
 
Figure 7. Effects of CSD on neural measures of the mesolimbic dopamine system at day 16. Fresh brains were 
obtained from 12 CSD and 10 CON mice (same mice as in Fig. 6G). A) Representative figure from (Franklin and 
Paxinos, 2008) depicting the VTA target region that was punched and processed for qPCR. Log2-relative mRNA 
expression for: B) Tyrosine hydroxylase, C) Vesicular monoamine transporter 2, D) Dopamine transporter, E) 
Dopamine receptor 2. F) Representative figure from (Franklin and Paxinos, 2008) depicting the NAcc target 
region that was punched and processed for HPLC-ED. G-H) Ratio of the metabolites DOPAC and HVA to DA as 
estimates of DA turnover in projections to the NAcc. p values were obtained in unpaired t-tests.   
 
 
Building on the ex vivo evidence that CSD alters the state of the mesolimbic DA system, we 
used the DAT inhibitor GBR 12909 to investigate CSD effects both in vivo and ex vivo (Expt 6, Fig. 1). 
On day 16, mice injected with GBR 12909 or vehicle were assessed in terms of locomotor activity 
during a 2 h period beginning 30 min after i.p. administration. In a 2 (Stress) x 2 (Drug) ANOVA of 
locomotor activity, there were main effects of Stress (F(1, 21)=7.4, p<0.02) and Drug (F(1, 21)=34.7, p < 
0.0005) and a borderline non-significant Stress X Drug interaction (F(1, 21)=3.7, p<0.07, Fig. 8A). Post-
hoc analysis revealed similar (baseline) activity in CON-VEH and CSD-VEH mice, increased activity in 
both CON-GBR and CSD-GBR mice relative to their respective VEH groups, but decreased activity in 
CSD-GBR versus CON-GBR mice. Thereafter, mice were returned to their home cage and activity was 
measured from 13:00 h to 07:00 h the following day. In a 2 (Stress) x 2 (Drug) x 19 (Hour-block) 
ANOVA of activity scores, there was a Stress x Time interaction (F(18, 378)=1.9, p < 0.05, Fig. 9). Post hoc 
analysis identified that CSD mice were less active that CON at the end of the active (dark) phase, i.e. 
at 16:00 to 20:00 h.  
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Figure 8. Effects of CSD and the specific DAT inhibitor GBR 12909 (6 mg/kg i.p.) on activity and accumbens 
immediate-early gene expression at days 16-17. CSD (N=12) and CON (N=13) mice were assigned equally to 
receive either GBR 12909 or saline vehicle (VEH). A) Day 16 locomotor activity in an arena during 2 h, starting 
30 min after injection. B)-C) Day 17 nucleus accumbens immediate-early gene expression, with brains collected 
at 30 min after a second injection. B) c-Fos, C) Arc. Values are mean +/- SD. p values were obtained in 2-way 
ANOVA followed by post hoc Bonferroni test. 
 
Figure 9. Effects of CSD and GBR 12909 on activity in the home cage at days 16-17 (same mice as in Fig. 8). Mice 
were returned to their home cage at 12:00 h following i.p. injection of GBR 12909 or VEH 2.5 h earlier, and  
activity was monitored across the remaining active (dark) phase and the subsequent inactive (light) phase. 
Activity was sampled at 1 min intervals, and average values for each hour were used for analysis. * p < 0.05, ** 
p < 0.01 for Stress X Time interaction in ANOVA followed by time-specific CSD vs. CON post hoc Bonferonni 
tests. 
  
On day 17, mice received a second injection of the same drug and were killed after 30 min, and the 
brains collected for qPCR of the immediate-early genes c-fos and Arc in the NAcc. For c-fos 
expression (Fig. 8B) there were main effects of Stress (F(1, 21)=6.19, p < 0.03) and Drug (F(1, 21)=7.44, p < 
0.02) and no interaction (p = 0.57). c-fos expression was reduced in CSD mice relative to CON mice 
and increased by GBR 12909 to a similar extent in CSD and CON mice.  For Arc expression (Fig. 8C), 
there was a main effect of Drug (F(1, 21)=6.06, p < 0.02), with GBR 12909 increasing Arc expression, in 
the absence of a Stress effect. 
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CSD induces deficits in operant responding for reward  
To allow comparison with several previous studies that have assessed CSD effects in the two-bottle 
sucrose/saccharin test (see Discussion), this test was also included in the present study (Expt 7, Fig. 
1). CSD mice (N=14) and CON mice (N=6 pairs) that had been exposed to the test conditions several 
times prior to CSD, were tested at day 16. There was no effect of CSD on absolute saccharin drinking 
(CON 5.2 ± 2.1 g, CSD 5.3 ± 1.1 g, p = 0.87). Interestingly, CSD mice exhibited increased water drinking 
(CON 0.08 ± 0.00 g, CSD 0.21 ± 0.02 g, t(18) = -2.35, p < 0.04). Primarily due to the latter, CSD mice 
exhibited a borderline non-significant decrease in % saccharin preference (CON 98.1 ± 0.04 %, CSD 
96.1 ± 0.04 %, p < 0.07). 
 In a separate, final experiment (Expt 8, Fig. 1), mice were trained in the operant paradigm for 
sucrose pellet reinforcement prior to CSD/CON. Operant training required mice to be maintained at 
90-95% of baseline body weight (BW) and they were returned to 100% baseline BW prior to 
CSD/CON. During the 15-day CSD/CON procedure, CON mice were 100 ± 3 % baseline BW and CSD 
mice were 103 ± 3 % (p < 0.01). Normal diet was always fed several hours after operant testing and 
was always fully consumed within the dark phase, such that mice did not eat for ≥ 12 h prior to 
operant tests. To assess reward motivation at CSD day 8, mice were given the fixed-ratio 1 (FR1) test. 
Given the difference in % baseline BW, behavioural measures were analysed using ANCOVA with % 
baseline BW included as a covariate. Reduced motivation for sucrose pellets in CSD mice was 
evidenced by, compared to CON mice: an increase in the number of omissions to initiate trials (F(1, 24) 
= 5.70, p < 0.03, Fig. 10A); a decrease in the number of pellets earned (F(1, 24) = 5.29, p < 0.04, Fig. 
10C); and an increase in the session duration (F(1, 24) = 7.55, p < 0.02, Fig. 10D). There was no effect of 
CSD on omissions to emit stimulus responses (F(1, 24) = 0.18, p = 0.67, Fig. 10B). 
 
Figure 10. Effects of CSD on operant reward motivation at CSD day 8 in the FR1 test with a time limit of 10 s to 
initiate each trial and 6 s to emit an operant response. Mice were trained in the operant test and then allocated 
to CSD (N=15) or CON (N=12). A) Omissions to initiate trials. B) Operant responses in initiated trials. C) Pellets 
earned. D) Session duration. The bar represents the mean for each group per measure. p values were obtained 
using ANCOVA, and % baseline BW was included as a covariate.   
 
 Beginning on day 16, the same mice were investigated in the LNR test. Mice were maintained 
at 95% baseline BW: it was necessary to provide CSD mice with more normal diet (2.20.4 g/day) to 
maintain the target BW (actual BW: 952% baseline) than was required by CON mice (1.40.3 g/day) 
to maintain the target BW (actual BW: 974% baseline) (CSD vs. CON daily diet weight during LNR 
testing, p < 0.001). In the spatial discrimination (SD) stage, there was no effect of CSD on the 
measures omissions to initiate trials (p = 0.53), omissions to make choice responses (p = 0.25), 
incorrect choice responses (p = 0.52), total errors (p = 0.62), and correct choice responses (p = 0.18). 
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At the LNR stage, CSD mice exhibited a borderline non-significant increase in omissions to initiate 
trials (t(14.4)= -2.4, p < 0.06, Fig. 11A), an increase in incorrect choice responses (t(24)= -2.2, p < 0.04, 
Fig. 11C), and an increase in total errors (t(17.6)= -2.4, p < 0.05, Fig. 11D). There was no effect of CSD 
on omissions to emit choice responses (p = 0.16, Fig. 11B) or on correct choice responses (p = 0.19). 
 
Figure 11. Effects of CSD on operant behaviour in the learned non-reward stage of the LNR test. Following 
simple discrimination testing to the learning criterion, mice were tested to learning criterion in the LNR test. 
One CON mouse had to be excluded due to a technical failure in the first LNR session (CON N=11, CSD N=15). A) 
Omissions to initiate trials. B) Omissions to make choice responses. C) Incorrect choice responses. D) Total 
errors. The bar represents the mean for each group per measure. p values were obtained in unpaired t-tests. 
 
Discussion 
The overall aim of the present study was to investigate effects of chronic exposure to a psychosocial 
stressor on peripheral and CNS immune responses, on the mesolimbic DA system and the associated 
changes in reward processing, in mice. 
We have previously demonstrated that CSD induces peripheral and CNS immune system 
(Azzinnari et al., 2014), in terms of increased plasma levels of TNF and IL-6, splenomegaly and 
increased expression of genes associated with inflammatory pathways in the hippocampus, mPFC 
and amygdala (Azzinnari et al., 2014). Here we extend the evidence for and understanding of CSD 
effects on immune system status in periphery and brain. Splenocyte flow cytometry identified an 
increased number of CD11b+/CD45+ monocytes in CSD relative to CON mice, in terms of both 
SSChi/Ly6Cint granulocytes and SSClo/Ly6Chi inflammatory monocytes. Using the manipulation of 
repeated social defeat (RSD) in mice, Avitsur et al. (2002) also demonstrated increased splenic 
granulocytes and CD11b+ monocytes. The splenic myeloid cells of CSD mice displayed increased 
proliferation, as indicated by expression of the marker Ki67, and also increased expression of the pro-
inflammatory cytokines TNF-α and IFN-γ. Thus, splenic myeloid cells might be a major contributor to 
the increased plasma levels of TNF-α and IFN-γ observed in CSD mice (Azzinnari et al., 2014; Fuertig 
et al., in prep). Interestingly, MHC II expression by splenic myeloid cells was reduced in CSD mice. 
Decreased monocyte MHC II surface expression combined with increased blood pro-inflammatory 
cytokines is associated with poor clinical outcome during the course of severe infections (Lekkou et 
al., 2004), and intracellular accumulation of MHC II molecules in myeloid cells occurs in severe 
infection (Fumeaux and Pugin, 2002). Further investigations are needed to assess whether 
intracellular sequestration of MHC II is also occurring in CSD mice.  
Regarding the effects of CSD on the adaptive immune system, flow cytometry identified a 
reduced number of total splenic CD11b-/CD45+ lymphocytes in CSD mice. Given that this was not 
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attributable to splenic CD4+ and CD8+ T cells, the observed reduction in splenic lymphocytes might be 
due to a decrease in B cells, and future experiments will need to test for this. Despite the lack of 
effect on total CD4+ T cells, CSD mice did exhibit a specific increase in CD4+/IL-17A+ Th17 cells. Th17 
cells selectively produce proinflammatory cytokines including IL-17A and F, IL-22, IL-6 and TNF-α 
(Kimura and Kishimoto, 2010). IL-17-producing T-helper cells play an important role in the induction 
of autoimmune diseases, including multiple sclerosis (MS) and an animal model thereof, 
experimental autoimmune encephalomyelitis (EAE) (Aranami and Yamamura, 2008). Naive T cells 
differentiate into Th17 cells under the influence of TGF-β, which is responsible for maturation of T 
regulatory (Treg) cells, and of IL-6 (Kimura and Kishimoto, 2010). As noted above, CSD mice exhibit 
increased blood IL-6 (Azzinnari et al., 2014), which might drive the development of Th17 cells and a 
consequent imbalance in Treg/Th17 ratio. Imbalance between Th17 and Treg cell numbers has been 
observed in mice exposed to chronic and acute stress (Beurel et al., 2013; Hong et al., 2013). 
Furthermore, administration of peripheral and CNS Th17 cells resulted in depression-relevant 
behaviour (Beurel et al., 2013). Schmidt et al. (2010) demonstrated increased T cell effector functions 
in the periphery of mice exposed to social stress. Once in the brain, Th17 cells can induce neuronal 
dysfunction in both cell bodies and axons (Siffrin et al., 2010).  
Despite the marked activation effect of CSD psychosocial stress on splenic immune cells, 
there was no effect of CSD on whole brain numbers of CD11b+/CD45lo microglia, CD11b+/CD45hi 
macrophages or lymphocytes. Previous studies have provided clear evidence for microglia activation 
(Gerecke et al., 2013; Nair and Bonneau, 2006; Wohleb et al., 2012), and also increased monocyte 
trafficking to the brain (Wohleb et al., 2014a), due to various stressors, including repeated social 
defeat (RSD) and restraint. To investigate whether CSD leads to brain region-specific microglia 
activation we quantified Iba1 immuno-activity in VTA, NAcc, amygdala and mPFC. CSD led to 
increased Iba1 staining in the VTA specifically. Increased expression of CD11b in a separate cohort of 
CSD mice provided further support for microglia activation in the VTA. Interestingly, Tanaka et al. 
(2012) also showed microglia activation on the VTA of CSD mice, although this co-occurred with 
microglia activation in other brain areas (e.g. mPFC).  One possible explanation for the lack of CSD 
effect on microglia/macrophages at the whole-brain level and on brain regions other than VTA 
examined using IHC might reside in the highly dynamic response of microglia to stressful stimuli. 
Indeed, microglia activation was observed on day 4 specifically of a 6-day restraint stress procedure 
(Nair and Bonneau, 2006), and Kreisel et al. (2014) found microglia activation after 2 days but 
microglia decline after 4 weeks of chronic unpredictable stress. Thus, in future studies it will be 
important to assess CSD effects on microglia activation and monocyte/T cell at earlier time points. At 
the same time the roust evidence for increased activation of microglia in the VTA has important 
implications for DA function and depression-relevant behaviour.  
Increased pro-inflammatory cytokine levels activate the KYN pathway (Campbell et al., 2014). 
For example, IDO and TDO expression is increased in mouse liver and brain after lipopolysaccharide 
administration (Walker et al., 2013), with increased TDO activity probably mediated indirectly via 
increased glucocorticoid receptor activation (Badawy, 2013). KYN pathway abnormalities have been 
reported in various human neurological (Schwarcz et al., 2012) and psychiatric disorders (Haroon et 
al., 2012; Myint and Kim, 2014), including depression (Fukuda, 2014; Muller and Schwarz, 2007; 
Steiner et al., 2012; Zunszain et al., 2011). A reduction in the kynurenic acid (KA): quinolinic acid (QA) 
ratio has been reported for depressed patients relative to control probands (Savitz et al., 2015c).  
Moreover, QA levels are altered in brain tissue in depression: microglial QA expression was increased 
in the cingulate cortex, whereas it was decreased or unchanged in the hippocampus (Busse et al., 
2015; Steiner et al., 2008). Here we demonstrate that CSD leads to activation of the KYN pathway in 
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liver, as indicated by increased mRNA levels for the key enzymes Ido2, Tdo2, Kmo, Kynu, and 3-Haao 
that catalyse the pathway of conversion of tryptophan to QA. Also in rats, restraint stress led to 
increased liver TDO activity and KYN levels, and co-administration of the TDO inhibitor allopurinol 
attenuated the depression-relevant behavioural changes observed in these rats (Gibney et al., 2014). 
Chronic mild stress in mice induced activation of KYN pathway enzymes in skeletal muscle and liver 
and increased plasma KYN and brain 3-HK levels (Agudelo et al., 2014). The present evidence 
complements our findings that CSD induces increased KYN and 3-HK in plasma and brain, and that 
these and increased conditioned fear expression are reversed by repeated administration of an IDO1 
inhibitor (Fuertig et al., in prep). 
Further to the above lines of evidence that CSD led to a state of immune-inflammatory 
activation in the day following the chronic procedure, plasma levels of inducible nitric oxide synthase 
(iNOS) were also increased in CSD mice, the same cohort that exhibited upregulated gene expression 
for KYN-pathway enzymes. Immune activation induces the expression of iNOS, with pro-
inflammatory cytokines (Sheng et al., 2011) and kynurenines (Colin-Gonzalez et al., 2013) being 
known activators iNOS and of oxidative stress. iNOS is one of the synthases responsible for catalysing 
nitric oxide (NO) production and the subsequent formation of free radicals (Miller et al., 2009b). 
Oxidative stress has been proposed to participate in depression pathophysiology (Bakunina et al., 
2015; Miller et al., 2009a), and increased oxidative stress markers have been reported in the blood 
(Bakunina et al., 2015; Lopresti et al., 2014) and brain (Michel et al., 2010; Shelton et al., 2011) of 
depressed patients. Interestingly, chronic stress-induced depression-like behaviour in rats can be 
prevented by administration of iNOS inhibitors (Wang et al., 2008). Oxidative stress is known to be 
important in the pathophysiology of neurodegenerative diseases, including Parkinson’s disease (PD) 
for example (Miller et al., 2009b), and to act at DA neurons among others (Bove et al., 2005).  
To assess the effects of CSD on the mesolimbic DA system we measured levels of DA and its 
metabolites, DOPAC and HVA, in NAcc tissue. Absolute NAcc tissue levels of DA, DOPAC and HVA 
were not affected by CSD. Nonetheless, CSD mice exhibited decreased DA turnover as assessed by 
the (reduced) DOPAC/DA ratio. Tanaka et al. (2012) report an increase in the DOPAC/DA ratio in NAcc 
and mPFC in mice after a single CSD exposure and a decrease in the same ratio after 10 days of CSD, 
when comparing 10-day to 1-day values within CSD subjects, but not relative to 10-day CON mice. 
We did not observe a CSD effect on DA turnover in the mPFC (data not shown). It is important to 
note that there are a number of methodological differences between the standard CSD procedure 
used in the Tanaka et al. study (Golden et al., 2011) and our procedure (Azzinnari et al., 2014), which 
aims to minimize physical wounding, and this could account for between-study differences. Reduced 
DA turnover in the basal ganglia has been reported for depression (Bowden et al., 1997). Regarding 
the expression of DA-related genes in the VTA, there was CSD effect of on expression levels of Drd2, 
Th or Dat, and Vmat2 expression was increased in the VTA of CSD mice. Several studies have 
reported association of reduced VMAT2 expression/function with depression-relevant behaviour; for 
example mutant Vmat2 +/- mice display a depression-like phenotype (Fukui et al., 2007), 
administration of the VMAT2  inhibitor tetrabenazine reduces reward motivation in mice (Nunes et 
al., 2013a), and exposure of rats to repeated swim stress leads to down-regulation of VMAT2 in NAcc 
and dorsal striatum. Nonetheless, elevated platelet VMAT2 density has been observed in depressed 
subjects (Zucker et al., 2002). There is high similarity between the pharmacodynamic characteristics 
of platelet and brain VMAT2 (Zucker et al., 2001), and increased platelet VMAT2 density has been 
proposed to reflect a compensatory enhancement of the capacity to accumulate monoamines in the 
vesicles in the presence of reduced monoamine turnover, as is proposed to occur in depression 
(Zucker et al., 2002). Interestingly, Duchemin et al. (2009) showed enhanced expression of VMAT2 
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mRNA and protein in midbrain DA neurons in a mouse model of nicotine abstinence, which was 
coincident with decreased basal DA release. Thus, the increased Vmat2 expression observed in the 
VTA in CSD mice might represent a compensatory mechanism to overcome a monoaminergic deficit. 
To assess effects of CSD on DA function, the selective DA transporter blocker and therefore 
reuptake inhibitor GBR 12909 was administered acutely as a DAergic probe. In mice, administration 
of GBR 12909 increases extracellular DA levels in the NAcc and dorsal striatum (Abdallah et al., 2009) 
and induces a hyper-locomotor response (Irifune et al., 1995). Whilst CSD and CON mice did not 
differ in their basal locomotor activity in a familiar arena, CSD mice exhibited attenuated locomotor 
responsiveness to GBR 12909 relative to that of CON mice. Several mechanisms might account for 
this CSD-induced hyposensitivity to GBR 12909. Firstly, it might be due to higher expression and 
therefore DA binding capacity of DAT in CSD mice. In rats, social stress increases DAT binding in the 
mPFC (Novick et al., 2011) and attenuates GBR 12909-induced extracellular DA accumulation (Novick 
et al., 2015).  Although there was no CSD effect on Dat mRNA levels in the VTA in the present study, 
DAT protein levels in the NAcc, dorsal striatum and other regions should be investigated in CSD and 
CON mice. Second, it might be due to alteration of the post-synaptic signalling elicited by DA in 
striatal neurons. Striatal function is highly regulated by dopamine- and cAMP-regulated 
phosphoprotein (DARPP-32), a 32 kDa phosphoprotein that is enriched in medium spiny neurons in 
NAcc and dorsal striatum (Svenningsson et al., 2004), and that integrates the physiological effects of 
multiple extracellular and intracellular signals (Svenningsson et al., 2004). Interestingly, mutation of 
the Thr-34 (protein kinase A) site in DARPP-32 reduces the locomotor activating effects of cocaine, 
indicating that DARPP-32 phosphorylation at Thr-34 influences behavioural effects of DA 
transmission (Zachariou et al., 2006). Given that DARPP-32 phosphorylation is affected by CSD (Jin et 
al., 2015) and Darpp-32 gene expression is impacted by CSD (Azzinnari et al., 2014), CSD effects on 
DARPP-32 might mediate its attenuating effects on sensitivity to GBR 12909. Psychostimulants (e.g. 
cocaine, GBR 12909) acutely up-regulates the expression of the immediate early genes (IEGs) c-fos, 
fosb and Arc (Zachariou et al., 2006). In accordance with previous reports (Iadarola et al., 1993), we 
demonstrate here that GBR 12909 up-regulates the expression of the IEGs c-fos and Arc in the NAcc. 
We also demonstrate that CSD down-regulates c-fos expression. Given that the increase in c-fos 
expression induced by GBR 12909 was similar in CSD and CON mice, CSD-GBR 12909 mice exhibited 
lower average NAcc c-fos expression than CON-GBR 12909 mice, paralleling their lower locomotor 
response to the DA probe. CSD did not impact on NAcc Arc expression in the present study, whereas 
chronic mild stress did do so in mice (Agudelo et al., 2014). It has been shown in rats that induction 
of ΔFosB protein levels is reduced in the NAcc shell of individuals susceptible to chronic restraint 
stress (Poulin et al., 2014). ΔFosB  is  a  truncated  and  unusually  stable  isoform  of  the immediate-
early  gene  fosb,  and  it  tends  to  accumulate overtime  in  the  brain  following  chronic  
stimulation (Nestler, 2015). However, in mice, a CSD-induced increase in ΔFosB in the NAcc has been 
reported to mediate resilience to the behavioural effects of CSD (Vialou et al., 2010). Responsiveness 
of IEG expression to a novel stressor has been investigated following exposure to various chronic 
stressors: c-fos expression was reduced in several brains regions in mice exposed to either chronic 
subordinate stress (Stone et al., 2007), uncontrollable physical stressors (Ons et al., 2010; Ostrander 
et al., 2009), or chronic unpredictable mild stress (Raineki et al., 2014), indicating a reduced evoked 
neural function of brain regions involved in stress-reactivity and motivation (Stone et al., 2007).   
In addition to their attenuated locomotor reactivity to a pharmacological DA probe, CSD mice 
also exhibited reduced activity in the home cage.  Building on this evidence, we conducted a final 
experiment investigating CSD effects on behaviour in operant reward tests known to be sensitive 
indices of NAcc DA function (Bergamini et al., Submitted manuscript).  Reduced interest in reward, 
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included impaired appetitive behaviour with respect to physical effort and cognitive flexibility 
required to obtain reward, is a core symptom and dimension of depression (i.e. DSM-5, RDoC)  (Eshel 
and Roiser, 2010). To investigate for CSD effects on reward processing we deployed a fixed-ratio 1 
schedule for reinforcement (FR1) with time constraints to respond and learned non-reward (LNR) 
test which requires relearning that the stimulus-non-reward association is now a stimulus-reward 
association and concomitant overcoming of avoidance due to learned non-reward (LNR). Critically, 
we have demonstrated elsewhere that these processes are impaired by depletion of NAcc DA 
(Bergamini et al., Submitted manuscript). In the FR1 test, conducted at CSD day 8, CSD mice were less 
motivated to obtain sucrose pellets than CON mice, particularly because of frequent omissions to 
initiate trials. Mice were tested at 100% baseline body weight, with the aim of maximising the 
palatable incentive-motivational value of sucrose pellets relative to their calorific value. In the LNR 
test, CSD mice were not deficient in the simple discrimination stage of the test, indicating that their 
motivation for reward (they were at 95% baseline body weight) and their stimulus-outcome 
association learning were intact. However, they demonstrated increased LNR, primarily due to 
increases in omission to initiate trials and commission of incorrect responses. Strikingly, these same 
two deficits, coincident with intact simple discrimination, also underlay increased LNR sensitivity in 
mice that had undergone depletion of NAcc DA (Bergamini et al., Submitted manuscript). In 
depression, the intra-/extra-dimensional set-shifting task has been used to assess learned non-
reward (and perseveration), and patients exhibit increased LNR relative to healthy subjects 
(Michopoulos et al., 2006). Using a progressive ratio schedule of reinforcement we obtained further 
evidence that CSD decreases reward motivation, and using reversal tests we obtained evidence that 
it impairs reward-related cognitive processing (present thesis, Study C: Bergamini et al. (in prep-a)). 
In contrast to the approach of investigating CSD effects on operant behaviour for reinforcement 
taken here, previous studies of CSD effects on reward-directed behaviour have used the two-bottle 
test of reward consumption. Several studies have reported a decrease in sweet-solution preference 
relative to water (e.g. (Covington et al., 2009; Krishnan et al., 2007). Despite the clear evidence for 
decreased motivation for reward under effortful conditions in the FR1 test, CSD mice did not exhibit 
a clear decrease in saccharin preference in the present study. Furthermore, the tendency for a 
reduced saccharin preference was due to the increase in water consumption by CSD mice relative to 
CON mice. This latter effect can probably be attributed to the increase in feeding observed in CSD 
mice (present thesis, Study C: (Bergamini et al., in prep-a)). Unfortunately, studies that report on 
CSD-induced decreased sweet-solution preference do not include data on absolute consumption of 
sweet-solution and water (e.g. (Covington et al., 2009; Krishnan et al., 2007). Therefore, to 
summarise our findings for reward-directed behaviour, CSD led to decreased motivation for reward 
under effortful and ambiguous conditions but was without effect on direct reward consumption. 
Each of these findings corresponds to those reported for experimental studies of reward processing 
in depression: thus, patients are less likely to exhibit high effort to obtain reward (Sherdell et al., 
2012) but do not show impaired consummatory pleasure as measured by the Sweet taste test 
(Dichter et al., 2010; Treadway, 2015; Treadway and Zald, 2011).    
 
This study provides some of the most robust evidence to-date in support of the hypothesis 
that stress-induced peripheral and brain inflammation co-occur with attenuated mesolimbic DA 
function including decreased interest in reward. 
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Supplementary Information 
 
Table S1. List of primer sequences used in this study 
             
 
Gene Primer F (5'->3') Primer R (5'->3') 
Actb TTCTTTGCAGCTCCTTCGTT ATGGAGGGGAATACAGCCC 
Hprt1 CTTCCTCCTCAGACCGCTTT TTTTCCAAATCCTCGGCATA 
Tbp CATCTCAGCAACCCACACAG GGGGTCATAGGAGTCATTGG 
Th AGAAGAGCCGTCTCAGAGCA GGGCATCCTCGATGAGACT 
Slc18a2 (Vmat2) CTCCTCACCAACCCATTCAT AAGGCATAGCTGCTGGAGAA 
Slc6a3 (Dat) TGATGCACATAGCAGCAACTC AGGTCATCAATGCCACGACT 
Drd2 GACACCACTCAAGGGCAACT TCCATTCTCCGCCTGTTCAC 
c-fos TCCTACTACCATTCCCCAGC TGGCACTAGAGACGGACAGA 
Arc TGAAGCAGCAGACCTGACAT GTGTGAGGACTCAGCCCCT 
Itgam (Cd11b) ATTCGGTGATCCCTTGGATT GTTTGTTGAAGGCATTTCCC 
Ido1 CAAAGCAATCCCCACTGTATCC ACAAAGTCACGCATCCTCTTAAA 
Ido2 CCTCATCCCTCCTTCCTTTC GGAGCAATTGCCTGGTATGT 
Tdo1 AACATGCTCAAGGTGATAGCTC GAACCGAGAACTGCTGTACCA 
Tdo2 AGGAACATGCTCAAGGTGATAGC CTGTAGACTCTGGAAGCCTGAT 
Kmo GGGGAAAAGAGTGGCTGTTA CCACGCGAATATCTTCCCTA 
Haao (3-HAO) GGAGGCCCCAATACCAGGA TATAGGCACGTCCCGGTGTT 
Kynu TCAAACCCTCCCATTTTGTTGG CCCCTTGTTTTCGGTGTTATCTT 
 
             
Abbreviations: Actb, actin, beta; Hprt1, hypoxanthine phosphoribosyltransferase 1; Tbp, TATA box 
binding protein; Th, tyrosine hydroxylase; Slc18a2, solute carrier family 18 (vesicular monoamine), 
member 2; Slc6a3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; 
Drd2, dopamine receptor D2; c-fos, FBJ osteosarcoma oncogene; Arc, activity regulated cytoskeletal-
associated protein; Itgam, integrin alpha M; Ido1, 2, indoleamine 2,3-dioxygenase 1,2; Tdo1,2, 
tryptophan 2,3-dioxygenase 1,2; Kmo, kynurenine 3-monooxygenase; Haao, 3-hydroxyanthranilate 
3,4-dioxygenase; Kynu, kynureninase. 
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Figure S1 
 
Figure S1. Effects of CSD on splenic T cells. Mice were subjected to CSD for 15 days or to CON conditions, and 
flow cytometric analysis was performed 24 h after the last CSD attack. Cells counts for CD4
+
/IFNγ
+ 
Th1 cells (A, 
B), and CD4
+
/Foxp3
+
 Treg cells (C, D). 
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Abstract 
Depression is a major and heterogeneous neuropsychiatric disorder, one core symptom of which is 
diminished interest in activities consistent with attenuated motivation to engage with positive 
situations and stimuli. Agomelatine (AGO) is a novel antidepressant with serotonergic 2C (5-HT2C) 
receptor antagonism and melatonergic (MT1/2) receptor agonism properties. AGO is efficacious in 
increasing interest in positive activities in depressed patients, as assessed by specific questionnaire. 
Translational automated operant tests with positive reinforcement can also be applied in humans, 
and indeed animal models, to study reward processing and the aetio-pathophysiology underlying 
deficits thereof. Here we present three iterative studies in mice with the overall aims of investigating 
effects of chronic psychosocial stress on appetitive reward processing and whether AGO reverses 
these. In a first study, non-manipulated mice were trained on a complex reversal learning (CRL) test, 
and acute AGO (25 mg/kg p.o.) and a 5-HT2C antagonist both increased reversals completed relative 
to vehicle (VEH). In a second study, mice were exposed to chronic social defeat (CSD) or control 
handling (CON) on days 1-15, and AGO or VEH on days 10-22: In a motivation test on day 15, CSD 
mice were less motivated and there was a tendency for AGO to reverse this effect. In a CRL test on 
day 22, CSD mice were less accurate and completed fewer reversals; repeated AGO (25 mg/kg p.o.) 
reduced the CSD effect on reversals, associated with increased and adaptive perseveration. In a third 
study, mice with continuous operant access to water and saccharin solution in the home cage were 
exposed to CSD or CON on days 1-15: CSD mice developed decreased appetitive-operant responding 
for saccharin and water during the active circadian period, decreased saccharin drinking during this 
period, and increased water drinking during the inactive period. In a separate cohort of CSD mice, 
repeated AGO (25 mg/kg p.o.) was without effect on these stress-induced changes. Therefore, mouse 
CSD led to depression-relevant reduced appetitive interest in reward under discrete-test and home-
cage conditions, and repeated AGO reduced specific deficits observed under demanding discrete-test 
conditions. 
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Introduction 
Depression is a major and heterogeneous neuropsychiatric disorder, with core psychopathological 
symptoms of depressed mood, diminished interest in activities, and increased fatigue, together with 
a number of common symptoms including weight loss or gain, psychomotor agitation or retardation, 
insomnia or hypersomnia, and reduced concentration and attention (DSM-5, 2013; ICD-10, 1994). 
The recent Research Domain Criteria (RDoC) project (Cuthbert, 2015; Cuthbert and Insel, 2013) 
proposes a classification system that takes diagnostic systems into account but also identifies the 
importance of understanding individual psychopathologies, which have been organised into 
domains: for example, the Positive valence systems domain, which includes approach motivation, 
responsiveness to reward and reward learning; and the Arousal/modulatory systems domain which 
includes arousal, biological rhythms and sleep-wake (Cuthbert and Insel, 2013). Integrating RDoC 
with depression symptoms, the Positive valence systems domain is clearly relevant to diminished 
interest in activities, and the Arousal/modulatory systems domain is clearly relevant to insomnia or 
hypersomnia. Depression is not well-understood in terms of aetio-pathophysiology, and patients 
with different symptom combinations are also likely to differ at the pathophysiological level. The 
RDoC approach is conducive with translational research aimed at increasing understanding of 
disorder pathophysiology. This includes evidence obtained in animal models that combine 
manipulations with aetiological validity with behavioural readout tests with face validity for specific 
psychopathologies (Pryce and Seifritz, 2011).  
 Chronic psychosocial stressors are major aetiological risk factors for depression (Kendler et 
al., 2003; Kessler, 1997). In mice, one manipulation that has been proposed to model aspects of this 
human environmental factor is chronic social defeat (CSD), which comprises 10-15 days of 
continuous intruder status in the home cages of different dominant mice but protected by a divider 
with brief daily experience of actual physical attack and defeat (Golden et al., 2011; Kudryavtseva et 
al., 1991). Mouse CSD has been reported to result in decreased preference for gustatory reward, 
namely sweet-tasting sucrose solution, over water in the two-bottle test of consummatory behaviour 
(Krishnan et al., 2007). Interestingly, for human depression, it has been reported that patients do not 
show reduced consummatory pleasure when given a rewarding stimulus (Dichter et al., 2010). 
However, when patients are required to exhibit high effort to obtain reward, they are less motivated 
to do so (Sherdell et al., 2012). Such evidence that, in depression, positive-valence processing is 
reduced at the motivational level rather than the consummatory level, highlights the need for animal 
models of stress-induced impairment of reward motivation and anticipation. These processes can be 
best-studied using behaviour-outcome (operant) tests. To our knowledge there is currently no 
published report on the effects of CSD on operant reward-directed behaviour in mice. 
 In order to investigate reward motivation per se, a single operant stimulus can be used with 
reinforcement earned according to a specific schedule. In animal studies the reinforcer typically takes 
the form of palatable food. The progressive ratio schedule (PRS) test requires the subject to make an 
increasing number of responses to obtain successive rewards and is therefore sensitive to assessing 
the motivation for effortful responding for reward. By conducting the PRS test with the animal 
subject close to hunger satiety, the anticipated palatability of the sucrose-pellet reward becomes 
more important relative to its calorific value, thereby increasing the test’s sensitivity for assessing 
reward motivation. For example, in adult rats it has been demonstrated that early life stress leads to 
decreased responding for reward in a PRS test (Leventopoulos et al., 2009). Using tests comprising 
two operant stimuli that need to be discriminated between in order to obtain reinforcement, then a 
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number of further depression-relevant reward processes can be investigated. When depression 
patients are assessed in discrimination tests that require low effort to obtain reward, typically either 
symbolic (emoticon) or monetary, they do not differ from healthy subjects in terms of accuracy of 
responding (Taylor Tavares et al., 2008). Their responding is characterised by high sensitivity to error 
feedback, however: when patients make an error and therefore fail to receive reinforcement on a 
trial, they are more likely to make an incorrect decision on the subsequent trial i.e. catastrophizing 
(Elliott et al., 1996; Elliott et al., 1997). The probabilistic reversal learning (PRL) test assesses reward-
directed decision making under conditions of accurate and misleading reinforcement/feedback 
(Chamberlain, 2006; Cools et al., 2002; Evers et al., 2005; Jocham et al., 2009). The test comprises 
reversal learning, which requires responding to regular shifts in the contingencies - reward, non-
reward - between the two operant stimuli and reinforcement and, superimposed on this, at a certain 
probability correct responses are not rewarded whereas incorrect responses are rewarded. The 
proportion of non-rewarded correct responses on which the subject shifts (to the incorrect stimulus) 
on the next trial, gives a measure of negative feedback sensitivity (NFS). High NFS is indicative of 
under-estimation of reward probability and is increased in depressed patients (Taylor Tavares et al., 
2008). Recently, rodent automated operant PRL tests have been developed, firstly for rat (Bari et al., 
2010) and then in our laboratory for mouse (Ineichen et al., 2012). In order to ensure that motivation 
is sufficient for rodents to engage in this demanding test for sucrose-pellet reinforcement, some food 
deprivation is essential. In the mouse PRL test, referred to here as a complex reversal learning (CRL) 
test, misleading feedback is restricted to non-rewarded correct responses. Non-manipulated mice 
exhibit: (1) reward-stay behaviour consistent with accurate monitoring of the average reward 
probability at each stimulus; (2) low perseveration and high NFS consistent with accurate monitoring 
of expected and unexpected non-reward; (3) reduced reversals achieved relative to a simple reversal 
learning test without non-rewarded correct responses (Ineichen et al., 2012).  
 Agomelatine (AGO; S 20098; N(2-(7-methoxy-1-naphthyl)ethyl)acetamide)) is a potent 
agonist at the melatonergic (MT1/2) receptors as well as an antagonist at the serotonin 2C (5-HT2C) 
receptor, and is a recently approved antidepressant (de Bodinat et al., 2010; Kennedy et al., 2014). 
During its preclinical development, using repeated dosing, AGO was efficacious in several rat and 
mouse models relevant to depression domains (de Bodinat et al., 2010). This included reversal of 
decreased saccharin consumption induced by chronic mild stress (Papp et al., 2003), reversal of 
specific learned helplessness (Bertaina-Anglade et al., 2006), antagonism of increased anxiety, poor 
physical state and decreased grooming induced by repeated corticosterone (Rainer et al., 2012), and 
antagonism of increased anxiety, immobility in the forced swim test, and altered circadian rhythm of 
activity and sleep-wake pattern induced by prenatal restraint stress (Mairesse et al., 2013; Marrocco 
et al., 2014; Morley-Fletcher et al., 2011). In clinical trials, AGO exhibits increased therapeutic 
efficacy relative to placebo in moderate-severe depression (Kennedy et al., 2014). When the core 
symptom/domain of interest-pleasure was measured using a self-report questionnaire, AGO 
exhibited greater efficacy relative to venlafaxine (Di Giannantonio and Martinotti, 2012). The 5-HT2C 
receptor has also been demonstrated to be relevant in reversal learning. For example, a 5-HT2C 
antagonist improved reversal learning associated with decreased perseveration (Boulougouris et al., 
2008). One neurochemical effect of AGO is to increased dopamine release in the frontal cortex 
(Millan, 2003); ant-/agonism of specific dopamine receptors in this brain region increased 
perseveration (Floresco et al., 2006).                
82 
 
 The iterative aims of the present mouse study were to: (1) Investigate the effects of CSD, 
which we have already demonstrated to lead to increased sensitivity to and impaired coping with 
aversive stimuli (Azzinnari et al., 2014), on reward processing in a PRS test and simple and complex 
reversal learning tests, and on reward processing and circadian activity in a home cage equipped with 
operant access to water and sweet solution. (2) Investigate the effects of the antidepressant AGO in 
terms of reversing CSD-induced changes in reward processing in these various tests and contexts. 
 
Materials and Methods 
Animals 
Experiments were conducted with adult male C57BL/6J mice bred in house, maintained in littermate 
pairs, and aged 10 weeks and weighing 26-28 g at study onset. Male CD-1 mice (Janvier, Le Genest-
Saint-Isle, France) used for social stress were aged 8 months, weighed 40-45 g, were ex-breeders, 
and caged singly. Mice were maintained on a reversed light-dark cycle (light off 07:00-19:00 h). 
Standard home cages were type 2L and maintained in an individually-ventilated caging system, and 
one study was conducted using IntelliCages (see below). Both cage types contained sawdust, tissue 
bedding and a sleep igloo. Temperature was maintained at 22°C and humidity at 50-60%. The 
standard diet was Complete Pellet (Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water, both 
available continuously unless otherwise stated below. BL/6J mice were handled on 5 days at study 
onset. The studies were conducted under a permit (170/2012) for animal experimentation issued by 
the Veterinary Office, Zurich, Switzerland. All efforts were made to minimize the number of mice 
studied and any unnecessary stress to those mice that were studied. 
 
Experimental design 
Three studies (A, B, C) were conducted, each with a different, naive cohort of mice (Figure 1). The 
first stage of each study was operant training for sucrose-pellet reinforcement (A, B) or saccharin-
solution and water (C) reinforcement. In Study A (N=24 BL/6J mice), we investigated the effects of 
acute agomelatine (AGO), melatonin and a 5-HT2C receptor antagonist on behaviour in a complex 
reversal learning (CRL) test in otherwise non-manipulated mice. In Study B (N=44 BL/6J mice), we 
investigated the effects of chronic social defeat (CSD, days 1-15, versus control handling (CON)) and 
AGO (days 10-22, versus vehicle (VEH)) on behaviour in a progressive ratio schedule (PRS) test (day 
15), a simple reversal learning (SRL) test (day 19) and the CRL test (day 22). Study C comprised two 
experiments in IntelliCage: Firstly, we investigated the effects of CSD (day 1-15, versus CON) (N=20 
BL/6J mice) on appetitive and consummatory behaviour towards water and saccharin solution during 
the dark- and light-phases of the circadian cycle. Second, in a new cohort of mice (N=16 BL/6J mice) 
the effects of AGO (days 7-20, versus VEH) on these same measures were studied in CSD mice (day 1-
15).   
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Figure 1. Experimental designs. Study A: effects of acute agomelatine melatonin and 5-HT2C receptor antagonist 
on behaviour in a complex reversal learning test in otherwise non-manipulated mice. Study B: effects of chronic 
social defeat versus control handling and agomelatine versus vehicle on behavour in a progressive ratio 
schedule test and simple and complex reversal learning tests. Study C: Experiment 1, effects of CSD on 
appetitive and consummatory behaviour towards water and saccharin solution during the dark- and light-
phases of the circadian cycle. Experiment 2, effects of agomelatine versus vehicle on these same measures. 
Baseline BW, b-BW: baseline body weight; FI: Food intake; SRL: simple reversal learning test; CRL: complex 
reversal learning test; D: acute drug; CSD: chronic social defeat; CON: control handling; PRS: progressive ratio 
schedule test; AGO: agomelatine; VEH: vehicle. 
 
Chronic social defeat 
Our refined protocol for chronic social defeat is described in detail elsewhere (Azzinnari et al., 2014). 
Briefly, in Study B, each BL/6 (CSD) mouse was placed singly in the 2L home cage of a CD-1 mouse, 
separated by a transparent, perforated divider. The CSD mouse was placed in the same compartment 
as the CD-1 mouse for either a cumulative total of 60-sec physical attack (chase, wrestle, bite) or 10 
min maximum. To prevent bite wounds, the lower incisors of CD-1 mice were trimmed every third 
day across CSD. The CSD mouse x CD-1 mouse pairings were rotated so that CSD mice were placed in 
the home cage and confronted with a novel CD-1 mouse each day. This CSD procedure was 
conducted for 15 days, between 14:00-16:00 h. From day 16 until the end of operant testing, each 
CSD mouse remained in one cage with the same CD-1 mouse without further attacks. Control (CON) 
mice remained in littermate pairs, the standard condition in our laboratory, and were handled and 
weighed daily. In Study C, each IntelliCage was divided into two compartments by a transparent, 
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perforated divider, and a CSD mouse was placed in one compartment and a CD-1 mouse in the other. 
The CSD mouse was placed in the compartment occupied by the CD-1 mouse for either a cumulative 
total of 60-sec physical attack or 10 min maximum. The CSD mouse then remained in this 
compartment and the CD-1 mouse was transferred to the opposite compartment. CD-1 mice were 
rotated between IntelliCages every fifth day and lower incisors were trimmed every third day. CSD 
was conducted for 15 days, between 16:00-17:00 h. On days 16-20, the CSD and CD-1 mice were 
exchanged between compartments at 16:00 h without further attacks. Control littermate pairs of 
BL/6 mice were maintained singly in the same IntelliCage, one per compartment, and were 
exchanged between compartments daily at 16:00-17:00 h.  
 
CSD effects on feeding homeostasis and appetite hormones 
Given that the reversal-learning operant tests require food deprivation (Ineichen et al., 2012), that 
CSD is known to increase food intake and alter blood levels of appetite-regulating hormones in a pro-
feeding direction (Kumar et al., 2013; Patterson et al., 2013), and that CSD effects on reversal 
learning tests were investigated in Study B, it was important to establish the effects of our CSD 
protocol on home-cage food intake and appetite hormone levels. In a separate experiment, daily 
intake of food pellet was measured in 11 littermate pairs for 5 days prior to allocation to CSD (N=12 
mice) and CON (N=10 mice) and measurement of daily intake of food pellet for 15 days of CSD/CON. 
For mice in pairs, mouse pellet consumption per mouse was estimated by dividing the total amount 
of pellet eaten by two and adjusting for relative body weight. On day 16, mice were decapitated and 
trunk blood collected into 500 µl tubes coated with EDTA (Microvette, Sarstedt), and 4-2-aminoethyl-
benzenesulfonyl fluoride (Sigma) was added at 1 mg/ml. The blood was centrifuged at 3000 rpm for 
15 min at 4°C, the plasma was removed to Eppendorf Protein LoBind tubes, and acidified with HCl to 
a final concentration of 0.05 N. Plasma samples were stored at -25°C until determination of leptin 
and ghrelin using ELISA kits according to the manufacturer’s protocol (Mouse Leptin EZML-82K, 
Rat/Mouse Ghrelin EZRGRA-90K, Merck Millipore).         
 
Operant training and testing  
Controlled feeding and body weight. In Studies A and B, body weight (BW) and food intake of BL/6 
mice were measured every day for one week and the mean values were calculated and taken as 
baseline for each mouse. To ensure that mice were motivated for operant training, BW was reduced 
to 90-95% baseline by controlling daily pellet allowance. In Study B, at 5 days prior to and throughout 
CSD, mice were given sufficient daily pellet to return to and maintain baseline BW. They were then 
maintained at baseline BW for progressive ratio schedule testing and reduced to 95% baseline BW 
for reversal learning tests. 
    
Operant boxes. Modular operant boxes (TSE Systems, Bad Homburg, Germany) were used for 
Studies A and B, details of which are provided elsewhere (Ineichen et al., 2012). Briefly, each box 
contained one (progressive ratio schedule test) or two (reversal learning tests) operant nose-poke 
port stimuli and one feeder that delivered one sucrose pellet per reinforcement (14 mg Dustless 
Precision Pellets, TSE Systems). Correct and incorrect nose-pokes and pellet retrieval were detected 
via infrared beam breaks. A loudspeaker above the feeder emitted a tone to signal reward delivery. 
After each session the boxes were wiped clean and odours were covered by wiping with 70% 
ethanol.    
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Training on fixed-ratio 1 (FR1) operant reinforcement. In Studies A and B, mice were conditioned to 
nose poke on a fixed-ratio 1 (FR1) schedule for sucrose pellet reinforcement during five sessions per 
week for 1-2 weeks, using the training stages detailed in (Ineichen et al., 2012). The basic settings 
were: trial onset was indicated by illumination of the nose-poke port(s); one nose poke (FR1) 
initiated tone and pellet delivery, and following pellet retrieval a 2.5 s inter-trial interval (ITI) was 
initiated; the session terminated after 40 reinforcements or 30 min. 
 
Progressive ratio schedule (PRS) test. The PRS test was used in Study B, and conducted as described 
elsewhere (Ineichen et al., 2012). Briefly, only one nose-poke stimulus was used. The maximum 
session duration was 40 min. Session parameters were: required number of responses on first trial = 
1, number of consecutive trials for which the ratio remained constant = 5, and number of responses 
by which the ratio increased per increment = 3, i.e. on trials 1-5, 1 response was required, on trials 6-
10, 4 responses were required, on trials 11-15, 7 responses were required, and so on. If there was no 
single response within any 600-s period the break point was reached and the session terminated. 
Measures were total number of nosepokes, number of reinforcements attained, final ratio attained, 
and total number of responses at the feeder. In Study B, at 100% baseline BW, mice were given two 
PRS tests on consecutive days, and the scores on the second day were used to counter-balance 
allocation of mice to CSD and CON groups in terms of reward motivation. Mice were tested at 100% 
baseline BW for CSD effects in the PRS test at CSD days 8 and 15, with testing conducted at 09:00-
12:00 h and therefore before the daily CSD session. Within CSD and CON mice, PRS behaviour at CSD 
day 8 was used to counter-balance allocation of mice to AGO and VEH drug groups.   
 
Simple reversal learning (SRL) test. In Studies A and B, mice were trained on reversal learning, using 
two nose-poke stimuli positioned left and right of the central feeder. The final parameters for 
reversal training, and also the parameters used in the SRL test itself, were: On FR1, a response at the 
correct stimulus initiated tone and pellet delivery followed by 2.5 s ITI, and a response at the 
incorrect stimulus initiated 5-s time out. Consistent reward-stay behaviour in the form of eight 
consecutive correct responses/reinforcements was required for reversal. At reversal the previously 
incorrect stimulus was now correct and vice versa, so that nonreward-shift behaviour was required. 
The total number of pellets available was 48, giving a maximum of six reversals. Criteria for 
completion of reversal-test training were all 48 reinforcements obtained and consumed, a minimum 
of 18 (p≥0.75) reward-stay responses per stimulus, and a minimum of 3 reversals completed. Mice 
required 35-40 sessions, 5 days per week, from onset of operant training to reach this criterion for 
reversal learning. The final settings described above were also the settings for the SRL test. The 
measures of interest were as described below for the complex reversal test, except there was no 
measure, negative feedback sensitivity.        
     
Complex reversal learning (CRL) test. The CRL test was used in Studies A and B, and was conducted as 
reported elsewhere (Ineichen et al., 2012) where the same test was described as probabilistic 
reversal learning. Briefly, the same parameters as in the SRL test were used with the addition of an 
overall probability of 0.15 that responses to the correct stimulus were not rewarded; these were 
called non-rewarded correct responses (NR-CRs). The first correct response per session was always 
rewarded and the maximum number of consecutive NR-CRs was two. A maximum of 60 pellets could 
be obtained and the maximum amount of reversals possible was 7, therefore. Measures of interest 
were: Reward-stay probability, the probability that the mouse stays at the active nose-poke stimulus 
after being rewarded on this stimulus, calculated as p (trials with response to the stimulus that was 
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correct on previous trial/total trials immediately following a correct trial). Number of reversals 
completed. Errors (perseverations)/reversal, immediately following reversal, the number of 
consecutive trials with non-rewarded responses to the previously correct but now incorrect 
stimulus/total reversal completed. Trials/reversal, mean number of trials required to complete a 
reversal. Negative feedback sensitivity, the probability that the mouse switches to the incorrect 
stimulus after receiving a NR-CR, calculated as p (trials with response to the opposite stimulus 
following a NR-CR/total trials immediately following a NR-CR). Average latency to collect reward, 
mean time (msec) required to collect the pellet from the feeder. Session duration, the time (sec) 
needed to finish the session by obtaining 60 pellets or 1800 sec maximum.  
 In Study A, all mice were given five CRL tests, each preceded by a different compound (see 
section Drugs below). Mice were given the SRL test on days between CRL tests, to ensure that they 
were exhibiting normal performance on the day prior to compound-CRL testing (Fig. 1).   
 In Study B, following CSD, mice were returned to food restriction on day 16, to reduce BW to 
95% baseline. They were given a SRL test on day 19, and a CRL test on day 22; these were days 10 
and 13 of daily AGO/VEH administration, respectively (Fig. 1, section Drugs below).  
  
IntelliCage appetitive and consummatory behaviour. In Study C, IntelliCage (TSE) was used, a system 
for automated continuous monitoring of appetitive and consummatory behaviour of mice in their 
home cage, as described elsewhere (Cathomas et al., 2015a; Cathomas et al., 2015c). Briefly, each 
IntelliCage was divided at the centre to give two independent compartments, and placed in an 
attenuation chamber with a 12:12 h reversed dark-light cycle (light off 07:00-19:00 h). Mice were 
fitted with a subcutaneous transponder to record: visits to the operant devices located in each 
corner; operant nosepokes into a light sensor at the door in each corner that opened on FR1 to allow 
access to a drinking bottle; and the number of licks, measured by electrical contact of the tongue 
with the drinking tip. Littermate pairs were habituated to the cage for 3 days with operant doors 
open, and then the doors were closed so that mice had to nosepoke to open a door and access the 
water bottle for 20 sec, for a training period of 7 days. This was followed by 5 days of training with 
one water bottle and one saccharin solution (0.1%, sodium salt hydrate, Sigma) bottle, the corner 
locations of which were alternated each day at 17:00 h. For 10-day baseline data collection, the 
littermate pair was separated with one mouse placed in each compartment, and they were 
exchanged between compartments each day at 17:00 h. In the first experiment, this continued for a 
further 15 days in the case of CON mice. In CSD mice, one littermate was removed and replaced by a 
CD-1 mouse. The CSD procedure was conducted at 16:00-17.00 h for 15 days: the CSD mouse was 
placed in the compartment occupied by the CD-1 mouse for the physical attack, and then the CSD 
mouse remained in this compartment and the CD-1 mouse was transferred to the opposite 
compartment. CD-1 mice were provided with a normal water bottle. In the second experiment, after 
the 10-day baseline data collection, the CSD procedure was conducted on days 1-15 and thereafter 
mice were transferred between compartments without attack on days 16-20. AGO/VEH were 
administered at days 7-20. For analysis, four time periods of interest were identified: two during the 
light phase, 20:00-00:00, 00:00-04:00, and two during the dark phase, 08:00-12:00, 12:00-16:00. 
Therefore, the data obtained in the 3-4 hours directly after CSD and CON compartment transfer were 
not included in the data analysis.   
 
Drugs 
To establish dose and time effects on AGO levels, mice (N=6-7 per dose x time point) were orally 
(p.o.) administered 10 or 25 mg/kg AGO, and trunk blood and brain were collected after 1 h or 3 h 
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and stored at -80°C prior to analysis. AGO measurement in plasma and brain-tissue homogenate was 
performed according to an established method involving liquid-liquid extraction of a sample volume 
of 20 µl, and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) detection. 
S 40706-1 (D5-20098) was used an internal standard. The limit of quantification (LLOQ) was 0.100 
ng/ml (range 0.100 to 30 ng/ml). All LC-MS/MS measurements were performed by a central 
analytical laboratory.  
 All compounds were prepared in a vehicle of 1% hydroxyethylcellulose (HEC) in water. In 
Study A, acute AGO (S 20098) was studied at 10 and 25 mg/kg p.o., acute melatonin (MT) at 10 
mg/kg p.o., and the 5-HT2C antagonist S 32006 acute at 2.5 mg/kg p.o. A latin square design was used 
to test compound effects in a counterbalanced order across mice. A period of 3-4 days was allowed 
between each day of compound-CRL testing (Fig. 1). In Study B, 13-day repeated AGO was studied at 
25 mg/kg p.o.. In Study C, 14-day repeated AGO was studied at 25 mg/kg p.o.. Compounds were 
administered at the end of the light phase (06:00-06:30 h) in all studies, and 1-2 hours prior to 
operant testing in Studies A and B.     
 
Statistical analysis 
Statistical analysis was conducted using SPSS (version 21, SPSS Inc., Chicago IL, USA). In Study A, 
compound effects on dependent measures in the CRL test were analysed using mixed model analysis 
of variance (ANOVA) with compound as a fixed effect and mouse as a random effect. In Study B, 
mixed model ANOVA with a 2 Stress (CSD, CON) x 2 Drug (AGO, VEH) design was used to study effects 
on measures in the PRS, SRL and CRL tests. CSD effects on food required to maintain baseline BW at 
specific time points were studied using t-tests. In Study C, in the first experiment a mixed model 
ANOVA with a 2 Stress (CSD, CON) x 4 Day-block (Baseline, CSD/CON 1-5, 6-10, 11-15) x 4 Time-block 
(20-00 h, 00-04 h, 08-12 h, 12-16 h) design was used to study effects on IntelliCage measures; and in 
the second experiment a mixed model ANOVA with a 2 Drug (AGO, VEH) x 5 Day-block (Baseline, CSD 
1-5, CSD-Drug 6-10, CSD-Drug 11-15, Drug 16-20) x 4 Time-block (20-00 h, 00-04 h, 08-12 h, 12-16 h) 
design was used to study effects on IntelliCage measures. In each study, significant main effects or 
interactions were analysed using post hoc testing with Bonferroni correction in the case of multiple 
comparisons. Significance was set at p≤0.05 and a non-significant trend at p<0.10. Data are given as 
means and where an estimate of variance is given this is the standard deviation (SD). 
Results 
Study A: Acute oral agomelatine enhances behaviour in the complex reversal learning test 
Agomelatine blood and brain levels following p.o. administration at 10 or 25 mg/kg and sample 
collection after 1 or 3 h are given in Figure 2. In both plasma (Fig. 2A) and whole brain (Fig. 2B), mean 
AGO concentration was increased at 1 h after injection of 25 mg/kg p.o..  
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Figure 2. Agomelatine concentrations in (A) mouse trunk blood plasma and (B) whole brain tissue from the 
same mice, following oral administration of agomelatine at 10 or 25 mg/kg and sample collection after 1 or 3 
hours. N=6-7 mice per dose and time point. 
 
 In the CRL test, each mouse was tested following acute p.o. AGO at 10 mg/kg (AGO 10) or 25 
mg/kg (AGO 25), melatonin (MT) at 10 mg/kg and 5-HT2C antagonist at 2.5 mg/kg (5-HT2C ANT), using 
a latin square design. As given in Figure 3, there was no Drug effect on reward-stay behaviour 
(p=0.30, Fig. 3A), and also no Drug effect on negative feedback sensitivity (p=0.40, Fig. 3B). For 
number of reversals completed, there was a main effect of Drug (F(4, 114)=3.06, p<0.05, Fig. 3C). 
Post hoc testing demonstrated that, relative to VEH, mice completed more reversals after AGO 25 
(p<0.05) and 5-HT2C ANT (p<0.03).     
 Based on these pharmacokinetic and CRL test data, 25 mg/kg AGO was the dose selected for 
repeated oral administration in Studies B and C. 
 
 
Figure 3. Study A: Compound- and dose-dependent effects of vehicle, agomelatine (AGO, 10 and 25 mg/kg), 
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melatonin (MT, 10 mg/kg) and 5-HT2C antagonist S 32006 (5-HT2C ANT, 2.5 mg/kg) on behaviour in the 
complex reversal learning (CRL) test. A latin square design for the order of compound/dose testing was used. 
Twenty four mice were studied, and each mouse obtained the maximum 60 reinforcements in each test 
session. Details of the experimental design are given in Figure 1. A) Probability of reward-stay responding. B) 
Negative feedback sensitivity with respect to switching stimulus after a non-rewarded correct response. C) 
Number of reversals. Values are meanSD. * p<0.05 for post hoc Bonferroni pairwise comparisons conducted 
after significant effect of Drug in ANOVA.  
 
Study B: CSD mice exhibit deficits in reward motivation and accuracy, and repeated agomelatine 
has some CSD-specific effects 
CSD increases food intake and decreases plasma leptin levels 
Prior to conducting Study B, in a separate cohort of mice we investigated CSD effects on food intake 
under ad libitum conditions and plasma levels of appetite hormones. CSD mice exhibited a marked 
increase in food intake: The mean daily weight of pellet eaten was calculated for the 5-day blocks, 
pre-CSD/CON -4 to 0, CSD/CON 1-5, CSD/CON 6-10, CSD/CON 11-15. There was a Group x Day-block 
interaction (F(3,60)=9.98, p<0.0005; Fig. 4A); pre-CSD/CON food intake was similar in CON and CSD 
mice, and CSD mice consumed more pellet than did CON mice at days 1-5, 6-10 and 11-15. For body 
weight, there was no effect of Group (p≥0.18, Fig. 4B), and a main effect of Day-block (F(3,60)=21.55, 
p<0.0005) due to increase in BW over time. This increase in food intake in CSD mice co-occurred with 
a decrease in plasma levels of the appetite-suppressant hormone leptin in samples collected on day 
16 (CON: 5.242.26 ng/ml, CSD: 2.120.93 ng/ml, t(21) = 4.77, p<0.0002). There was no overall effect 
of CSD on plasma levels of the appetite-enhancing hormone ghrelin in the same mice (CON: 
75.9028.42 pg/ml, CSD: 107.8070.24 pg/ml, p=0.19). These findings demonstrate the important 
need to control the BW and pellet allocation for each mouse individually and on a daily basis, in 
order to maintain all mice at the same BW relative to baseline, and therefore in as similar 
homeostatic state as possible, for operant testing. 
 
 
Figure 4. Effects of chronic social defeat on mouse food intake and body weight. A) Mean food intake per 5-day 
block. B) Body weight per 5-day block. The weight of food given and remaining was measured each day at 
16:00 h. Values are mean+/-SD. In A) *** p<0.001 for post hoc Bonferroni pairwise comparisons conducted for 
Stress group in specific Day-blocks following Stress group x Day-block interaction in ANOVA. In B) day-blocks 
with different letters p<0.05 or less for post hoc Bonferroni pairwise comparisons following main effect of Day-
block in ANOVA. 
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CSD and agomelatine effects in the progressive ratio schedule test 
In Study B, with respect to baseline body weight and pellet intake, mice (N=22) that were later 
allocated to CON weighed 28.21.62 g (=100% baseline BW) and consumed 3.80.4 g pellet/day, and 
mice (N=22) that were later allocated to CSD weighed 28.71.6 g and consumed 3.80.5 g pellet/day. 
During the 15-day CSD/CON period, CON mice were given 3.10.5 g food pellet/day to maintain 
100% baseline BW (actual values: 101.42.2%), whereas CSD mice had to be given 4.70.7 g food 
pellet/day to maintain 100% baseline BW (actual values: 101.51.5%). Therefore, as observed in the 
ad libitumg food intake experiment (Fig. 4), the CSD mice required more food to maintain physical 
homeostasis. 
 At CSD/CON day 8, which was prior to commencement of AGO administration (day 10, Fig. 
1), mice were given a PRS test. At this stage there was no effect of CSD on the main measures of total 
number of responses (CON: 9973, CSD: 104113, p=0.85), reinforcements attained (CON: 17.25.6, 
CSD: 16.38.7, p=0.69), and final ratio attained (CON: 10.53.2, CSD: 9.65.2, p=0.46). The number of 
responses at the feeder was decreased in CSD mice (CON: 8244, CSD: 5534, t(42)=2.33 p<0.03), 
suggesting decreased reward anticipation/motivation. Within CON and CSD groups, the total number 
of PRS responses was used to counter-balance allocation of mice to AGO and VEH groups. 
 At CSD/CON day 15, which was day 6 of AGO administration, a further PRS test was 
conducted. The data are presented in Figure 5. At this stage, there was a consistent effect of CSD on 
PRS test behaviour. Thus, for total number of responses there was a main effect of Stress group 
(F(1,40)=11.44, p<0.002, Fig 5A) with CSD mice making less responses. CSD mice also attained fewer 
reinforcements (p<0.001, Fig 5B) and a lower final ratio (p<0.001; Fig. 5C) relative to CON mice. The 
number of responses at the feeder was also decreased in CSD mice (CON: 298156, CSD: 146140, 
p<0.002). With the exception of three CSD-VEH mice which reached their break point, all mice 
continued responding to the end of the 40-min session. There was no Stress x Drug interaction or 
main effect of Drug for any PRS measure. However, as is evident in each data set in Figure 5, in CSD 
mice specifically there was an increase in the mean scores in mice receiving AGO; in t-tests, there 
was a borderline non-significant increase in the final ratio attained in CSD-AGO versus CSD-VEH mice 
(p=0.07; Fig. 5C). 
 
Figure 5. Study B: Effects of chronic social defeat and agomelatine (25 mg/kg per os) on mouse behaviour in the 
progressive ratio schedule test, at day 15 (last day) of CSD and after 6 days of AGO. The test was conducted 1-2 
hours after daily administration of AGO/VEH at the end of the inactive phase. Details of the experimental 
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design are given in Figure 1. Eleven mice per group were tested, counter-balanced with respect to baseline 
behaviour in this test. (A) Total number of nosepoke responses. (B) Number of reinforcements attained. (C) 
Final ratio attained. In A-C, p values are for the main effect of Stress group in Stress group x Drug dose ANOVA. 
In C, in a Stress group-specific t-test, there was a borderline non-significant increase in the final ratio attained 
in CSD-AGO versus CSD-VEH mice. 
 
CSD and agomelatine effects in the reversal learning tests 
The same mice were then reduced to 95% baseline BW (CON: 96.22.2%, CSD: 973.3%, p=0.37) and 
studied in terms of CSD and AGO effects on reversal learning. At day 19, 4 days after the end of CSD 
and day 10 of AGO administration, mice were tested in the simple reversal test (Figure 6). There 
were main effects of Stress group, consistent with impaired test performance in CSD mice, for: 
number of reinforcements obtained (CON: 480, CSD: 4013, p<0.007), probability of reward-stay 
responding (p<0.001, Fig. 6A), reversals completed (p<0.001, Fig. 6B), trials per reversal (p<0.02, Fig. 
6D), average latency to collect reward (p<0.05, Fig. 6E) and session duration (p<0.03, Fig. 6F). There 
was no effect of CSD on perseverations per reversal (p=0.27, Fig. 6C). There was no Stress X Drug 
interaction or main effect of Drug for any SRL measure. 
 
 
Figure 6. Study B: Effects of chronic social defeat and agomelatine (25 mg/kg per os) on mouse behaviour in the 
simple reversal learning test, at 4 days after completion of CSD and after 10 days of AGO. The test was 
conducted 1-2 hours after daily administration of AGO/VEH at the end of the inactive phase. Details of the 
experimental design are given in Figure 1. Eleven mice per group were tested. (A) Probability of reward-stay 
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responding. (B) Number of reversals completed. (C) Perseverations per reversal. (D) Trials per reversal. (E) 
Latency to collect reward from feeder. (F) Session duration. p values are for the main effect of Stress group in 
Stress group x Drug dose ANOVA.        
 
 At day 22, 7 days after the end of CSD and day 13 of AGO administration, mice were tested in 
the complex reversal test (Figure 7). There were main effects of Stress group, consistent with 
impaired test performance in CSD mice, for: number of reinforcements obtained (CON: 601, CSD: 
5211, p<0.002), probability of reward-stay responding (p<0.004, Fig. 7A), reversals completed 
(p<0.001, Fig. 7B), trials per reversal (p<0.03, Fig. 7D), average latency to collect reward (p<0.04) and 
session duration (p<0.0005, Fig. 7F). Negative feedback sensitivity was actually reduced in CSD mice 
relative to CON mice (p<0.02, Fig. 7E). In addition to the CSD effect on reversals completed, there 
was also a borderline non-significant effect of Drug (p<0.08); in Stress group-specific t-tests, CSD-
AGO mice completed more reversals than did CSD-VEH mice (p<0.03; Fig. 7B). For perseverations per 
reversal, there was a Stress x Drug interaction (p<0.03, Fig. 7C), and post hoc tests identified that 
CSD-AGO mice perseverated more than each of the other three groups. 
 
Figure 7. Study B: Effects of chronic social defeat and agomelatine (25 mg/kg per os) on mouse behaviour in the 
complex reversal learning test, at 7 days after completion of CSD and after 13 days of AGO. The test was 
conducted 1-2 hours after daily administration of AGO/VEH at the end of the inactive phase. Details of the 
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experimental design are given in Figure 1. Eleven mice per group were tested. (A) Probability of reward-stay 
responding. (B) Number of reversals completed. (C) Perseverations per reversal. (D) Trials per reversal. (E) 
Negative feedback sensitivity to non-reward of a correct response. (F) Session duration. In A, D-F, p values are 
for the main effect of Stress group in Stress group x Drug dose ANOVA. In B, there was a main effect of Stress 
group and borderline main effect of Drug group and Stress group-specific t-tests identified increased reversals 
due to AGO in CSD mice specifically. In C, there was a Stress group x Drug dose interaction, and p values are for 
post hoc Bonferroni pairwise comparisons. 
 
Study C: CSD mice exhibit deficits in reward motivation and altered circadian rhythm, effects which 
do not respond to repeated agomelatine  
In the first IntelliCage study (C1), saccharin- and water-directed visits, nosepokes and licks, were 
compared in CSD and CON mice (Figure 8 and Table S1). In the Stress x Day-block x Time-block 
ANOVA model, in cases of significant interactions of Stress x Day x Time and/or Stress x Day and/or 
Stress x Time, a posteriori Stress X Time ANOVAs were conducted for each day-block separately. 
Baseline (days -4 to 0) behaviour was similar in mice allocated at random to CON and CSD groups 
(Fig. 8A-D). As expected (e.g. (Cathomas et al., 2015a)), under baseline and CON conditions and 
primarily during the dark phase, mice had a moderate preference for the saccharin corner versus 
water corner in terms of visits and nosepokes, and a marked preference for saccharin over water in 
terms of licks. For saccharin visits (Table S1), CSD mice made less visits than CON mice during the 
dark phase at day-blocks CSD 1-5, 6-10 and 11-15. The same CSD effect pertained for water visits 
(Table S1). Together, these data suggest a general decrease in goal-directed activity. For saccharin 
nosepokes (Fig. 8A), CSD mice made less nosepokes than did CON mice during the dark phase at day-
blocks CSD 1-5, 6-10 and 11-15. The same CSD effect pertained for water nosepokes (Fig. 8B), again 
consistent with a general decrease in appetitive behaviour. For saccharin licking (Fig. 8C), CSD mice 
made less licks than did CON mice during the dark phase at day-block CSD 11-15, consistent with a 
decrease in interest in saccharin by this stage. For water licks (Fig. 8D), CSD mice made more licks 
than CON mice during the light phase at day-blocks CSD 1-5 and 6-10, which possibly reflected 
increased activity and feeding during this period (see Discussion).  
 In the second IntelliCage study (C2), in which CSD-AGO and CSD-VEH mice were compared 
(Figure 9A-D and Table S2), the saccharin- and water-directed behavioural profiles of these mice 
were similar to those of the CSD mice in the first experiment. This was indicated by the main effect of 
Day-block in the Drug x Day-block x Time-block ANOVA model, attributable to a decrease in 
behaviour relative to baseline (days -4 to 0) in at least one CSD/post-CSD day-block, for dark-phase 
saccharin visits, dark-phase saccharin nosepokes (see Fig. 9A) and dark-phase saccharin licks (see Fig. 
9C). Furthermore, light-phase water licks were increased in CSD/post-CSD day-blocks relative to 
baseline (see Fig. 9D). There were no significant effects involving Drug for any behavioural measure 
in these CSD mice. 
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Figure 8. Study C: Effects of chronic social defeat on mouse behaviour relative to saccharin and water, as 
measured continuously in IntelliCage. A) Saccharin nosepokes. B) Water nosepokes. C) Saccharin licks. D) Water 
licks. Seven CSD and 11 CON mice were studied; one mouse from each group had to be excluded because of 
technical problems. Each data point is the overall mean of 5-day-mean values per mouse, obtained in 5 days 
prior to CSD/CON, CSD/CON days 1-5, 6-10 and 11-15, for each given 4-h period. Time periods were 20:00-
00:00 and 00:00-04:00 during the light/inactive phase, 04:00-08:00 spanning the light-dark transition, and 
08:00-12:00 and 12:00-16:00 during the dark/active phase. Daily CSD/CON procedures were carried out at 
16:00-17:00 and the data obtained in the 3-4 h period thereafter were excluded from the analysis. Following 
Stress group x Time period interaction, * p<0.05, ** p<0.01, *** p < 0.001 are for CSD versus CON post hoc 
Bonferroni pairwise comparisons. For additional data see Table S1.      
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Figure 9. Study C: Effects of agomelatine (25 mg/kg per os) in mice exposed to chronic social defeat on 
behaviour relative to saccharin and water, as measured continuously in IntelliCage. A) Saccharin nosepokes. B) 
Water nosepokes. C) Saccharin licks. D) Water licks. Eight CSD and 8 CON mice were studied. Each data point is 
the overall mean of 5-day-mean values per mouse, obtained in 5 days prior to CSD, on CSD days 1-5 without 
AGO/VEH, on CSD days 6-10 with AGO/VEH administration starting on day 7, on CSD days 11-15 with AGO/VEH, 
and on post-CSD days 16-20 with AGO/VEH, for each given 4-h period. Time periods were 20:00-00:00 and 
00:00-04:00 during the light/inactive phase, 04:00-08:00 spanning the light-dark transition, and 08:00-12:00 
and 12:00-16:00 during the dark/active phase. Daily CSD was carried out at 16:00-17:00 and the data obtained 
in the 3-4 h period thereafter were excluded from the analysis, as were the data obtained at 04:00-08:00. 
AGO/VEH were administered at 06:00-07:00. For additional data see Table S2. 
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Discussion 
In the present study we could demonstrate in discrete operant tests that exposure of mice to chronic 
psychosocial stress results in a decrease in motivation to exert physical effort for gustatory reward, 
and to decreased accuracy and negative feedback sensitivity when cognitive effort was required to 
obtain gustatory reward. In the home cage setting we could also demonstrate that appetitive, and to 
a lesser extent, consummatory responding to gustatory reward was decreased. The antidepressant 
agomelatine was effective in reducing the stress-induced deficit in complex reversals completed, and 
this co-occurred with an increased perseveration which was adaptive under the conditions of the 
test. These findings add considerably to the evidence that mice can provide useful models for the 
study of stress-induced disruption of the motivation and cognitive capacity to interact with stimuli 
that are normally rewarding, which is a core and common psychopathology in depression.  
 In the complex reversal learning (CRL) test, an acute dose of AGO at 25 mg/kg or 5-HT2C 
antagonist, administered orally 1-2 hours prior to testing, led to an increase in the number of 
reversals completed by otherwise non-manipulated mice. Although neither measure responded 
significantly, each drug increased average reward-stay probability and decreased average negative 
feedback sensitivity (NFS), suggesting that these two additive effects underlay the observed 
consistent drug effect on reversals completed. In a previous study, a low, acute dose of the 
antidepressant escitalopram increased reward-stay, decreased NFS and increased reversals 
completed in mice in this CRL test (Ineichen et al., 2012). In a simple reversal learning test in rat, the 
5-HT2C antagonist SB 242084 improved reversal learning (Boulougouris et al., 2008). 5-HT2C receptors 
are expressed in a number of forebrain regions important in the regulation of operant behaviour, 
including frontal cortex, amygdala, hippocampus, and dorsal and ventral striatum. 5-HT2C 
antagonism, including AGO, disinhibits DA release into frontal cortex specifically (Di Giovanni et al., 
2006; Millan, 2003). 5-HT2C receptors are also expressed in monoamine cell-body regions, including 
ventral tegmental area (VTA) for dopamine (DA) and locus coeruleus for noradrenaline (NA) 
(Pompeiano et al., 1994; Racagni et al., 2011). In VTA, 5-HT2C is expressed by GABA interneurons that 
project onto DA neurons (Eberle-Wang et al., 1997). AGO, acute and chronic, increases the number 
of spontaneously active VTA DA neurons and the bursting activity thereof (Chenu et al., 2013). 
Nonetheless, 5-HT2C antagonism does not disinhibit DA release in nucleus accumbens or dorsal 
striatum (Millan, 2003).   
 Chronic social defeat, as described previously (Kumar et al., 2013), resulted in increased food 
intake. This occurred in the absence of an effect on body weight, consistent with CSD inducing an 
increase in energy expenditure. In blood samples collected on day 16 from these same mice, there 
was a decrease in plasma leptin levels, as reported previously for CSD (Kumar et al., 2013). Leptin is 
an adipokine released from fat into the circulation. It is transported across the blood brain barrier 
where it acts to suppress feeding. It acts at homeostatic areas (e.g. brainstem, hypothalamus) as well 
as areas involved in reward-motivation such as VTA. The reduction in plasma leptin observed in CSD 
mice relative to CON mice under free-feeding conditions would be expected to contribute to their 
increased feeding by disinhibition. There was no consistent effect of CSD on the active form of 
ghrelin, which acts to promote feeding and has been reported to be increased by CSD and to underlie 
the increased feeding by CSD mice that, in contrast to the present study, exhibited increased body 
weight (Patterson et al., 2013). These findings confirmed the importance of providing CSD and CON 
mice with the group- and individual-specific feeding regimens that were required for maintaining the 
required level of baseline body weight, to establish appropriate conditions for operant testing. 
 Chronic social defeat was without effect on the principle measures of the progressive ratio 
schedule (PRS) test at CSD 8, and resulted in a decrease in responding by the final day of CSD, day 15. 
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In the same mice, tested in the simple reversal learning (SRL) test at day 19 and the CRL test at day 
22, there were further effects of CSD on operant behaviour for reward. In the SRL test, CSD mice 
exhibited decreased reward-stay accuracy and, as a consequence of this, completed less reversals, 
requiring more trials per reversal. That these CSD effects were partly a consequence of reduced 
reward motivation – despite testing being conducted at 95% baseline body weight - was indicated by 
the increased latency to collect the sucrose-pellet after a correct response. In the CRL test, the 
decreases in reward-stay accuracy, reversals completed, trials required per reversal, and the 
increased latency to collect the reward, as observed in the SRL test, still pertained. Impaired ability to 
maintain accurate monitoring of the correct stimulus under cognitively effortful conditions might 
have contributed to these CSD effects, as might reduced reward expectancy. The effects co-occurred 
with a decrease in negative feedback sensitivity (NFS). Non-manipulated mice, in contrast to humans, 
exhibit high NFS, which suggests that mice are indeed able to monitor reward expectancy in the CRL 
test, experience it as aversive when an expected reinforcement is withheld and, in contrast to 
healthy humans, cannot inhibit the disposition to switch stimuli on the next trial (Ineichen et al., 
2012). Against this background, the reduced NFS in CSD mice could indicate reduced cognitive ability 
to monitor reward expectancy, reduced negative emotionality when an expected reinforcement is 
withheld, or reduced reward expectancy. In the human PRL test, depressed patients exhibit intact 
reward-stay accuracy and reversals completed and increased NFS, relative to healthy controls (Taylor 
Tavares et al., 2008). Therefore, the constellation of CSD effects in the mouse CRL test is the opposite 
of the constellation of effects of depression in the human PRL test. Nonetheless, the mouse CRL test 
provides clear evidence for impaired reward-directed behaviour under cognitively demanding 
conditions in mice that had been exposed to CSD, which is certainly relevant to the major depression 
psychopathology of reduced interest in daily activities.  
 Evidence from an ecological setting (Cathomas et al., 2015b) that CSD reduces motivation to 
engage in appetitive behaviour, complementary to that obtained in the discrete testing conditions 
pertaining in the PRS test, was provided by the IntelliCage experiment. CSD mice developed reduced 
goal-directed behaviour (visits, nosepokes) for saccharin and water during the active period of their 
circadian cycle from the first days of the 15-day CSD procedure. Towards the end of CSD they had 
also developed reduced consumption (licks) of saccharin during the active period. During the inactive 
period, the water consumption of CSD mice increased, possibly indicating that they were more active 
than CON mice during this period and eating more food, which stimulates drinking. 
 Agomelatine, using the dose at which acute administration led to increased reversals 
completed in the CRL test in non-manipulated mice, also exerted some deficit-reducing effects when 
administered repeatedly in CSD mice. Firstly, there was a tendency to increase motivation for reward 
in the PRS test conducted after 6 days of repeated AGO, in CSD mice. Deficient motivation  in the PRS 
test is also induced by NAcc DA depletion (Bergamini et al., Submitted manuscript), suggesting AGO 
effects on VTA DA neurons (Chenu et al., 2013) could have contributed to the partial AGO effect on 
motivation in CSD mice. Whilst there were no effects of 10 days of AGO in the SRL test, 13 days of 
AGO resulted in an increase in reversals completed in the CRL test in CSD mice specifically. 
Furthermore, this co-occurred with an increase in the average number of perseverations per reversal 
in CSD-AGO mice compared with each of the other groups. In the CRL test, where some correct 
responses are not rewarded and could therefore be regarded - incorrectly - as a reversal, it is actually 
adaptive to be perseverative and thereby to increase the ability to differentiate non-rewarded 
correct responses from actual reversals. Two perseverations per reversal are sufficient: CSD-AGO 
mice made 2-3 on average and each of the other groups made 1-2. This co-occurred with CSD-AGO 
mice also exhibiting the lowest average NFS score of each of the groups. Therefore, repeated AGO 
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produced increased perseveration specifically in CSD mice and specifically in the CRL test. This might 
represent a first indicator of restoration of normal reward expectancy and motivation in CSD mice, 
due to repeated administration of AGO. With regards to underlying mechanisms, as described above, 
the medial prefrontal cortex is a major region in the regulation of perseveration, and both 5-HT2C 
antagonism and increased DA receptor-specific agonism in this region could mediate the positive 
effects of AGO observed (Boulougouris et al., 2008; Floresco et al., 2006; Millan, 2003). There were 
no effects of AGO on the CSD-induced home-cage deficits in appetitive behaviour and shifts in 
circadian activity, perhaps indicating that its effects are specific to physically effortful (cf. PRS test) or 
cognitively effortful (cf. CRL test). Nonetheless, this study has provided original and substantive 
evidence that chronic psychosocial stress can be combined with operant tests of reward-directed 
behaviour to provide mouse models for the deficit in reward motivation that is a major 
psychopathology of depression. 
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Supplementary information 
Table S1. Summary of IntelliCage behaviour in Experiment C1, according to reward, stress group, 
day-block and time-period 
              
 Light Phase (20-00 h, 00-04 h) Dark Phase (08-12 h, 12-16 h) 
Reward/Measure/Day-block CON/CSD CON/CSD 
Saccharin Visits -4 to 0 2.22±0.94/1.80±1.00 11.60±3.88/9.20±2.43 
Saccharin Visits 1-5 1.91±0.87/4.97±1.13 11.42±6.70/5.14±2.81* 
Saccharin Visits 6-10 2.20±1.68/3.83±1.68 10.58±5.45/5.40±2.85* 
Saccharin Visits 11-15 1.75±0.81/4.07±2.39 10.29±3.41/4.99±3.27** 
   
Saccharin Nosepokes -4 to 0 4.00±2.55/2.74±1.66 23±11.90/18.71±6.73 
Saccharin Nosepokes 1-5 3.02±1.28/8.74±3.07 22.71±12.61/8.31±4.89* 
Saccharin Nosepokes 6-10 3.95±4.40/6.74±2.34 23.04±17.34/8.34±5.81* 
Saccharin Nosepokes 11-15 2.76±1.39/6.36±3.36 20.80±10.07/9.04±6.61* 
   
Saccharin Licks -4 to 0 89.16±55.43/72.69±75.55 449.55±239.39/493.86±136.51 
Saccharin Licks 1-5 77.60±63.48/261.03±141.84 438.87±241.30/322.91±259.64 
Saccharin Licks 6-10 73.02±53.62/206.26±85.20 401.15±226.82/260.66±254.38 
Saccharin Licks 11-15 54.65±37.93/153.14±118.60 454.47±193.53/210.41±209.70* 
   
Water Visits -4 to 0 0.84±0.44/0.97±0.65 6.27±4.22/4.75±2.62 
Water Visits 1-5 1.07±0.75/1.86±1.16 7.33±4.95/1.03±0.61* 
Water Visits 6-10 1.65±1.19/6.57±3.46** 6.39±5.05/1.69±1.29** 
Water Visits 11-15 1.13±1.06/4.75±3.70* 7.83±4.11/2.39±2.05** 
   
Water Nosepokes -4 to 0 1.13±1.22/1.60±1.60 12.75±18.38/10.74±10.88 
Water Nosepokes 1-5 1.51±1.28/2.03±1.08 11.27±11.77/1.03±1.56** 
Water Nosepokes 6-10 1.38±1.16/4.89±3.55 13.78±18.66/1.06±0.98* 
Water Nosepokes 11-15 1.24±1.06/4.25±2.94 15.45±16.40/3.09±2.71* 
   
Water Licks -4 to 0 2.84±3.94/3.43±6.31 20.60±30.60/35.34±67.25 
Water Licks 1-5 10.20±14.14/114.23±120.18** 36.15±63.86/8.23±9.38 
Water Licks 6-10 8.04±11.53/178.74±193.32*** 16.85±32.51/23.09±44.37 
Water Licks 11-15 5.46±7.39/74.18±107.45 38.95±70.58/22.77±30.57 
   
Preference Visits -4 to 0 73.39±6.47/65.20±17.70 66.81±9.04/67.94±11.96 
Preference Visits 1-5 68.96±14.08/74.09±11.20 62.71±9.25/81.66±9.78** 
Preference Visits 6-10 69.27±9.89/58.84±8.63* 67.13±8.94/79.64±11.39* 
Preference Visits 11-15 70.95±17.40/59.42±16.45 59.42±10.86/70.58±17.10 
   
Preference Nosepokes -4 to 0 80.61±9.61/67.03±22.96 72.14±16.14/70.02±15.43 
Preference Nosepokes 1-5 71.23±14.89/81.60±9.55 71.38±10.34/88.10±11.34* 
Preference Nosepokes 6-10 71.52±18.67/62.51±13.15 71.26±16.39/87.88±10.21 
Preference Nosepokes 11-15 73.86±22.14/58.96±23.84 66.33±16.60/74.89±17.83 
   
Preference Licks -4 to 0 97.60±3.31/91.46±18.28 96.24±3.67/93.40±12.56 
Preference Licks 1-5 92.89±8.48/75.55±17.50* 93.88±8.80/93.94±7.40 
Preference Licks 6-10 91.76±14.15/77.46±15.67 96.22±8.03/96.01±6.17 
Preference Licks 11-15 87.53±23.70/70.17±27.79 92.69±11.53/87.10±16.35 
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Table S2. Summary of IntelliCage behaviour in Experiment C2, according to reward, drug group, 
day-block and time-period 
              
 Light Phase (20-00 h, 00-04 h) Dark Phase (08-12 h, 12-16 h) 
Reward/Measure/Day-block VEH/AGO VEH/AGO 
Saccharin Visits -4 to 0 1.85±1.11/2.45±1.23 14.30±6.32/12.28±3.93 
Saccharin Visits 1-5 4.23±1.48/3.45±1.47 11.03±3.53/9.43±2.71 
Saccharin Visits 6-10 2.88±1.23/3.10±1.89 8.23±4.66/12.45±6.35 
Saccharin Visits 11-15 1.58±0.94/2.50±0.87 10.93±4.30/10.78±3.08 
Saccharin Visits 16-20 1.63±0.74/2.35±1.44 11.28±3.12/8.69±2.15 
   
Saccharin Nosepokes -4 to 0 2.83±1.59/3.78±2.12 27.45±21.47/19.73±6.62 
Saccharin Nosepokes 1-5 7.65±3.60/5.60±2.35 19.15±11.10/14.80±4.32 
Saccharin Nosepokes 6-10 6.25±3.67/5.88±3.93 14.18±7.59/17.95±5.45 
Saccharin Nosepokes 11-15 3.05±1.65/4.18±1.41 15.88±9.59/16.25±5.43 
Saccharin Nosepokes 16-20 2.67±1.60/4.16±2.78 11.43±13.7114.08±4.87 
   
Saccharin Licks -4 to 0 60.70±58.53/82.95±46.83 557.63±149.45/723.08±249.23 
Saccharin Licks 1-5 225.93±163.18/135.23±34.58 666.23±280.45/448.53±237.54 
Saccharin Licks 6-10 170.58±120.48/115.08±67.63 532.45±316.55/428.93±198.57 
Saccharin Licks 11-15 62.43±44.38/120.13±74.29 379.25±178.36/475.83±200.32 
Saccharin Licks 16-20 64.43±50.11/110.17±61.19 515.45±220.31/334.64±120.43 
   
Water Visits -4 to 0 0.68±0.46/0.78±0.37 6.40±3.53/4.98±2.70 
Water Visits 1-5 1.08±0.59/1.58±1.27 3.48±1.76/3.83±2.01 
Water Visits 6-10 1.40±0.57/1.78±1.12 3.95±2.26/5.70±3.94 
Water Visits 11-15 0.85±0.48/1.05±0.62 6.50±3.99/5.35±3.59 
Water Visits 16-20 1.38±0.43/1.35±0.61 5.48±2.14/3.30±2.33 
   
Water Nosepokes -4 to 0 0.70±0.54/0.63±0.27 8.43±7.02/6.53±4.55 
Water Nosepokes 1-5 1.48±1.34/3.20±3.11 3.93±3.87/3.93±3.14 
Water Nosepokes 6-10 2.10±1.36/2.9±2.45 5.13±4.88/5.80±5.45 
Water Nosepokes 11-15 1.33±1.26/1.85±1.22 7.93±7.84/5.90±3.77 
Water Nosepokes 16-20 1.68±0.92/2.08±0.88 6.55±3.26/4.16±3.3.7 
   
Water Licks -4 to 0 0.08±0.20/0.80±1.44 3.45±5.37/4.68±10.06 
Water Licks 1-5 22.13±31.11/39.45±59.39 36.05±53.63/59.43±79.29 
Water Licks 6-10 35.73±35.02/45.16±86.44 81.78±131.70/80.75±176.67 
Water Licks 11-15 12.55±15.52/37.63±52.55 67.70±96.33/78.65±130.54 
Water Licks 16-20 12.53±14.98/33.61±42.62 27.68±50.65/62.73±111.84 
   
Preference Visits -4 to 0 73.22±15.32/78.09±9.62 69.16±10.86/73.20±10.11 
Preference Visits 1-5 80.37±8.49/71.44±16.03 76.14±9.15/71.17±13.85 
Preference Visits 6-10 66.69±8.13/64.97±13.66 66.75±14.22/69.34±17.49 
Preference Visits 11-15 67.29±14.83/72.18±10.75 64.06±9.19/69.65±11.39 
Preference Visits 16-20 52.40±14.96/65.34±20.03 67.15±9.47/75.02±12.52 
   
Preference Nosepokes -4 to 0 79.91±19.27/85.45±8.90 75.11±15.51/75.91±13.37 
Preference Nosepokes 1-5 85.25±8.29/69.91±23.54 84.81±8.62/80.32±14.00 
Preference Nosepokes 6-10 72.38±12.86/70.05±19.69 73.89±15.81/77.09±20.41 
Preference Nosepokes 11-15 75.63±15.30/71.88±13.19 68.59±14.20/75.27±11.85 
Preference Nosepokes 16-20 59.58±19.56/67.70±17.59 74.28±13.22/80.07±13.98 
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Preference Licks -4 to 0 99.46±1.42/98.59±2.90 99.32±1.23/99.04±2.01 
Preference Licks 1-5 91.74±10.22/85.41±18.89 94.42±6.73/89.31±17.10 
Preference Licks 6-10 86.29±11.62/83.69±27.40 83.45±20.18/87.94±25.78 
Preference Licks 11-15 85.95±13.64/84.04±19.60 85.57±15.87/88.72±15.83 
Preference Licks 16-20 88.28±9.08/81.37±22.13 93.84±10.05/89.29±19.07 
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General discussion 
1. Stress, inflammation and dopamine: a route to depression 
In the present PhD thesis the effects of neurochemical, environmental and pharmacological 
manipulations on reward and punishment processing in mice have been investigated. 
In Study A it was demonstrated that chronic DA depletion in the NAcc, achieved using the 
catecholaminergic neurotoxin 6-OHDA, impacts on mouse motivation, namely impairing approach 
behaviour towards positive stimuli (i.e. palatable rewards) and reducing escape/avoid behaviour 
towards negative events (i.e. footshocks). Specifically, NAcc DA depletion led to decreased 
responding for rewards in the progressive ratio schedule (PRS) test, and to a stimulus with changing 
association with gustatory reward in the learned non-reward (LNR) test. It reduced responding to 
footshock recently experienced as uncontrollable in the learned helplessness (LH) test, and to 
footshock that could only be avoided-escaped by physical effort in the treadmill test. In contrast to 
these motivational effects on operant behaviour, NAcc DA depletion did not affect the learning of or 
memory for stimulus-stimulus learning in the Pavlovian fear conditioning test. In Study B I have 
demonstrated that CSD leads to reduced DA turnover and c-fos expression in the NAcc, and to 
reduced sensitivity to pharmacologically-induced increased synaptic DA availability, in terms of 
locomotion/exploration and NAcc immediate-early gene expression. Furthermore, in Studies B and C 
I have demonstrated that CSD leads to reduced reward-directed behaviour in the LNR and PRS tests 
and also in the probabilistic reversal learning (PRL) test. Therefore, integrating the findings from 
these two studies provides robust evidence that CSD effects on NAcc DA neurotransmission underlies 
the CSD-induced deficits in reward-directed behaviour, particularly in terms of impaired motivation. 
With regard to CSD-induced effects on behaviour towards negative events, a previous study in our 
laboratory has demonstrated that CSD leads to increased fear conditioning, to decreased 2-way 
avoid-escape responding (i.e. increased helplessness) similar to that induced by NAcc DA depletion, 
and to reduced running in the treadmill, again similar to that induced by NAcc DA depletion 
(Azzinnari et al., 2014). Extrapolating from Study A, it would appear that CSD induces motivational 
deficits with respect to positive- and negative-valence stimuli and that altered NAcc DA function 
contributes significantly to these deficits. Furthermore, given that CSD increases fear conditioning 
whereas NAcc DA depletion is without effect, CSD effects clearly extend beyond the VTA-NAcc DA 
pathway with altered amygdala function being a major candidate (Azzinnari et al., 2014). 
 Thus, the current PhD thesis, adopting an RDoC-informed approach on translational research 
for depression, suggests that behavioural domains pertaining to positive and negative valence 
system (PVS and NVS) are directly affected by social stress and inhibition of DA transmission. 
Moreover, as presented in Study B, stress-induced inflammation represents a candidate mechanism 
linking stress, mesolimbic DA dysregulation and the observed behavioural changes. 
1.1 Cell-mediated immune activation and inflammation in depression 
As mentioned in section 3.1 of Introduction, depression is characterized by inflammation and cell-
mediated immune activation (Maes, 2011). Indeed, it has been shown that depression is 
characterized by higher numbers of peripheral blood mononuclear cells (PBMCs), including both 
lymphocytes and monocytes (Maes et al., 1992; Seidel et al., 1996). Moreover, Chen et al. (2011) 
showed an increase in peripheral Th17 cell number, a higher level of mRNA expression for retinoic 
acid-related orphan receptor-γt (RORγt), the specific transcription factor of Th17 cells, in peripheral 
blood lymphocytes, and increased serum concentration of IL-17, in depressed subjects. In my thesis I 
demonstrate that CSD leads to a higher number of splenic myeloid cells (namely, granulocytes and 
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inflammatory monocytes) and Th17 cells. It has been shown proposed that stress increases the 
production of myeloid cells in the bone marrow, that then traffic to the blood, spleen and brain 
(Reader et al., 2015; Wohleb et al., 2014b), thus contributing to the increased inflammatory 
cytokines levels observed in tissues and blood. Interestingly, chronic stress-induced leucocytosis is 
associated with non-response to the anti-inflammatory effects of glucocorticoid (GC) and a 
transcriptional profile that is consistent with the expansion and priming of myeloid-derived cells, in 
both humans and rodents (Cohen et al., 2012; Powell et al., 2013; Reader et al., 2015). In addition to 
immune system activation, acute stress is also known to induce suppression of the immune system, 
in part by the anti-inflammatory effects of increased GC. Stressful life experiences, including long-
term threat, are associated with a higher probability of developing a cold following exposure to a 
rhinovirus (Cohen et al., 2012; Miller et al., 2008b). This effect has been proposed to depend on 
chronic stress-induced GC resistance  (Engler et al., 2004), resulting in reduced control over the 
inflammatory response to the viral infection, thus leading to a greater expression of the disease 
(Cohen et al., 2012). Interestingly, in Study B, the reduced MHC II surface expression on splenic 
myeloid cells in CSD mice is suggestive of stress-induced immunosuppression. Together with 
leucocytosis, depressed subjects also show increased levels of inflammation and immune response 
biomarkers in the blood, including C-reactive protein (CRP) and the pro-inflammatory cytokines TNF-
α and IL-6 (Lopresti et al., 2014). Interestingly, studies from this laboratory demonstrate that CSD 
leads to increased peripheral levels of TNF-α, IL-6, IFNγ (Azzinnari et al., 2014; Fuertig et al., in prep). 
These effects co-occur with CSD-induced marked adrenomegaly, suggesting chronic activation of the 
hypothalamic-pituitary-adrenal axis (Azzinnari et al., 2014). I have shown that myeloid cells in the 
spleen express higher levels of TNF-α and IFNγ (Study B). Oxidative stress markers (e.g. superoxide 
dismutase, 8-Hydroxy-2-deoxyguanosine (8-OHdG)) have also been shown to be increased in the 
blood of depressed patients (Lopresti et al., 2014). To assess oxidative stress response to CSD, I 
measured plasma levels of inducible nitric oxide synthase (iNOS), and found this to be increased in 
CSD mice (Study B). 
 Inflammatory conditions are known to regulate the metabolism of tryptophan (Schwarcz et 
al., 2012). Tryptophan is converted into kynurenine (KYN) by the enzymes indoleamine 2,3-
dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). KYN is further metabolized into other 
tryptophan catabolites (TRYCATs), namely 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid 
(3-HANA), through the enzymatic activity of kynurenine 3-monooxygenase (KMO) and kynureninase 
(Kynu). KYN can also be converted into kynurenic acid (KYNA) by kynurenine aminotransferases 
(KATs). The neuroactive metabolite quinolinic acid (QA) is also formed from 3-HK with the enzymatic 
participation of 3-hydroxyanthranilate oxygenase (3-HAO) (Colin-Gonzalez et al., 2013). KYN and 3-HK 
can be transported across the blood-brain barrier (BBB); indeed about 60% of brain KYN is derived 
from the periphery. Conversely, KYNA and QA cannot be transported across the BBB (Schwarcz et al., 
2012) and need to be formed in the brain. In the brain, tryptophan degradation takes place mainly in 
microglia and astrocytes (Myint and Kim, 2014), with microglia cells producing KYN, 3-HK and QA and 
astrocytes being a major source of KYNA (Schwarcz et al., 2012). In addition, astrocytes can 
metabolize QUIN produced by microglia (Guillemin et al., 2001), thus controlling brain levels of QA. 
During inflammatory conditions, pro-inflammatory cytokines and reactive oxygen species (ROS) can 
enhance the activity of the enzyme IDO in extrahepatic tissues (lungs, placenta, kidneys, spleen, 
blood and brain) and of TDO in the liver and brain (Lestage et al., 2002; Walker et al., 2013). Although 
IDO expression is directly regulated by inflammatory molecules (e.g. IFN-γ), TDO up-regulation is 
mainly mediated by increased GC secretion (Campbell et al., 2014). Interestingly, the KYN pathway of 
tryptophan degradation is activated directly by inflammatory factors (Gibney et al., 2013) as well as 
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by environmental stress (Agudelo et al., 2014; Liu et al., 2013). This laboratory has recently 
demonstrated that CSD increases plasma and brain levels of KYN and 3-HK (Fuertig et al., in prep). In 
Study B of my thesis I demonstrate that the increased levels of TRYCATs might stem from the 
activation of KYN pathway enzymes in the liver, primarily under the rate-limiting factor of increased 
TDO. Interestingly, there are reports of KYN pathway activation in depression, both in the periphery 
and in the brain (Steiner et al., 2011; Sublette et al., 2011). Moreover, effective antidepressant 
treatments have been shown to modulate the KYN pathway, shifting KYN TRYCATs balance towards 
metabolites with a neuroprotective profile (Guloksuz et al., 2015). 
 Thus, CSD-induced peripheral immune response can activate the KYN pathway in the liver, 
and this, possibly in combination with increased KYN pathway activity in other tissues, leads to 
increased levels of KYN and 3-HK in the blood and translocation to the brain, where they can be 
converted to QA by microglia cells, with the latter increased in specific brain regions including the 
VTA (see Study B). In the brain, TRYCATs can exert a number of effects on neural and glial physiology, 
thus influencing the occurrence of behavioural changes.   
1.2 Impact of Kynurenine pathway activation on brain cells 
TRYCATs exert a plethora of effects that could contribute to the pathophysiology of depression, 
including modulation of neuronal cell death, glutamate transmission, and neuroinflammation (Myint 
and Kim, 2014). The KYN metabolites contribute directly to the neuroprotective/neurodegenerative 
changes in the brain through the interaction with several neurotransmitter systems and cell types.  
 KYNA and QA exert opposite effects on brain physiology. KYNA acts as an antagonist on 
glutamate NMDA receptors and on α7 nicotinic acetylcholine receptors (α7nAChR) (Schwarcz et al., 
2012). In addition, KYNA can be considered as a potential endogenous antioxidant, through its free-
radical scavenging activity (Lugo-Huitron et al., 2011). Conversely, QA is an agonist on NMDAR and is 
a source of oxidative stress (Rios and Santamaria, 1991). Since QA is a strong NMDAR agonist, 
sustained activation of NMDAR by QA may induce neuronal excitotoxicity through increased 
intracellular calcium concentration (Vandresen-Filho et al., 2015). It has been shown that when a 
single dose of QA is administered to the striatum, a reduction in the number of striatal neurons, with 
a decrement in the GABAergic neuronal population, is observed (Moresco et al., 2008; Perez-De La 
Cruz et al., 2012).  
 Regarding the effect of 3-HK on brain cells, there is currently no consensus with respect to 
whether it is primarily neuroprotective or neurodegenerative (Colin-Gonzalez et al., 2014). Under 
homeostatic conditions, 3-HK acts as a modulatory metabolite, with a major function of maintaining 
cellular redox homeostasis (Colin-Gonzalez et al., 2013). In vitro studies suggest that high levels of 3-
HK can induce apoptotic cell death in cultures of striatal and cortical neurons, and in cerebellar 
granule cells (Chiarugi et al., 2001; Colin-Gonzalez et al., 2013). However, it is debated as to whether 
such effects are of relevance to in vivo effects of high 3-HK levels in brain (Colin-Gonzalez et al., 
2014). Nakagami et al. (1996) showed that intra-striatal injection of 3-HK induces tissue damage 
around the injected site, but the cellular mechanism mediating its effects are unclear. It has been 
shown that the striatum of animals infused with 3-HK exhibits moderate levels of lipid and protein 
oxidation at a few hours post-lesion and that these effects are diminished across longer time 
intervals (days), such that long-term behavioural alterations or morphological changes in the injected 
striata are absent (Colin-Gonzalez et al., 2014). These data suggest that whilst 3-HK might exert pro-
oxidant actions under certain conditions, it acts more as a redox modulatory molecule than as a 
neurotoxic metabolite (Colin-Gonzalez et al., 2014). 
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 Thus, although CSD results in activation of the KYN pathway in the periphery, and blood and 
brain levels of KYN and 3-HK are increased in CSD mice (Fuertig et al., in prep), investigating the 
effects of CSD on brain levels of QA will be essential to understanding of the extent to which KYN-
pathway activation is a neuropathological process affecting brain cell physiology (e.g. neurons, 
oligodendrocytes, astrocytes), and inducing behavioural changes. CSD-induced increase in QA levels 
might affect the physiology of several neuronal populations, including DAergic cells and inhibitory 
GABAergic interneurons. Interestingly, QA influences several neurotransmitter systems in the 
striatum, including DA and serotonin levels (Jamwal et al., 2015). Moreover, Feng et al. (2014) 
showed that intra-striatal injection of QA induces motor and cognitive impairments that correlate 
with a reduced number of striatal (DARPP-32+) projection neurons and parvalbumin (Pvalb)+ 
GABAergic interneurons. However, the degenerative effects of QA are not only restricted to neurons 
and also include astrocytes (Guillemin et al., 2005) and oligodendrocytes (Cammer, 2001; Sundaram 
et al., 2014). Using whole-transcriptome RNA sequencing (RNA-seq), this laboratory has 
demonstrated that CSD mice show lower expression levels of GABA interneuron markers (e.g. Pvalb) 
and of oligodendrocyte-myelin genes (e.g. Mag, Mobp, Opalin, Aspa), in the amygdala (Azzinnari et 
al., 2014). Thus, it can by hypothesized that CSD-induced activation of the KYN pathway includes 
increased brain levels of QA, which in turn could affect the function/survival of DAergic and 
GABAergic neurons, and of oligodendrocytes. 
 As indicated above, QA is an agonist at NMDAR, and its detrimental effects on brain cells 
might be mediated by excitotoxic mechanisms (Schwarcz et al., 2012).  It has been shown that QA 
stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes (Tavares et 
al., 2002). These effects could contribute to increase extracellular glutamate concentrations, which 
then lead to overstimulation of the glutamatergic system (Tavares et al., 2002). Interestingly, 
depressive-like behaviours induced by the inflammatory toxin lipopolysaccharide (LPS) can be 
prevented by co-administration of the NMDAR antagonist and experimental anti-depressant, 
ketamine (Walker et al., 2013). This suggests that LPS-induces an increase in QA that then induces 
depressive-like behaviours, such that pharmacological blockade of NMDAR can prevent their onset. 
These findings are highly relevant for depression research, given the now fairly numerous reports 
that ketamine is efficacious as a rapid-onset therapy for treatment-resistant depression (Kirby, 2015; 
Yang et al., 2015; Zarate et al., 2006). This laboratory has shown that inhibition of the KYN pathway 
using an IDO1 inhibitor reverses CSD-induced behavioural changes (Fuertig et al., in prep), suggesting 
that activation of the KYN pathway is not only a marker for immune system activation but plays a 
causal role in CSD-induced behavioural changes.  
 Therefore, a link can be made between these and previous findings with the CSD mouse 
model and the hypothesis that stress-induced activation of the KYN pathway, and the consequent 
increase in brain QA levels, contributes to the aetiopathophysiology of depression-relevant 
behaviours. Accordingly, targeting of this pathway represents a promising approach for the 
identification of effective antidepressant pharmacological treatments. 
2. Limitations of the thesis and outlook 
This thesis provides evidence for the psycho-neuro-immune hypothesis for depression, suggesting 
that psychosocial stress activates the immune system, which in turn affects dopamine transmission 
and disrupts reward processing. In Study A, a causal relationship between reduced DA signaling in the 
NAcc and disrupted processing of positive and aversive stimuli has been demonstrated, providing 
indirect evidence that some of the same behavioural deficits observed in CSD mice might be 
underlain by the DA deregulation also observed in CSD mice. Moreover, this laboratory has 
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conducted a study demonstrating that an inhibitor of IDO1 reverses the increases in KYN and 3-HK 
plasma and brain levels and conditioned fear expression in CSD mice (Fuertig et al., in prep). This 
constitutes further support for the existence of a causal link between CSD-induced inflammation and 
behavioural changes. However, despite the aforementioned findings, direct evidence for a causal 
relationship linking CSD-induced inflammation to DA signaling deregulation is still lacking. Further 
investigations will need to address this issue. For example, this should include experiments assessing 
the effects of KYN pathway blockade on markers of DA signalling that are affected by CSD (i.e. NAcc 
DA turnover and behavioural sensitivity to GBR 12909). 
 Another critical question regards the potential contribution of the different TRYCATs to the 
observed brain and behavioural effects. Studies from this laboratory have demonstrated that KYN 
and 3-HK brain levels are increased in CSD mice, but CSD effects on QA brain levels could not be 
determined to-date due to the insufficient sensitivity for QA of the LC-MS/MS methodology used  
(Fuertig et al., in prep). To overcome this issue, we have recently established an 
immunohistochemical method for detection of QA in brain cells, based on a human report (Steiner et 
al., 2011). Thus, using immunohistochemistry it will be possible to assess CSD effects on brain QA 
levels. In the case that both 3-HK and QA brain levels are increased by CSD, brain region-specific 
infusion of both compounds followed by behavioural testing would provide important indications 
regarding their contributions to the CSD model. Given the findings of this thesis, then the VTA-NAcc 
pathway would be a major network of interest for such TRYCAT infusion experiments. Moreover, 
given the differences in the mechanism of action of 3-HK and QA, identification of the molecule 
contributing to the behavioural changes would have important implications regarding the 
understanding of CSD-induced brain pathology and the development of novel therapeutics. As stated 
above, there is currently diverse evidence for the cellular and molecular effects of 3-HK. Whilst 3-HK 
has been associated with free radical generation and induction of cell apoptosis, in vitro (Schwarcz 
and Pellicciari, 2002), it has also been proposed, based on in vivo evidence, that 3-HK acts more as a 
redox modulatory molecule than a neurotoxic metabolite (Colin-Gonzalez et al. (2014). In contrast, 
QA, with its NMDAR agonistic activity, is unequivocally recognised as a neurotoxic molecule 
(Schwarcz et al., 2012). Interestingly, 3-HK can interact synergistically with QA to potentiate the 
latter’s effects on brain cells (Guidetti and Schwarcz, 1999), thus suggesting that both TRYCATs might 
act in unison to induce KYN pathway activation-dependent neuropathology. 
 Given our findings of CSD-induced DA deregulation and increased TRYCATs levels, studying 3-
HK and QA effects on the DA system will be important with respect to attempting to identify the 
pathophysiological mechanism of stress-induced inflammation, brain pathology and behavioural 
disruption. As described above, 3-HK acts as a redox modulatory molecule while QA mainly acts via 
excitotoxicity and oxidative stress mechanisms (Colin-Gonzalez et al., 2014; Perez-De La Cruz et al., 
2012). Of note, VTA DAergic neurons are under extensive control of glutamatergic transmission 
(Ungless et al., 2003) acting through NMDA receptors (Zweifel et al., 2011). Interestingly, Parkinson’s 
disease (PD) research has shown that DA neurons are vulnerable to both excitotoxicity (Ambrosi et 
al., 2014) and oxidative stress (Blesa et al., 2015). Moreover, anti-oxidant compounds (e.g. N-
acetylcysteine) and NMDAR antagonists (e.g. ifenprodil) provide neuroprotection to DA cells (Assous 
et al., 2014). This suggests that one of the mechanisms of action of the NMDAR antagonist ketamine 
as an antidepressant would be to counteract QA-induced excitotoxicity (Walker et al., 2013); at least 
in a subpopulation of patients with increased brain QA levels (Steiner et al., 2011). Thus, 
excitotoxicity and oxidative stress represent two ‘drugable’ molecular processes, blockade of which 
might counteract the relevant neuronal effects of stress-induced inflammation. 
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 Another possibility is that TRYCATs might exert detrimental effects on DA transmission 
affecting dopaminoceptive cells. For example, QA increases Ca2+ influx and induces excitotoxicity in 
GABAergic striatal medium spiny neurons (MSNs), the major cell type in the NAcc (Perez-De La Cruz 
et al., 2012), and reduces striatal adenosine A2A and dopamine D2 receptors (Moresco et al., 2008). 
QA-induced Ca2+ influx provokes long-lasting dysregulation of the cytoskeletal homeostasis (Pierozan 
et al., 2014), and these effects are mediated by phosphorylating proteins, including PKA and Cdk5 
(Pierozan et al., 2012). Activity of PKA and Cdk5 controls DARPP-32 phosphorylation status at Thr-34 
and Thr-75 (see Introduction, section 2.1). DARPP-32 is enriched in striatal MSNs (Zachariou et al., 
2006) and is a crucial mediator of the biochemical, electrophysiological, transcriptional, and 
behavioural effects of DA (Svenningsson et al., 2004). Therefore, QA might impact on post-synaptic 
DA signaling by modulating DARPP-32 activity, such that local synthesis of QA could disrupt 
dopaminoceptive cell function throughout the brain (Pierozan et al., 2014). 
 As presented above, excitotoxicity mechanisms represent a possible neuropathological 
pathway in depression (Steiner et al., 2012). However, the KYN pathway is certainly not the only 
potential candidate responsible for glutamate-dependent cell damage. Indeed, it has been proposed 
that Th17 cells could use glutamate-mediated excitotoxicity as a mechanism in the pathogenesis of 
multiple sclerosis (MS) (Kostic et al., 2014). Siffrin et al. (2010) have shown that Th17 cells induce Ca2+ 
changes in an antigen-independent manner in brain cells, thus inducing neuronal dysfunction. 
Interestingly, it has been shown that stress increases Th17 cells in the brain (Beurel et al., 2013), and 
I report increased Th17 cells in the spleen of CSD mice (Study B). However, I could not identify any 
effect of CSD on Th17 cells at the level of the whole brain. Histological analysis is needed to 
investigate whether a higher number of T cells is evident in the brain at different time points during 
CSD or if there might be a brain-region specific increase. 
 Studying the cellular and molecular effects of CSD on specific cell populations will be 
essential for a thorough understanding of the neuropathology associated with CSD-induced 
inflammation and behavioural changes, and for the identification of possible drug targets. As 
mentioned above, together with deregulation of the mesolimbic DA system, this laboratory has 
shown reduced expression of genes related to GABAergic interneurons (Pvalb) and oligodendrocytes 
(i.e. Mag, Mobp, Opalin, Aspa) in the amygdala (Azzinnari et al., 2014). However, despite the 
indication that CSD affects the GABAergic interneurons and oligodendrocytes, these data do not 
provide any information on the signaling pathways affected by CSD in those specific cell types. To 
answer this question, transgenic mice expressing fluorescent proteins (e.g. EGFP) controlled by cell-
specific promoters (Lobo et al., 2006) can be used in combination with FACS to isolate DAergic 
neurons, GABAergic interneurons and oligodendrocytes. Analysing cell-type specific transcriptome 
changes using RNA-seq will be informative regarding the molecular events occurring in neurons and 
oligodendrocytes. Dysregulated genes and pathways will then need to be further validated in vivo 
using loss/gain-of-function experiments (Stuber and Mason, 2013), in order to identify those playing 
a causal role in the occurrence of CSD-induced behavioural disturbances. The ultimate goal of such 
an approach is to develop cell-specific pharmacotherapies targeting a defined dysfunctional gene 
product (Stuber and Mason, 2013). The advantage of cell-specific pharmacotherapies would be to 
overcome systemic toxicity and off-target effects, while enhancing therapeutic efficiency (Stuber and 
Mason, 2013). For example, pharmacological targeting of the KYN pathway using cell-specific IDO1 
inhibition might be preferred to systemic administration (Sundaram et al., 2014). Indeed, despite the 
positive effect of systemic IDO1 inhibition in reducing the synthesis of QA within myeloid cells, it 
could also reduce the production of the neuroprotective KYNA in astrocytes, thus impairing the 
formation of neuroprotective metabolites within the brain (Sundaram et al., 2014). Interestingly, it 
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has been shown that systemic IDO inhibition can exacerbate clinical and histopathological 
parameters in the experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis 
(Sakurai et al., 2002). In preclinical animal research, cell type-specific transcriptional profiles 
associated to stress exposure as well as the targeting of specific gene products in a brain region- and 
cell type-specific manner, can be achieved using RNA-seq of FACS sorted cells and viral-mediated 
overexpression or knockdown of target genes to reverse the behavioural effect of stress (Stuber and 
Mason, 2013). However, the translational capability of such an approach to humans is limited. Thus, 
the development of biological tools allowing the assessment of cell-type specific status and cell-type 
specific targeting in humans is necessary (Stuber and Mason, 2013).  
3. Implication for depression research 
As I stated in the Introduction to my thesis, the clinical heterogeneity of depression is the 
phenomenological reflection of multiple pathophysiological routes targeting particular 
behavioural/cognitive domains (Webb et al., 2015). Resolution of such an heterogeneity and 
classification of mental disorders in term of dysfunction in specific behavioural domains is the 
objective of the NIHM RDoC initiative (Cuthbert, 2015). The RDoC project considers psychiatric 
diseases from a translational research perspective and supports the development of a precision 
medicine approach for mental disorders (Cuthbert and Insel, 2013). A precision medicine approach in 
psychiatry can be operationalized with studies that investigate the contribution of genetic, 
environmental and developmental factors to alteration of a defined behavioural dimension. 
However, behavioural assessment has to be coupled with the measurement of biomarkers to further 
boost the patient stratification and give precise indication for treatments. The link between the 
immune system and depression offers an example for such an approach. It has been shown that 
depression is associated with microglia activation in cortico-limbic brain regions, both in post-
mortem studies (Torres-Platas et al., 2014) and in vivo using PET imaging (Setiawan et al., 2015). PET 
imaging provides brain region-specific information on microglia activation that can be used for 
patient-specific treatment indications. For example, administration of minocycline, which suppresses 
microglia activation (Seabrook et al., 2006), has been proposed as an adjunctive therapy for 
depression (Miyaoka et al., 2012; Soczynska et al., 2012). Thus, regarding the psycho-neuro-immune 
hypothesis for depression presented in this thesis, future human studies will have to investigate the 
existence of CNS inflammatory markers (e.g. TSPO PET imaging) and DA system dysregulation (e.g. 
fMRI brain activity during reward-related tasks) in homogeneous populations of patients sharing the 
alteration of a specific behavioural domain (e.g. reduced approach motivation). Preclinical 
investigations would focus on the same behavioural domain using the appropriate behavioural tests 
and investigate the effects of experimental manipulations (e.g. stress exposure) on brain 
inflammation and neurotransmission. Mechanistic experiments would then be informative on the 
causality existing between brain inflammation, neural transmission deregulation and behavioural 
disturbances, and would help identifying and validating novel treatment targets. 
  
111 
 
  
112 
 
References 
 
Abdallah, L., Bonasera, S.J., Hopf, F.W., O'Dell, L., Giorgetti, M., Jongsma, M., Carra, S., Pierucci, M., Di 
Giovanni, G., Esposito, E., et al. (2009). Impact of serotonin 2C receptor null mutation on physiology 
and behavior associated with nigrostriatal dopamine pathway function. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 29, 8156-8165. 
Aberman, J.E., and Salamone, J.D. (1999). Nucleus accumbens dopamine depletions make rats more 
sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience 92, 
545-552. 
Abramson, L.Y., Seligman, M.E., and Teasdale, J.D. (1978). Learned helplessness in humans: critique and 
reformulation. J Abnorm Psychol 87, 49-74. 
Agudelo, L.Z., Femenia, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, 
J.C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., et al. (2014). Skeletal muscle PGC-1alpha1 modulates 
kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159, 33-45. 
Alexander, G.E., Crutcher, M.D., and DeLong, M.R. (1990). Basal ganglia-thalamocortical circuits: Parallel 
substrates for motor, oculomotor, “prefrontal” and “limbic” functions. In Progress in Brain Research 
(Elsevier BV), pp. 119-146. 
Allen, C.P., and Leri, F. (2014). Perseveration in the presence of punishment: The effects of chronic 
cocaine exposure and lesions to the prefrontal cortex. Behavioural brain research 261, 185-192. 
Amat, J., Paul, E., Watkins, L.R., and Maier, S.F. (2008). Activation of the ventral medial prefrontal cortex 
during an uncontrollable stressor reproduces both the immediate and long-term protective effects of 
behavioral control. Neuroscience 154, 1178-1186. 
Ambrosi, G., Cerri, S., and Blandini, F. (2014). A further update on the role of excitotoxicity in the 
pathogenesis of Parkinson's disease. Journal of neural transmission 121, 849-859. 
Amital, D., Fostick, L., Silberman, A., Beckman, M., and Spivak, B. (2008). Serious life events among 
resistant and non-resistant MDD patients. Journal of affective disorders 110, 260-264. 
Anisman, H., and Merali, Z. (2001). Rodent models of depression: learned helplessness induced in mice. 
Current protocols in neuroscience / editorial board, Jacqueline N Crawley  [et al] Chapter 8, Unit 8 
10C. 
Aranami, T., and Yamamura, T. (2008). Th17 Cells and Autoimmune Encephalomyelitis (EAE-MS). 
Assadi, S.M., Yücel, M., and Pantelis, C. (2009). Dopamine modulates neural networks involved in effort-
based decision-making. Neuroscience & Biobehavioral Reviews 33, 383-393. 
Assous, M., Had-Aissouni, L., Gubellini, P., Melon, C., Nafia, I., Salin, P., Kerkerian-Le-Goff, L., and 
Kachidian, P. (2014). Progressive Parkinsonism by acute dysfunction of excitatory amino acid 
transporters in the rat substantia nigra. Neurobiology of disease 65, 69-81. 
Ataka, K., Asakawa, A., Nagaishi, K., Kaimoto, K., Sawada, A., Hayakawa, Y., Tatezawa, R., Inui, A., and 
Fujimiya, M. (2013). Bone marrow-derived microglia infiltrate into the paraventricular nucleus of 
chronic psychological stress-loaded mice. PloS one 8, e81744. 
Avitsur, R., Stark, J.L., Dhabhar, F.S., Padgett, D.A., and Sheridan, J.F. (2002). Social disruption-induced 
glucocorticoid resistance: kinetics and site specificity. Journal of neuroimmunology 124, 54-61. 
Azzinnari, D., Sigrist, H., Staehli, S., Palme, R., Hildebrandt, T., Leparc, G., Hengerer, B., Seifritz, E., and 
Pryce, C.R. (2014). Mouse social stress induces increased fear conditioning, helplessness and fatigue 
to physical challenge together with markers of altered immune and dopamine function. 
Neuropharmacology 85, 328-341. 
Badawy, A.A. (2013). Tryptophan: the key to boosting brain serotonin synthesis in depressive illness. 
Journal of psychopharmacology 27, 878-893. 
Bakunina, N., Pariante, C.M., and Zunszain, P.A. (2015). Immune mechanisms linked to depression via 
oxidative stress and neuroprogression. Immunology. 
Balkowiec-Iskra, E., Kurkowska-Jastrzebska, I., Joniec, I., Ciesielska, A., Czlonkowska, A., and Czlonkowski, 
A. (2007). Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following 
myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) 
administration. Acta neurobiologiae experimentalis 67, 379-388. 
113 
 
Barch, D.M., Treadway, M.T., and Schoen, N. (2014). Effort, anhedonia, and function in schizophrenia: 
reduced effort allocation predicts amotivation and functional impairment. J Abnorm Psychol 123, 
387-397. 
Bari, A., Theobald, D.E., Caprioli, D., Mar, A.C., Aidoo-Micah, A., Dalley, J.W., and Robbins, T.W. (2010). 
Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning 
task in rats. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 35, 1290-1301. 
Bekris, S., Antoniou, K., Daskas, S., and Papadopoulou-Daifoti, Z. (2005). Behavioural and neurochemical 
effects induced by chronic mild stress applied to two different rat strains. Behavioural brain research 
161, 45-59. 
Belujon, P., and Grace, A.A. (2015). Regulation of dopamine system responsivity and its adaptive and 
pathological response to stress. Proc Biol Sci 282. 
Bergamini, G., Cathomas, F., Auer, S., Sigrist, H., Seifritz, E., Patterson, M., Mocaer, E., Gabriel, C., and 
Pryce, C.R. (in prep-a). Mouse chronic social stress disrupts reward motivation and cognitive 
flexibility and certain of these effects are responsive to the antidepressant agomelatine. 
Bergamini, G., Mechtersheimer, J., Azzinnari, D., Sigrist, H., Buerge, M., Seifritz, E., Hengerer, B., Ferger, 
B., Suter, T., and Pryce, C.R. (in prep-b). Mouse chronic social stress induces peripheral and CNS 
inflammation, dopamine deregulation and disrupted reward processing  
Bergamini, G., Sigrist, H., Ferger, B., Singewald, N., Seifritz, E., and Pryce, C.R. (Submitted manuscript). 
Decreased nucleus accumbens dopamine causes motivation pathologies in operant reward and 
punishment tests in mice. 
Berman, R.M., Sanacora, G., Anand, A., Roach, L.M., Fasula, M.K., Finkelstein, C.O., Wachen, R.M., Oren, 
D.A., Heninger, G.R., and Charney, D.S. (2002). Monoamine depletion in unmedicated depressed 
subjects. Biological psychiatry 51, 469-473. 
Berridge, K.C. (2003). Pleasures of the brain. Brain Cogn 52, 106-128. 
Berridge, K.C., and Kringelbach, M.L. (2015). Pleasure systems in the brain. Neuron 86, 646-664. 
Berridge, K.C., and Robinson, T.E. (1998). What is the role of dopamine in reward: hedonic impact, reward 
learning, or incentive salience? Brain research reviews 28, 309-369. 
Bertaina-Anglade, V., Drieu la Rochelle, C., Boyer, P.-A., and Mocaer, E. (2006). Antidepressant-like effects 
of agomelatine (S 20098) in the learned helplessness model. Behavioural pharmacology 17, 703-713. 
Bestmann, S., Ruge, D., Rothwell, J., and Galea, J.M. (2015). The role of dopamine in motor flexibility. 
Journal of cognitive neuroscience 27, 365-376. 
Beumer, W., Gibney, S.M., Drexhage, R.C., Pont-Lezica, L., Doorduin, J., Klein, H.C., Steiner, J., Connor, T.J., 
Harkin, A., Versnel, M.A., et al. (2012). The immune theory of psychiatric diseases: a key role for 
activated microglia and circulating monocytes. Journal of leukocyte biology 92, 959-975. 
Beurel, E., Harrington, L.E., and Jope, R.S. (2013). Inflammatory T helper 17 cells promote depression-like 
behavior in mice. Biological psychiatry 73, 622-630. 
Bezzina, G., Boon, F.S.d., Hampson, C.L., Cheung, T.H.C., Body, S., Bradshaw, C.M., Szabadi, E., Anderson, 
I.M., and Deakin, J.F.W. (2008). Effect of quinolinic acid-induced lesions of the subthalamic nucleus 
on performance on a progressive-ratio schedule of reinforcement: A quantitative analysis. 
Behavioural brain research 195, 223-230. 
Bibb, J.A., Snyder, G.L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A.A., Tsai, L.H., Kwon, Y.T., Girault, J.A., 
Czernik, A.J., et al. (1999). Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in 
neurons. Nature 402, 669-671. 
Bierhaus, A., Wolf, J., Andrassy, M., Rohleder, N., Humpert, P.M., Petrov, D., Ferstl, R., von Eynatten, M., 
Wendt, T., Rudofsky, G., et al. (2003). A mechanism converting psychosocial stress into mononuclear 
cell activation. Proceedings of the National Academy of Sciences 100, 1920-1925. 
Blair, H.T., Schafe, G.E., Bauer, E.P., Rodrigues, S.M., and LeDoux, J.E. (2001). Synaptic plasticity in the 
lateral amygdala: a cellular hypothesis of fear conditioning. Learning & memory 8, 229-242. 
Blank, T., and Prinz, M. (2013). Microglia as modulators of cognition and neuropsychiatric disorders. Glia 
61, 62-70. 
114 
 
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., and Jackson-Lewis, V.R. (2015). Oxidative stress and 
Parkinson’s disease. Front Neuroanat 9. 
Boulougouris, V., Glennon, J.C., and Robbins, T.W. (2008). Dissociable effects of selective 5-HT2A and 5-
HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology : 
official publication of the American College of Neuropsychopharmacology 33, 2007-2019. 
Bove, J., Prou, D., Perier, C., and Przedborski, S. (2005). Toxin-induced models of Parkinson's disease. 
NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 2, 484-494. 
Bowden, C., Cheetham, S.C., Lowther, S., Katona, C.L., Crompton, M.R., and Horton, R.W. (1997). Reduced 
dopamine turnover in the basal ganglia of depressed suicides. Brain research 769, 135-140. 
Bower, J.E., Ganz, P.A., Aziz, N., and Fahey, J.L. (2002). Fatigue and Proinflammatory Cytokine Activity in 
Breast Cancer Survivors. Psychosomatic medicine 64, 604-611. 
Brake, W.G., Zhang, T.Y., Diorio, J., Meaney, M.J., and Gratton, A. (2004). Influence of early postnatal 
rearing conditions on mesocorticolimbic dopamine and behavioural responses to psychostimulants 
and stressors in adult rats. European Journal of Neuroscience 19, 1863-1874. 
Bremner, J.D., Vythilingam, M., Ng, C.K., Vermetten, E., Nazeer, A., Oren, D.A., Berman, R.M., and 
Charney, D.S. (2003). Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced 
Depressive Symptoms. Jama 289, 3125. 
Bromberg-Martin, E.S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in motivational control: 
rewarding, aversive, and alerting. Neuron 68, 815-834. 
Brooks, D.J. (2006). Dopaminergic action beyond its effects on motor function: imaging studies. Journal of 
neurology 253 Suppl 4, IV8-15. 
Brown, G.W., and Harris, T. (1978). Social origins of depression: a reply. Psychological medicine 8, 577-
588. 
Brown, V.J., and Bowman, E.M. (2002). Rodent models of prefrontal cortical function. Trends in 
neurosciences 25, 340-343. 
Brydon, L., Harrison, N.A., Walker, C., Steptoe, A., and Critchley, H.D. (2008). Peripheral Inflammation is 
Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. Biological 
psychiatry 63, 1022-1029. 
Busse, M., Busse, S., Myint, A.M., Gos, T., Dobrowolny, H., Müller, U.J., Bogerts, B., Bernstein, H.-G., and 
Steiner, J. (2015). Decreased quinolinic acid in the hippocampus of depressive patients: evidence for 
local anti-inflammatory and neuroprotective responses? European archives of psychiatry and clinical 
neuroscience 265, 321-329. 
Bylsma, L.M., Morris, B.H., and Rottenberg, J. (2008). A meta-analysis of emotional reactivity in major 
depressive disorder. Clinical psychology review 28, 676-691. 
Cabib, S., and Puglisi-Allegra, S. (2012). The mesoaccumbens dopamine in coping with stress. 
Neuroscience & Biobehavioral Reviews 36, 79-89. 
Cammer, W. (2001). Oligodendrocyte killing by quinolinic acid in vitro. Brain research 896, 157-160. 
Campbell, B.M., Charych, E., Lee, A.W., and Moller, T. (2014). Kynurenines in CNS disease: regulation by 
inflammatory cytokines. Frontiers in neuroscience 8, 12. 
Capuron, L., Fornwalt, F.B., Knight, B.T., Harvey, P.D., Ninan, P.T., and Miller, A.H. (2009). Does cytokine-
induced depression differ from idiopathic major depression in medically healthy individuals? Journal 
of affective disorders 119, 181-185. 
Capuron, L., Pagnoni, G., Demetrashvili, M.F., Lawson, D.H., Fornwalt, F.B., Woolwine, B., Berns, G.S., 
Nemeroff, C.B., and Miller, A.H. (2007). Basal Ganglia Hypermetabolism and Symptoms of Fatigue 
during Interferon-α Therapy. Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology 32, 2384-2392. 
Carmichael, M.D., Davis, J.M., Murphy, E.A., Brown, A.S., Carson, J.A., Mayer, E.P., and Ghaffar, A. (2006). 
Role of brain IL-1beta on fatigue after exercise-induced muscle damage. AJP: Regulatory, Integrative 
and Comparative Physiology 291, R1344-R1348. 
Cathomas, F., Fuertig, R., Sigrist, H., Newman, G.N., Hoop, V., Bizzozzero, M., Mueller, A., Luippold, A., 
Ceci, A., Hengerer, B., et al. (2015a). CD40-TNF activation in mice induces extended sickness behavior 
115 
 
syndrome co-incident with but not dependent on activation of the kynurenine pathway. Brain, 
behavior, and immunity 50, 125-140. 
Cathomas, F., Hartmann, M.N., Seifritz, E., Pryce, C.R., and Kaiser, S. (2015b). The translatonal study of 
apathy - an ecological approach. Frontiers in behavioral neuroscience 9, 1-9. 
Cathomas, F., Stegen, M., Sigrist, H., Schmid, L., Seifritz, E., Gassmann, M., Bettler, B., and Pryce, C.R. 
(2015c). Altered emotionality and neuronal excitability in mice lacking KCTD12, an auxillary subunit 
of GABAB receptors associated with mood disorders. Translational psychiatry 5:e510. doi: 
10.1038/tp.2015.8. 
Chamberlain, S.R. (2006). Neurochemical Modulation of Response Inhibition and Probabilistic Learning in 
Humans. Science 311, 861-863. 
Chaudhury, D., Walsh, J.J., Friedman, A.K., Juarez, B., Ku, S.M., Koo, J.W., Ferguson, D., Tsai, H.-C., 
Pomeranz, L., Christoffel, D.J., et al. (2013). Rapid regulation of depression-related behaviours by 
control of midbrain dopamine neurons. Nature 493, 532-536. 
Chen, Y., Jiang, T., Chen, P., Ouyang, J., Xu, G., Zeng, Z., and Sun, Y. (2011). Emerging tendency towards 
autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry 
research 188, 224-230. 
Chenu, F., El Mansari, M., and Blier, P. (2013). Electrophysiological effects of repeated administration of 
agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 38, 275-284. 
Chiang, J.J., Eisenberger, N.I., Seeman, T.E., and Taylor, S.E. (2012). Negative and competitive social 
interactions are related to heightened proinflammatory cytokine activity. Proceedings of the National 
Academy of Sciences 109, 1878-1882. 
Chiarugi, A., Meli, E., and Moroni, F. (2001). Similarities and differences in the neuronal death processes 
activated by 3OH-kynurenine and quinolinic acid. Journal of neurochemistry 77, 1310-1318. 
Chrapusta, S.J., Wyatt, R.J., and Masserano, J.M. (1997). Effects of Single and Repeated Footshock on 
Dopamine Release and Metabolism in the Brains of Fischer Rats. Journal of neurochemistry 68, 2024-
2031. 
Clarke, H.F. (2004). Cognitive Inflexibility After Prefrontal Serotonin Depletion. Science 304, 878-880. 
Cohen, S., Janicki-Deverts, D., Doyle, W.J., Miller, G.E., Frank, E., Rabin, B.S., and Turner, R.B. (2012). 
Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proceedings of the 
National Academy of Sciences of the United States of America 109, 5995-5999. 
Colin-Gonzalez, A.L., Maldonado, P.D., and Santamaria, A. (2013). 3-Hydroxykynurenine: an intriguing 
molecule exerting dual actions in the central nervous system. Neurotoxicology 34, 189-204. 
Colin-Gonzalez, A.L., Maya-Lopez, M., Pedraza-Chaverri, J., Ali, S.F., Chavarria, A., and Santamaria, A. 
(2014). The Janus faces of 3-hydroxykynurenine: dual redox modulatory activity and lack of 
neurotoxicity in the rat striatum. Brain research 1589, 1-14. 
Cools, R., Clark, L., Owen, A.M., and Robbins, T.W. (2002). Defining the neural mechanisms of probabilistic 
reversal learning using event-related functional magnetic imaging. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 22, 4563-4567. 
Cools, R., Nakamura, K., and Daw, N.D. (2011). Serotonin and dopamine: unifying affective, activational, 
and decision functions. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 36, 98-113. 
Cools, R., Roberts, A.C., and Robbins, T.W. (2008). Serotoninergic regulation of emotional and behavioural 
control processes. Trends in cognitive sciences 12, 31-40. 
Couch, Y., Anthony, D.C., Dolgov, O., Revischin, A., Festoff, B., Santos, A.I., Steinbusch, H.W., and 
Strekalova, T. (2013). Microglial activation, increased TNF and SERT expression in the prefrontal 
cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain, behavior, and 
immunity 29, 136-146. 
Cousins, M.S., and Salamone, J.D. (1994). Nucleus accumbens dopamine depletions in rats affect relative 
response allocation in a novel cost/benefit procedure. Pharmacology Biochemistry and Behavior 49, 
85-91. 
116 
 
Cousins, M.S., Wei, W., and Salamone, J.D. (1994). Pharmacological characterization of performance on a 
concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, 
cholinomimetic, sedative and stimulant drugs. Psychopharmacology 116, 529-537. 
Covington, H.E., 3rd, Maze, I., LaPlant, Q.C., Vialou, V.F., Ohnishi, Y.N., Berton, O., Fass, D.M., Renthal, W., 
Rush, A.J., 3rd, Wu, E.Y., et al. (2009). Antidepressant actions of histone deacetylase inhibitors. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 29, 11451-11460. 
Cuadra, G., Zurita, A., Lacerra, C., and Molina, V.c. (1999). Chronic stress sensitizes frontal cortex 
dopamine release in response to a subsequent novel stressor: reversal by naloxone. Brain research 
bulletin 48, 303-308. 
Cuthbert, B.N. (2015). Research Domain Criteria: toward future psychiatric nosologies. Dialogues Clin 
Neurosci 17, 89-97. 
Cuthbert, B.N., and Insel, T.R. (2013). Toward the future of psychiatric diagnosis: the seven pillars of 
RDoC. BMC medicine 11, 126. 
Dai, X., and Zhu, B.T. (2010). Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in 
mice: implications for its biological functions. The journal of histochemistry and cytochemistry : 
official journal of the Histochemistry Society 58, 17-28. 
Daley, S.E., Hammen, C., and Rao, U. (2000). Predictors of first onset and recurrence of major depression 
in young women during the 5 years following high school graduation. J Abnorm Psychol 109, 525-
533. 
Dalley, J.W., and Everitt, B.J. (2009). Dopamine receptors in the learning, memory and drug reward 
circuitry. Semin Cell Dev Biol 20, 403-410. 
Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., and Kelley, K.W. (2008). From inflammation to 
sickness and depression: when the immune system subjugates the brain. Nature Reviews 
Neuroscience 9, 46-56. 
Dantzer, R., and Walker, A.K. (2014). Is there a role for glutamate-mediated excitotoxicity in 
inflammation-induced depression? Journal of neural transmission 121, 925-932. 
Darvas, M., Fadok, J.P., and Palmiter, R.D. (2011). Requirement of dopamine signaling in the amygdala 
and striatum for learning and maintenance of a conditioned avoidance response. Learning & memory 
18, 136-143. 
de Bodinat, C., Guardiola-Lemaitre, B., Mocaer, E., Renard, P., Munoz, C., and Millan, M.J. (2010). 
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. 
Nature Rev Drug Discovery 9, 628-642. 
de Pablos, R.M., Herrera, A.J., Espinosa-Oliva, A.M., Sarmiento, M., Munoz, M.F., Machado, A., and 
Venero, J.L. (2014). Chronic stress enhances microglia activation and exacerbates death of nigral 
dopaminergic neurons under conditions of inflammation. Journal of neuroinflammation 11, 34. 
Demyttenaere, K., De Fruyt, J., and Stahl, S.M. (2005). The many faces of fatigue in major depressive 
disorder. The international journal of neuropsychopharmacology / official scientific journal of the 
Collegium Internationale Neuropsychopharmacologicum 8, 93-105. 
Di Chiara, G., Loddo, P., and Tanda, G. (1999). Reciprocal changes in prefrontal and limbic dopamine 
responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the 
psychobiology of depression. Biological psychiatry 46, 1624-1633. 
Di Giannantonio, M., and Martinotti, G. (2012). Anhedonia and major depression: the role of 
agomelatine. European Neuropsychopharmacology 22, S505-S510. 
Di Giovanni, G., Di Matteo, V., ;, P., Benigno, A., and Esposito, E. (2006). Central serotonin2C receptor: 
from physiology to pathology. Current Topics in Medical Chemistry 6, 1909-1925. 
Di Matteo, V., De Blasi, A., Di Giulio, C., and Esposito, E. (2001). Role of 5-HT2C receptors in the control of 
central dopamine function. Trends in pharmacological sciences 22, 229-232. 
Dichter, G.S., Smoski, M.J., Kampov-Polevoy, A.B., Gallop, R., and Garbutt, J.C. (2010). Unipolar 
depression does not moderate responses to the Sweet Taste Test. Depression and anxiety 27, 859-
863. 
Dickerson, S.S., and Kemeny, M.E. (2004). Acute stressors and cortisol responses: a theoretical integration 
and synthesis of laboratory research. Psychological bulletin 130, 355-391. 
117 
 
Dickson, P.W., and Briggs, G.D. (2013). Tyrosine hydroxylase: regulation by feedback inhibition and 
phosphorylation. Advances in pharmacology 68, 13-21. 
Diener, C., Kuehner, C., Brusniak, W., Struve, M., and Flor, H. (2009). Effects of stressor controllability on 
psychophysiological, cognitive and behavioural responses in patients with major depression and 
dysthymia. Psychological medicine 39, 77-86. 
Dillon, D.G., Holmes, A.J., Jahn, A.L., Bogdan, R., Wald, L.L., and Pizzagalli, D.A. (2008). Dissociation of 
neural regions associated with anticipatory versus consummatory phases of incentive processing. 
Psychophysiology 45, 36-49. 
Dillon, D.G., Rosso, I.M., Pechtel, P., Killgore, W.D., Rauch, S.L., and Pizzagalli, D.A. (2014). Peril and 
pleasure: an rdoc-inspired examination of threat responses and reward processing in anxiety and 
depression. Depression and anxiety 31, 233-249. 
DSM-5 (2013). Diagnostic and Statistical Manual of Mental Disorders. 5th edn. Revision  American 
Psychiatric Association, Washington, DC (Washington, DC: American Psychiatric Association). 
Duchemin, A.M., Zhang, H., Neff, N.H., and Hadjiconstantinou, M. (2009). Increased expression of VMAT2 
in dopaminergic neurons during nicotine withdrawal. Neuroscience letters 467, 182-186. 
Dunlop, B.W., and Nemeroff, C.B. (2007). The role of dopamine in the pathophysiology of depression. 
Archives of general psychiatry 64, 327-337. 
Eberle-Wang, K., Mikeladze, Z., Uryu, K., and Chesselet, M.-F. (1997). Pattern of expression of the 
serotonin2C receptor messneger RNA in the basal ganglia of adult rats. The Journal of comparative 
neurology 384, 233-247. 
Eisenberger, N.I., Berkman, E.T., Inagaki, T.K., Rameson, L.T., Mashal, N.M., and Irwin, M.R. (2010). 
Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. 
Biological psychiatry 68, 748-754. 
Elenkov, I.J., Wilder, R.L., Chrousos, G.P., and Vizi, E.S. (2000). The sympathetic nerve--an integrative 
interface between two supersystems: the brain and the immune system. Pharmacol Rev 52, 595-638. 
Elliott, R., Sahakian, B., McKay, A.P., Herrod, J.J., Robbins, T.W., and Paykel, E.S. (1996). 
Neuropsychological impairments in unipolar depression: the influence of perceived failure on 
subsequent performance. Psychological medicine 26, 975-989. 
Elliott, R., Sahakian, B.J., Herrod, J.J., Robbins, T.W., and Paykel, E.S. (1997). Abnormal response to 
negative feedback in unipolar depression: evidence for a diagnosis specific impairment. Journal of 
neurology, neurosurgery, and psychiatry 63, 74-82. 
Emerson, C.S., Harrison, D.W., Everhart, D.E., and Williamson, J.B. (2001). Grip strength asymmetry in 
depressed boys. Neuropsychiatry, neuropsychology, and behavioral neurology 14, 130-134. 
Engler, H., Bailey, M.T., Engler, A., and Sheridan, J.F. (2004). Effects of repeated social stress on leukocyte 
distribution in bone marrow, peripheral blood and spleen. Journal of neuroimmunology 148, 106-
115. 
Engler, H., Bailey, M.T., Engler, A., Stiner-Jones, L.M., Quan, N., and Sheridan, J.F. (2008). Interleukin-1 
receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the 
spleen. Psychoneuroendocrinology 33, 108-117. 
Enkel, T., Gholizadeh, D., von Bohlen Und Halbach, O., Sanchis-Segura, C., Hurlemann, R., Spanagel, R., 
Gass, P., and Vollmayr, B. (2010). Ambiguous-cue interpretation is biased under stress- and 
depression-like states in rats. Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology 35, 1008-1015. 
Eshel, N., and Roiser, J.P. (2010). Reward and punishment processing in depression. Biological psychiatry 
68, 118-124. 
Euteneuer, F., Schwarz, M.J., Dannehl, K., Hartung, A., Westermann, S., and Rief, W. (2012). Increased 
soluble interleukin-2 receptor levels are related to somatic but not to cognitive-affective features in 
major depression. Brain, behavior, and immunity 26, 1244-1248. 
Evers, E.A., Cools, R., Clark, L., van der Veen, F.M., Jolles, J., Sahakian, B.J., and Robbins, T.W. (2005). 
Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal 
learning. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 30, 1138-1147. 
118 
 
Fanous, A.H., Chen, X., Wang, X., Amdur, R.L., O'Neill, F.A., Walsh, D., and Kendler, K.S. (2007). Association 
between the 5q31.1 gene neurogenin1 and schizophrenia. American journal of medical genetics Part 
B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric 
Genetics 144B, 207-214. 
Feinstein, A., Magalhaes, S., Richard, J.-F., Audet, B., and Moore, C. (2014). The link between multiple 
sclerosis and depression. Nature Reviews Neurology 10, 507-517. 
Felger, J.C., and Miller, A.H. (2012). Cytokine effects on the basal ganglia and dopamine function: the 
subcortical source of inflammatory malaise. Frontiers in neuroendocrinology 33, 315-327. 
Felger, J.C., Mun, J., Kimmel, H.L., Nye, J.A., Drake, D.F., Hernandez, C.R., Freeman, A.A., Rye, D.B., 
Goodman, M.M., Howell, L.L., et al. (2013). Chronic interferon-alpha decreases dopamine 2 receptor 
binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman 
primates. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 38, 2179-2187. 
Feng, Q., Ma, Y., Mu, S., Wu, J., Chen, S., Ouyang, L., and Lei, W. (2014). Specific reactions of different 
striatal neuron types in morphology induced by quinolinic acid in rats. PloS one 9, e91512. 
Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A., O'Callaghan, 
J.P., Miller, D.B., Cole, D.G., et al. (1998). DARPP-32: regulator of the efficacy of dopaminergic 
neurotransmission. Science 281, 838-842. 
Fitzgerald, P., O'Brien, S.M., Scully, P., Rijkers, K.I.M., Scott, L.V., and Dinan, T.G. (2006). Cutaneous 
glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant 
depression. Psychological medicine 36, 37. 
Floresco, S.B. (2013). Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward 
a family of functions. Frontiers in neuroscience 7, 62. 
Floresco, S.B., Magyar, O., Ghods-Sharifi, S., Vexelman, C., and Tse, M.T. (2006). Multiple dopamine 
receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 31, 297-309. 
Ford, C.P., and Williams, J.T. (2008). Mesoprefrontal dopamine neurons distinguish themselves. Neuron 
57, 631-632. 
Franklin, K.B.J., and Paxinos, G. (2008). The mouse brain in stereotaxic coordinates, 3rd edn. 
Fuertig, R., Bergamini, G., Sigrist, H., Seifritz, E., Ceci, A., Hengerer, B., and Pryce, C.R. (in prep). Mouse 
chronic social stress increases kynurenine pathway activity and conditioned fear, and both effects are 
reversed by inhibition of indoleamine 2 3-dioxygenase. 
Fukuda, K. (2014). Etiological classification of depression based on the enzymes of tryptophan 
metabolism. BMC psychiatry 14, 372. 
Fukui, M., Rodriguiz, R.M., Zhou, J., Jiang, S.X., Phillips, L.E., Caron, M.G., and Wetsel, W.C. (2007). Vmat2 
heterozygous mutant mice display a depressive-like phenotype. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 27, 10520-10529. 
Fumeaux, T., and Pugin, J. (2002). Role of interleukin-10 in the intracellular sequestration of human 
leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166, 1475-1482. 
Gambarana, C., Masi, F., Tagliamonte, A., Scheggi, S., Ghiglieri, O., and De Montis, M.G. (1999). A chronic 
stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus 
accumbens: a microdialysis study. Journal of neurochemistry 72, 2039-2046. 
Gao, H.-M., Jiang, J., Wilson, B., Zhang, W., Hong, J.-S., and Liu, B. (2002). Microglial activation-mediated 
delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's 
disease. Journal of neurochemistry 81, 1285-1297. 
Gentile, A., Fresegna, D., Federici, M., Musella, A., Rizzo, F.R., Sepman, H., Bullitta, S., De Vito, F., Haji, N., 
Rossi, S., et al. (2015). Dopaminergic dysfunction is associated with IL-1beta-dependent mood 
alterations in experimental autoimmune encephalomyelitis. Neurobiology of disease 74, 347-358. 
Gepshtein, S., Li, X., Snider, J., Plank, M., Lee, D., and Poizner, H. (2014). Dopamine function and the 
efficiency of human movement. Journal of cognitive neuroscience 26, 645-657. 
119 
 
Gerecke, K.M., Kolobova, A., Allen, S., and Fawer, J.L. (2013). Exercise protects against chronic restraint 
stress-induced oxidative stress in the cortex and hippocampus. Brain research 1509, 66-78. 
Gibney, S.M., Fagan, E.M., Waldron, A.M., O'Byrne, J., Connor, T.J., and Harkin, A. (2014). Inhibition of 
stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal 
model of depressive behaviour. The international journal of neuropsychopharmacology / official 
scientific journal of the Collegium Internationale Neuropsychopharmacologicum 17, 917-928. 
Gibney, S.M., McGuinness, B., Prendergast, C., Harkin, A., and Connor, T.J. (2013). Poly I:C-induced 
activation of the immune response is accompanied by depression and anxiety-like behaviours, 
kynurenine pathway activation and reduced BDNF expression. Brain, behavior, and immunity 28, 
170-181. 
Gilbert, P. (1992). Depression: The evolution of powerlessness. 
Gold, S.M., and Irwin, M.R. (2006). Depression and Immunity: Inflammation and Depressive Symptoms in 
Multiple Sclerosis. Neurologic clinics 24, 507-519. 
Golden, S.A., Covington, H.E., 3rd, Berton, O., and Russo, S.J. (2011). A standardized protocol for repeated 
social defeat stress in mice. Nature protocols 6, 1183-1191. 
Gotlib, I.H., Kasch, K.L., Traill, S., Joormann, J., Arnow, B.A., and Johnson, S.L. (2004). Coherence and 
specificity of information-processing biases in depression and social phobia. J Abnorm Psychol 113, 
386-398. 
Grosse, L., Carvalho, L.A., Birkenhager, T.K., Hoogendijk, W.J., Kushner, S.A., Drexhage, H.A., and Bergink, 
V. (2015). Circulating cytotoxic T cells and natural killer cells as potential predictors for 
antidepressant response in melancholic depression. Restoration of T regulatory cell populations after 
antidepressant therapy. Psychopharmacology. 
Gruenewald, T.L., Cohen, S., Matthews, K.A., Tracy, R., and Seeman, T.E. (2009). Association of 
socioeconomic status with inflammation markers in black and white men and women in the Coronary 
Artery Risk Development in Young Adults (CARDIA) study. Social Science & Medicine 69, 451-459. 
Guidetti, P., and Schwarcz, R. (1999). 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity 
in the rat striatum. The European journal of neuroscience 11, 3857-3863. 
Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., Croitoru, J., and Brew, B.J. 
(2001). Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. 
Journal of neurochemistry 78, 842-853. 
Guillemin, G.J., Meininger, V., and Brew, B.J. (2005). Implications for the kynurenine pathway and 
quinolinic acid in amyotrophic lateral sclerosis. Neuro-degenerative diseases 2, 166-176. 
Guloksuz, S., Arts, B., Walter, S., Drukker, M., Rodriguez, L., Myint, A.M., Schwarz, M.J., Ponds, R., van Os, 
J., Kenis, G., et al. (2015). The impact of electroconvulsive therapy on the tryptophan-kynurenine 
metabolic pathway. Brain, behavior, and immunity 48, 48-52. 
Haber, S.N. (2014). The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 282, 248-257. 
Halaris, A. (2013). Co-Morbidity between Cardiovascular Pathology and Depression: Role of Inflammation. 
In Inflammation in Psychiatry (S. Karger AG), pp. 144-161. 
Haluk, D.M., and Floresco, S.B. (2009). Ventral striatal dopamine modulation of different forms of 
behavioral flexibility. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 34, 2041-2052. 
Hamill, S., Trevitt, J.T., Nowend, K.L., Carlson, B.B., and Salamone, J.D. (1999). Nucleus accumbens 
dopamine depletions and time-constrained progressive ratio performance: effects of different ratio 
requirements. Pharmacology, biochemistry, and behavior 64, 21-27. 
Hammen, C. (2005). Stress and depression. Annual review of clinical psychology 1, 293-319. 
Hannestad, J., DellaGioia, N., and Bloch, M. (2011a). The Effect of Antidepressant Medication Treatment 
on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology : official 
publication of the American College of Neuropsychopharmacology 36, 2452-2459. 
Hannestad, J., DellaGioia, N., Ortiz, N., Pittman, B., and Bhagwagar, Z. (2011b). Citalopram reduces 
endotoxin-induced fatigue. Brain, behavior, and immunity 25, 256-259. 
Haroon, E., Raison, C.L., and Miller, A.H. (2012). Psychoneuroimmunology meets 
neuropsychopharmacology: translational implications of the impact of inflammation on behavior. 
120 
 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 37, 137-162. 
Harrison, N.A., Brydon, L., Walker, C., Gray, M.A., Steptoe, A., and Critchley, H.D. (2009). Inflammation 
Causes Mood Changes Through Alterations in Subgenual Cingulate Activity and Mesolimbic 
Connectivity. Biological psychiatry 66, 407-414. 
Hart, B.L. (1988). Biological basis of the behavior of sick animals. Neuroscience & Biobehavioral Reviews 
12, 123-137. 
Hasler, G., Drevets, W.C., Manji, H.K., and Charney, D.S. (2004). Discovering Endophenotypes for Major 
Depression. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 29, 1765-1781. 
Hattori, T. (1993). Conceptual history of the nigrostriatal dopamine system. Neuroscience research 16, 
239-262. 
Hemmings, H.C., Jr., Nairn, A.C., and Greengard, P. (1984). DARPP-32, a dopamine- and adenosine 3':5'-
monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of 
phosphorylation of DARPP-32 and phosphatase inhibitor 1. The Journal of biological chemistry 259, 
14491-14497. 
Herzog, C.J., Czeh, B., Corbach, S., Wuttke, W., Schulte-Herbruggen, O., Hellweg, R., Flugge, G., and Fuchs, 
E. (2009). Chronic social instability stress in female rats: a potential animal model for female 
depression. Neuroscience 159, 982-992. 
Hinwood, M., Morandini, J., Day, T.A., and Walker, F.R. (2012). Evidence that microglia mediate the 
neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cerebral 
cortex 22, 1442-1454. 
Hinwood, M., Tynan, R.J., Charnley, J.L., Beynon, S.B., Day, T.A., and Walker, F.R. (2013). Chronic stress 
induced remodeling of the prefrontal cortex: structural re-organization of microglia and the 
inhibitory effect of minocycline. Cerebral cortex 23, 1784-1797. 
Hong, M., Zheng, J., Ding, Z.Y., Chen, J.H., Yu, L., Niu, Y., Hua, Y.Q., and Wang, L.L. (2013). Imbalance 
between Th17 and Treg cells may play an important role in the development of chronic 
unpredictable mild stress-induced depression in mice. Neuroimmunomodulation 20, 39-50. 
Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T., Codelli, J.A., Chow, J., Reisman, 
S.E., Petrosino, J.F., et al. (2013). Microbiota modulate behavioral and physiological abnormalities 
associated with neurodevelopmental disorders. Cell 155, 1451-1463. 
Iadarola, M.J., Chuang, E.J., Yeung, C.L., Hoo, Y., Silverthorn, M., Gu, J., and Draisci, G. (1993). Induction 
and suppression of proto-oncogenes in rat striatum after single or multiple treatments with cocaine 
or GBR-12909. NIDA Res Monogr 125, 181-211. 
ICD-10 (1994). International Statistical Classification of Diseases and Related Health Problems. 10th 
Revision. 
Ifuku, M., Hossain, S.M., Noda, M., and Katafuchi, T. (2014). Induction of interleukin-1beta by activated 
microglia is a prerequisite for immunologically induced fatigue. The European journal of 
neuroscience 40, 3253-3263. 
Ineichen, C., Sigrist, H., Spinelli, S., Lesch, K.P., Sautter, E., Seifritz, E., and Pryce, C.R. (2012). Establishing a 
probabilistic reversal learning test in mice: evidence for the processes mediating reward-stay and 
punishment-shift behaviour and for their modulation by serotonin. Neuropharmacology 63, 1012-
1021. 
Insel, T.R. (2014). The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. 
The American journal of psychiatry 171, 395-397. 
Irifune, M., Nomoto, M., and Fukuda, T. (1995). Effects of GBR 12909 on locomotor activity and dopamine 
turnover in mice: comparison with apomorphine. Eur J Pharmacol 272, 79-85. 
Ishiwari, K., Weber, S.M., Mingote, S., Correa, M., and Salamone, J.D. (2004). Accumbens dopamine and 
the regulation of effort in food-seeking behavior: modulation of work output by different ratio or 
force requirements. Behavioural brain research 151, 83-91. 
Jaisinghani, S., and Rosenkranz, J.A. (2015). Repeated social defeat stress enhances the anxiogenic effect 
of bright light on operant reward-seeking behavior in rats. Behavioural brain research 290, 172-179. 
121 
 
Jamwal, S., Singh, S., Kaur, N., and Kumar, P. (2015). Protective Effect of Spermidine Against Excitotoxic 
Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and 
Neuroinflammatory Mechanism. Neurotoxicity research 28, 171-184. 
Jayatissa, M.N., Bisgaard, C.F., West, M.J., and Wiborg, O. (2008). The number of granule cells in rat 
hippocampus is reduced after chronic mild stress and re-established after chronic escitalopram 
treatment. Neuropharmacology 54, 530-541. 
Jiao, X., Paré, W.P., and Tejani-Butt, S. (2003). Strain differences in the distribution of dopamine 
transporter sites in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 
913-919. 
Jin, H.M., Shrestha Muna, S., Bagalkot, T.R., Cui, Y., Yadav, B.K., and Chung, Y.C. (2015). The effects of 
social defeat on behavior and dopaminergic markers in mice. Neuroscience 288, 167-177. 
Jo, W.K., Zhang, Y., Emrich, H.M., and Dietrich, D.E. (2015). Glia in the cytokine-mediated onset of 
depression: fine tuning the immune response. Frontiers in cellular neuroscience 9. 
Jocham, G., Klein, T.A., Neumann, J., von Cramon, D.Y., Reuter, M., and Ullsperger, M. (2009). Dopamine 
DRD2 polymorphism alters reversal learning and associated neural activity. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 29, 3695-3704. 
Johnson, J.D., Campisi, J., Sharkey, C.M., Kennedy, S.L., Nickerson, M., Greenwood, B.N., and Fleshner, M. 
(2005). Catecholamines mediate stress-induced increases in peripheral and central inflammatory 
cytokines. Neuroscience 135, 1295-1307. 
Kannarkat, G.T., Boss, J.M., and Tansey, M.G. (2013). The role of innate and adaptive immunity in 
Parkinson's disease. Journal of Parkinson's disease 3, 493-514. 
Kendler, K.S., Hettema, J.M., Butera, F., Gardner, C.O., and Prescott, C.A. (2003). Life event dimensions of 
loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and 
generalized anxiety. Archives of general psychiatry 60, 789-796. 
Kendler, K.S., Karkowski, L.M., and Prescott, C.A. (1998). Stressful life events and major depression: risk 
period, long-term contextual threat, and diagnostic specificity. The Journal of nervous and mental 
disease 186, 661-669. 
Kendler, K.S., Karkowski, L.M., and Prescott, C.A. (1999). Causal relationship between stressful life events 
and the onset of major depression. The American journal of psychiatry 156, 837-841. 
Kendler, K.S., Thornton, L.M., and Gardner, C.O. (2000). Stressful life events and previous episodes in the 
etiology of major depression in women: an evaluation of the "kindling" hypothesis. The American 
journal of psychiatry 157, 1243-1251. 
Kennedy, S.H., Avedisova, A., Giménez-Montesinos, N., Belaïdi, C., and Christian de, B. (2014). A placebo-
controlled study of three agomelatine dose regimens (10mg, 25mg, 25–50mg) in patients with major 
depressive disorder. European Neuropsychopharmacology 24, 553-563. 
Kessler, R.C. (1997). The effects of stressful life events on depression. Annual Review of Psychology 48, 
191-214. 
Kimura, A., and Kishimoto, T. (2010). IL-6: regulator of Treg/Th17 balance. European journal of 
immunology 40, 1830-1835. 
King, D., and Finlay, J.M. (1997). Loss of dopamine terminals in the medial prefrontal cortex increased the 
ratio of DOPAC to DA in tissue of the nucleus accumbens shell: role of stress. Brain research 767, 192-
200. 
Kirby, T. (2015). Ketamine for depression: the highs and lows. Lancet Psychiatry 2, 783-784. 
Klimek, V., Schenck, J.E., Han, H., Stockmeier, C.A., and Ordway, G.A. (2002). Dopaminergic abnormalities 
in amygdaloid nuclei in major depression: a postmortem study. Biological psychiatry 52, 740-748. 
Kluger, B.M., Krupp, L.B., and Enoka, R.M. (2013). Fatigue and fatigability in neurologic illnesses: Proposal 
for a unified taxonomy. Neurology 80, 409-416. 
Kopp, B.L., Wick, D., and Herman, J.P. (2013). Differential effects of homotypic vs. heterotypic chronic 
stress regimens on microglial activation in the prefrontal cortex. Physiology & behavior 122, 246-252. 
Kostic, M., Dzopalic, T., Zivanovic, S., Zivkovic, N., Cvetanovic, A., Stojanovic, I., Vojinovic, S., Marjanovic, 
G., Savic, V., and Colic, M. (2014). IL-17 and glutamate excitotoxicity in the pathogenesis of multiple 
sclerosis. Scand J Immunol 79, 181-186. 
122 
 
Krackow, S., Vannoni, E., Codita, A., Mohammed, A.H., Cirulli, F., Branchi, I., Alleva, E., Reichelt, A., 
Willuweit, A., Voikar, V., et al. (2010). Consistent behavioral phenotype differences between inbred 
mouse strains in the IntelliCage. Genes, brain, and behavior 9, 722-731. 
Kreisel, T., Frank, M.G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M.V., Maier, S.F., and 
Yirmiya, R. (2014). Dynamic microglial alterations underlie stress-induced depressive-like behavior 
and suppressed neurogenesis. Molecular psychiatry 19, 699-709. 
Krishnan, V., Han, M.H., Graham, D.L., Berton, O., Renthal, W., Russo, S.J., Laplant, Q., Graham, A., Lutter, 
M., Lagace, D.C., et al. (2007). Molecular adaptations underlying susceptibility and resistance to 
social defeat in brain reward regions. Cell 131, 391-404. 
Krishnan, V., and Nestler, E.J. (2011). Animal models of depression: molecular perspectives. Current 
topics in behavioral neurosciences 7, 121-147. 
Kudryavtseva, N.N., Bakshtanovskaya, I.V., and Koryakina, L.A. (1991). Social model of depression in mice 
of C57BL/6J strain. Pharm Biochem Behav 38, 315-320. 
Kullmann, J.S., Grigoleit, J.-S., Lichte, P., Kobbe, P., Rosenberger, C., Banner, C., Wolf, O.T., Engler, H., 
Oberbeck, R., Elsenbruch, S., et al. (2013). Neural response to emotional stimuli during experimental 
human endotoxemia. Human brain mapping 34, 2217-2227. 
Kumar, J., Chuang, J.C., Na, E.S., Kuperman, A., Gillman, A.G., Mukherjee, S., Zigman, J.M., McClung, C.A., 
and Lutter, M. (2013). Differential effects of chronic social stress and fluoxetine on meal patterns in 
mice. Appetite 64, 81-88. 
Lambert, G., Johansson, M., Ågren, H., and Friberg, P. (2000). Reduced Brain Norepinephrine and 
Dopamine Release in Treatment-Refractory Depressive Illness. Archives of general psychiatry 57, 787. 
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., and Roeper, J. (2008). Unique Properties of 
Mesoprefrontal Neurons within a Dual Mesocorticolimbic Dopamine System. Neuron 57, 760-773. 
Lammel, S., Tye, K.M., and Warden, M.R. (2014). Progress in understanding mood disorders: optogenetic 
dissection of neural circuits. Genes, brain, and behavior 13, 38-51. 
Langenecker, S.A., Bieliauskas, L.A., Rapport, L.J., Zubieta, J.K., Wilde, E.A., and Berent, S. (2005). Face 
emotion perception and executive functioning deficits in depression. Journal of clinical and 
experimental neuropsychology 27, 320-333. 
Langenecker, S.A., Jacobs, R.H., and Passarotti, A.M. (2014). Current Neural and Behavioral Dimensional 
Constructs across Mood Disorders. Current behavioral neuroscience reports 1, 144-153. 
Lanquillon, S. (2000). Cytokine Production and Treatment Response in Major Depressive Disorder. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 22, 370-379. 
Lekkou, A., Karakantza, M., Mouzaki, A., Kalfarentzos, F., and Gogos, C.A. (2004). Cytokine production and 
monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe 
infections. Clin Diagn Lab Immunol 11, 161-167. 
Leskela, U., Rytsala, H., Komulainen, E., Melartin, T., Sokero, P., Lestela-Mielonen, P., and Isometsa, E. 
(2006). The influence of adversity and perceived social support on the outcome of major depressive 
disorder in subjects with different levels of depressive symptoms. Psychological medicine 36, 779-
788. 
Lestage, J., Verrier, D., Palin, K., and Dantzer, R. (2002). The enzyme indoleamine 2,3-dioxygenase is 
induced in the mouse brain in response to peripheral administration of lipopolysaccharide and 
superantigen. Brain, behavior, and immunity 16, 596-601. 
Lethbridge, R., and Allen, N.B. (2008). Mood induced cognitive and emotional reactivity, life stress, and 
the prediction of depressive relapse. Behaviour research and therapy 46, 1142-1150. 
Leventopoulos, M., Russig, H., Feldon, J., Pryce, C.R., and Opacka-Juffry, J. (2009). Early deprivation leads 
to long-term reductions in motivation for reward and 5-HT1A binding and both effects are reversed 
by fluoxetine. Neuropharmacology 56, 692-701. 
Levita, L., Dalley, J.W., and Robbins, T.W. (2002a). Disruption of Pavlovian contextual conditioning by 
excitotoxic lesions of the nucleus accumbens core. Behavioral Neuroscience 116, 539-552. 
Levita, L., Dalley, J.W., and Robbins, T.W. (2002b). Nucleus accumbens dopamine and learned fear 
revisited: a review and some new findings. Behavioural brain research 137, 115-127. 
123 
 
Liu, W., Sheng, H., Xu, Y., Liu, Y., Lu, J., and Ni, X. (2013). Swimming exercise ameliorates depression-like 
behavior in chronically stressed rats: relevant to proinflammatory cytokines and IDO activation. 
Behavioural brain research 242, 110-116. 
Lobo, M.K., Karsten, S.L., Gray, M., Geschwind, D.H., and Yang, X.W. (2006). FACS-array profiling of striatal 
projection neuron subtypes in juvenile and adult mouse brains. Nature neuroscience 9, 443-452. 
Lopresti, A.L., Maker, G.L., Hood, S.D., and Drummond, P.D. (2014). A review of peripheral biomarkers in 
major depression: the potential of inflammatory and oxidative stress biomarkers. Progress in neuro-
psychopharmacology & biological psychiatry 48, 102-111. 
Lora, A., and Fava, E. (1992). Provoking agents, vulnerability factors and depression in an Italian setting: a 
replication of Brown and Harris's model. Journal of affective disorders 24, 227-235. 
Lu, A., Steiner, M.A., Whittle, N., Vogl, A.M., Walser, S.M., Ableitner, M., Refojo, D., Ekker, M., 
Rubenstein, J.L., Stalla, G.K., et al. (2008). Conditional mouse mutants highlight mechanisms of 
corticotropin-releasing hormone effects on stress-coping behavior. Molecular psychiatry 13, 1028-
1042. 
Lucas, L.R., Celen, Z., Tamashiro, K.L., Blanchard, R.J., Blanchard, D.C., Markham, C., Sakai, R.R., and 
McEwen, B.S. (2004). Repeated exposure to social stress has long-term effects on indirect markers of 
dopaminergic activity in brain regions associated with motivated behavior. Neuroscience 124, 449-
457. 
Lucas, L.R., Wang, C.-J., McCall, T.J., and McEwen, B.S. (2007). Effects of immobilization stress on 
neurochemical markers in the motivational system of the male rat. Brain research 1155, 108-115. 
Lugo-Huitron, R., Blanco-Ayala, T., Ugalde-Muniz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, 
D., Maldonado, P.D., Torres, I., Pinzon, E., Ortiz-Islas, E., et al. (2011). On the antioxidant properties 
of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol 
Teratol 33, 538-547. 
Lukic, I., Mitic, M., Djordjevic, J., Tatalovic, N., Bozovic, N., Soldatovic, I., Mihaljevic, M., Pavlovic, Z., 
Radojcic, M.B., Maric, N.P., et al. (2014). Lymphocyte levels of redox-sensitive transcription factors 
and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. 
Neuropsychobiology 70, 1-9. 
Maes, J.H., Eling, P.A., Wezenberg, E., Vissers, C.T., and Kan, C.C. (2011). Attentional set shifting in autism 
spectrum disorder: differentiating between the role of perseveration, learned irrelevance, and 
novelty processing. Journal of clinical and experimental neuropsychology 33, 210-217. 
Maes, J.H., Vich, J., and Eling, P.A. (2006). Learned irrelevance and response perseveration in a total 
change dimensional shift task. Brain Cogn 62, 74-79. 
Maes, M. (2011). Depression is an inflammatory disease, but cell-mediated immune activation is the key 
component of depression. Progress in neuro-psychopharmacology & biological psychiatry 35, 664-
675. 
Maes, M., Bosnians, E., Suy, E., Vandervorst, C., De Jonckheere, C., and Raus, J. (1990). Immune 
Disturbances during Major Depression: Upregulated Expression of Interleukin-2 Receptors. 
Neuropsychobiology 24, 115-120. 
Maes, M., Lambrechts, J., Bosmans, E., Jacobs, J., Suy, E., Vandervorst, C., De Jonckheere, C., Minner, B., 
and Raus, J. (1992). Evidence for a systemic immune activation during depression: results of 
leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. 
Psychological medicine 22, 45. 
Maes, M., Ringel, K., Kubera, M., Berk, M., and Rybakowski, J. (2012). Increased autoimmune activity 
against 5-HT: A key component of depression that is associated with inflammation and activation of 
cell-mediated immunity, and with severity and staging of depression. Journal of affective disorders 
136, 386-392. 
Maier, S.F., and Seligman, M.E. (1976). Learned helplessness: Theory and evidence. Journal of 
Experimental Psychology: General 105, 3-46. 
Mairesse, J., Silletti, V., Laloux, C., Zuena, A.R., Giovine, A., Consolazione, M., van Camp, G., Malagodi, M., 
Gaetini, S., Cianci, S., et al. (2013). Chronic agomelatine treatment corrects the abnormalities in the 
124 
 
circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restrain stress in adult 
rats. International Journal of Neuropsychopharmacology 16, 323-338. 
Mangiavacchi, S., Masi, F., Scheggi, S., Leggio, B., De Montis, M.G., and Gambarana, C. (2001). Long-term 
behavioral and neurochemical effects of chronic stress exposure in rats. Journal of neurochemistry 
79, 1113-1121. 
Marrocco, J., Reynaert, M.L., Gatta, E., Gabriel, C., Mocaer, E., Di Prisco, S., Merega, E., Pittaluga, A., 
Nicoletti, F., Maccari, S., et al. (2014). The Effects of Antidepressant Treatment in Prenatally Stressed 
Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders. Journal of Neuroscience 34, 
2015-2024. 
Martinez-Hernandez, J., Lanuza, E., and Martinez-Garcia, F. (2012). Lesions of the dopaminergic 
innervation of the nucleus accumbens medial shell delay the generation of preference for sucrose, 
but not of sexual pheromones. Behavioural brain research 226, 538-547. 
Martinot, M.-L.P., Bragulat, V., Artiges, E., Dollé, F., Hinnen, F., Jouvent, R., and Martinot, J.-L. (2001). 
Decreased Presynaptic Dopamine Function in the Left Caudate of Depressed Patients With Affective 
Flattening and Psychomotor Retardation. Am J Psychiat 158, 314-316. 
Massett, M.P. (2005). Strain-dependent differences in responses to exercise training in inbred and hybrid 
mice. AJP: Regulatory, Integrative and Comparative Physiology 288, R1006-R1013. 
McClure, S.M., Daw, N.D., and Montague, P.R. (2003). A computational substrate for incentive salience. 
Trends in neurosciences 26, 423-428. 
McCullough, L.D., Sokolowski, J.D., and Salamone, J.D. (1993). A neurochemical and behavioral 
investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. 
Neuroscience 52, 919-925. 
Meyers, C.A., Albitar, M., and Estey, E. (2005). Cognitive impairment, fatigue, and cytokine levels in 
patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104, 788-793. 
Michel, T.M., Camara, S., Tatschner, T., Frangou, S., Sheldrick, A.J., Riederer, P., and Grunblatt, E. (2010). 
Increased xanthine oxidase in the thalamus and putamen in depression. The world journal of 
biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 
11, 314-320. 
Michopoulos, I., Zervas, I.M., Papakosta, V.M., Tsaltas, E., Papageorgiou, C., Manessi, T., Papakostas, Y.G., 
Lykouras, L., and Soldatos, C.R. (2006). Set shifting deficits in melancholic vs. non-melancholic 
depression: preliminary findings. European psychiatry : the journal of the Association of European 
Psychiatrists 21, 361-363. 
Millan, M.J. (2003). The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-
Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical 
Dopaminergic and Adrenergic Pathways. Journal of Pharmacology and Experimental Therapeutics 
306, 954-964. 
Miller, A.H. (2010). Depression and immunity: A role for T cells? Brain, behavior, and immunity 24, 1-8. 
Miller, A.H., Haroon, E., Raison, C.L., and Felger, J.C. (2013). Cytokine targets in the brain: impact on 
neurotransmitters and neurocircuits. Depression and anxiety 30, 297-306. 
Miller, A.H., Maletic, V., and Raison, C.L. (2009a). Inflammation and Its Discontents: The Role of Cytokines 
in the Pathophysiology of Major Depression. Biological psychiatry 65, 732-741. 
Miller, G.E., Chen, E., Sze, J., Marin, T., Arevalo, J.M., Doll, R., Ma, R., and Cole, S.W. (2008a). A functional 
genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB 
signaling. Biological psychiatry 64, 266-272. 
Miller, G.E., Chen, E., Sze, J., Marin, T., Arevalo, J.M.G., Doll, R., Ma, R., and Cole, S.W. (2008b). A 
Functional Genomic Fingerprint of Chronic Stress in Humans: Blunted Glucocorticoid and Increased 
NF-κB Signaling. Biological psychiatry 64, 266-272. 
Miller, H.L. (1996). Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-
Induced Remission of Depression. Archives of general psychiatry 53, 117. 
Miller, R.L., James-Kracke, M., Sun, G.Y., and Sun, A.Y. (2009b). Oxidative and inflammatory pathways in 
Parkinson's disease. Neurochemical research 34, 55-65. 
125 
 
Mitani, H., Shirayama, Y., Yamada, T., and Kawahara, R. (2006). Plasma levels of homovanillic acid, 5-
hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Progress in 
neuro-psychopharmacology & biological psychiatry 30, 531-534. 
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., 
Araki, T., et al. (2012). Minocycline as adjunctive therapy for patients with unipolar psychotic 
depression: an open-label study. Progress in neuro-psychopharmacology & biological psychiatry 37, 
222-226. 
Moore, H. (2001). Chronic Cold Stress Reduces the Spontaneous Activity of Ventral Tegmental Dopamine 
Neurons. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 24, 410-419. 
Moransard, M., Sawitzky, M., Fontana, A., and Suter, T. (2010). Expression of the HGF receptor c-met by 
macrophages in experimental autoimmune encephalomyelitis. Glia, NA-NA. 
Moreau, J.L., Jenck, F., Martin, J.R., Mortas, P., and Haefely, W.E. (1992). Antidepressant treatment 
prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum 
self-stimulation behavior in rats. European Neuropsychopharmacology 2, 43-49. 
Moreau, M., Andre, C., O'Connor, J.C., Dumich, S.A., Woods, J.A., Kelley, K.W., Dantzer, R., Lestage, J., and 
Castanon, N. (2008). Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of 
sickness behavior followed by chronic depressive-like behavior. Brain, behavior, and immunity 22, 
1087-1095. 
Moresco, R.M., Lavazza, T., Belloli, S., Lecchi, M., Pezzola, A., Todde, S., Matarrese, M., Carpinelli, A., 
Turolla, E., Zimarino, V., et al. (2008). Quinolinic acid induced neurodegeneration in the striatum: a 
combined in vivo and in vitro analysis of receptor changes and microglia activation. European journal 
of nuclear medicine and molecular imaging 35, 704-715. 
Morley-Fletcher, S., Mairesse, J., Soumier, A., Banasr, M., Fagioli, F., Gabriel, C., Mocaer, E., Daszuta, A., 
McEwen, B., Nicoletti, F., et al. (2011). Chronic agomelatine treatment corrects behavioral, cellular, 
and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 217, 301-313. 
Motivala, S.J., Sarfatti, A., Olmos, L., and Irwin, M.R. (2005). Inflammatory Markers and Sleep Disturbance 
in Major Depression. Psychosomatic medicine 67, 187-194. 
Muller, N. (2014). Immunology of major depression. Neuroimmunomodulation 21, 123-130. 
Muller, N., and Schwarz, M.J. (2007). The immune-mediated alteration of serotonin and glutamate: 
towards an integrated view of depression. Molecular psychiatry 12, 988-1000. 
Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., 
Nemeroff, C.B., and Miller, A.H. (2001). Paroxetine for the Prevention of Depression Induced by High-
Dose Interferon Alfa. New England Journal of Medicine 344, 961-966. 
Myint, A.M., and Kim, Y.K. (2014). Network beyond IDO in psychiatric disorders: revisiting 
neurodegeneration hypothesis. Progress in neuro-psychopharmacology & biological psychiatry 48, 
304-313. 
Nabeshima, T., and Kim, H.C. (2013). Involvement of genetic and environmental factors in the onset of 
depression. Experimental neurobiology 22, 235-243. 
Nair, A., and Bonneau, R.H. (2006). Stress-induced elevation of glucocorticoids increases microglia 
proliferation through NMDA receptor activation. Journal of neuroimmunology 171, 72-85. 
Nakagami, Y., Saito, H., and Katsuki, H. (1996). 3-Hydroxykynurenine toxicity on the rat striatum in vivo. 
Jpn J Pharmacol 71, 183-186. 
Narendran, R., Jedema, H.P., Lopresti, B.J., Mason, N.S., Himes, M.L., and Bradberry, C.W. (2015). 
Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic 
cocaine self-administration in nonhuman primates. Biological psychiatry 77, 488-492. 
Nestler, E.J. (2015). FosB: a transcriptional regulator of stress and antidepressant responses. Eur J 
Pharmacol 753, 66-72. 
Nilsson, S.R., Ripley, T.L., Somerville, E.M., and Clifton, P.G. (2012). Reduced activity at the 5-HT(2C) 
receptor enhances reversal learning by decreasing the influence of previously non-rewarded 
associations. Psychopharmacology 224, 241-254. 
126 
 
Nissen, C., Holz, J., Blechert, J., Feige, B., Riemann, D., Voderholzer, U., and Normann, C. (2010). Learning 
as a model for neural plasticity in major depression. Biological psychiatry 68, 544-552. 
Novick, A.M., Forster, G.L., Hassell, J.E., Davies, D.R., Scholl, J.L., Renner, K.J., and Watt, M.J. (2015). 
Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult 
infralimbic medial prefrontal cortex following adolescent social stress. Neuropharmacology 97, 194-
200. 
Novick, A.M., Forster, G.L., Tejani-Butt, S.M., and Watt, M.J. (2011). Adolescent social defeat alters 
markers of adult dopaminergic function. Brain research bulletin 86, 123-128. 
Nunes, E.J., Randall, P.A., Estrada, A., Epling, B., Hart, E.E., Lee, C.A., Baqi, Y., Muller, C.E., Correa, M., and 
Salamone, J.D. (2014). Effort-related motivational effects of the pro-inflammatory cytokine 
interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. 
Psychopharmacology 231, 727-736. 
Nunes, E.J., Randall, P.A., Hart, E.E., Freeland, C., Yohn, S.E., Baqi, Y., Muller, C.E., Lopez-Cruz, L., Correa, 
M., and Salamone, J.D. (2013a). Effort-related motivational effects of the VMAT-2 inhibitor 
tetrabenazine: implications for animal models of the motivational symptoms of depression. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 33, 19120-19130. 
Nunes, E.J., Randall, P.A., Podurgiel, S., Correa, M., and Salamone, J.D. (2013b). Nucleus accumbens 
neurotransmission and effort-related choice behavior in food motivation: effects of drugs acting on 
dopamine, adenosine, and muscarinic acetylcholine receptors. Neuroscience and biobehavioral 
reviews 37, 2015-2025. 
O'Brien, S.M., Scully, P., Fitzgerald, P., Scott, L.V., and Dinan, T.G. (2007). Plasma cytokine profiles in 
depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of 
psychiatric research 41, 326-331. 
O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., and Dantzer, 
R. (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-
dioxygenase activation in mice. Molecular psychiatry 14, 511-522. 
O'Doherty, J.P. (2004). Reward representations and reward-related learning in the human brain: insights 
from neuroimaging. Current opinion in neurobiology 14, 769-776. 
Oeckl, P., Lattke, M., Wirth, T., Baumann, B., and Ferger, B. (2012). Astrocyte-specific IKK2 activation in 
mice is sufficient to induce neuroinflammation but does not increase susceptibility to MPTP. 
Neurobiology of disease 48, 481-487. 
Ons, S., Rotllant, D., Marin-Blasco, I.J., and Armario, A. (2010). Immediate-early gene response to 
repeated immobilization: Fos protein and arc mRNA levels appear to be less sensitive than c-fos 
mRNA to adaptation. The European journal of neuroscience 31, 2043-2052. 
Ostrander, M.M., Ulrich-Lai, Y.M., Choi, D.C., Flak, J.N., Richtand, N.M., and Herman, J.P. (2009). Chronic 
stress produces enduring decreases in novel stress-evoked c-fos mRNA expression in discrete brain 
regions of the rat. Stress 12, 469-477. 
Pace, T.W.W., Mletzko, T.C., Alagbe, O., Musselman, D.L., Nemeroff, C.B., Miller, A.H., and Heim, C.M. 
(2006). Increased Stress-Induced Inflammatory Responses in Male Patients With Major Depression 
and Increased Early Life Stress. Am J Psychiat 163, 1630-1633. 
Pan, Y., Chen, X.Y., Zhang, Q.Y., and Kong, L.D. (2014). Microglial NLRP3 inflammasome activation 
mediates IL-1beta-related inflammation in prefrontal cortex of depressive rats. Brain, behavior, and 
immunity 41, 90-100. 
Papciak, J., Popik, P., Fuchs, E., and Rygula, R. (2013). Chronic psychosocial stress makes rats more 
'pessimistic' in the ambiguous-cue interpretation paradigm. Behavioural brain research 256, 305-310. 
Papp, M., Gruca, P., Boyer, P.-A., and Mocaer, E. (2003). Effect of agomelatine in the chronic mild stress 
model of depression in the rat. Neuropsychopharmacol 28, 694-703. 
Papp, M., Willner, P., and Muscat, R. (1991). An animal model of anhedonia: attenuation of sucrose 
consumption and place preference conditioning by chronic unpredictable mild stress. 
Psychopharmacology 104, 255-259. 
127 
 
Patterson, Z.R., Khazall, R., MacKay, H., Anisman, H., and Abizaid, A. (2013). Central ghrelin signaling 
mediates the metabolic response of C57BL/6 male mice to chronic social defeat stress. Endocrinology 
154, 1080-1091. 
Pena, C.J., Neugut, Y.D., Calarco, C.A., and Champagne, F.A. (2014). Effects of maternal care on the 
development of midbrain dopamine pathways and reward-directed behavior in female offspring. The 
European journal of neuroscience 39, 946-956. 
Perez-De La Cruz, V., Carrillo-Mora, P., and Santamaria, A. (2012). Quinolinic Acid, an endogenous 
molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. International journal 
of tryptophan research : IJTR 5, 1-8. 
Pezze, M.A., and Feldon, J. (2004). Mesolimbic dopaminergic pathways in fear conditioning. Progress in 
neurobiology 74, 301-320. 
Pfaffl, M.W., Horgan, G.W., and Dempfle, L. (2002). Relative expression software tool (REST) for group-
wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic acids 
research 30, e36. 
Pierozan, P., Goncalves Fernandes, C., Ferreira, F., and Pessoa-Pureur, R. (2014). Acute intrastriatal 
injection of quinolinic acid provokes long-lasting misregulation of the cytoskeleton in the striatum, 
cerebral cortex and hippocampus of young rats. Brain research 1577, 1-10. 
Pierozan, P., Zamoner, A., Soska, A.K., de Lima, B.O., Reis, K.P., Zamboni, F., Wajner, M., and Pessoa-
Pureur, R. (2012). Signaling mechanisms downstream of quinolinic acid targeting the cytoskeleton of 
rat striatal neurons and astrocytes. Experimental neurology 233, 391-399. 
Pizzagalli, D.A. (2014). Depression, stress, and anhedonia: toward a synthesis and integrated model. 
Annual review of clinical psychology 10, 393-423. 
Pizzagalli, D.A., Holmes, A.J., Dillon, D.G., Goetz, E.L., Birk, J.L., Bogdan, R., Dougherty, D.D., Iosifescu, 
D.V., Rauch, S.L., and Fava, M. (2009). Reduced caudate and nucleus accumbens response to rewards 
in unmedicated individuals with major depressive disorder. The American journal of psychiatry 166, 
702-710. 
Pizzagalli, D.A., Iosifescu, D., Hallett, L.A., Ratner, K.G., and Fava, M. (2008). Reduced hedonic capacity in 
major depressive disorder: evidence from a probabilistic reward task. Journal of psychiatric research 
43, 76-87. 
Pizzagalli, D.A., Jahn, A.L., and O’Shea, J.P. (2005). Toward an objective characterization of an anhedonic 
phenotype: A signal-detection approach. Biological psychiatry 57, 319-327. 
Pompeiano, M., Palacios, J.M., and Mengod, G. (1994). Distribution of the serotonin 5-HT2 reecptor 
family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Research Molecular Brain 
Research 23, 163-178. 
Post, R.M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective 
disorder. The American journal of psychiatry 149, 999-1010. 
Poulin, J.F., Laforest, S., and Drolet, G. (2014). Enkephalin downregulation in the nucleus accumbens 
underlies chronic stress-induced anhedonia. Stress 17, 88-96. 
Powell, N.D., Sloan, E.K., Bailey, M.T., Arevalo, J.M., Miller, G.E., Chen, E., Kobor, M.S., Reader, B.F., 
Sheridan, J.F., and Cole, S.W. (2013). Social stress up-regulates inflammatory gene expression in the 
leukocyte transcriptome via beta-adrenergic induction of myelopoiesis. Proceedings of the National 
Academy of Sciences of the United States of America 110, 16574-16579. 
Prinz, M., and Priller, J. (2014). Microglia and brain macrophages in the molecular age: from origin to 
neuropsychiatric disease. Nature reviews Neuroscience 15, 300-312. 
Pryce, C.R., Azzinnari, D., Sigrist, H., Gschwind, T., Lesch, K.P., and Seifritz, E. (2012). Establishing a 
learned-helplessness effect paradigm in C57BL/6 mice: behavioural evidence for emotional, 
motivational and cognitive effects of aversive uncontrollability per se. Neuropharmacology 62, 358-
372. 
Pryce, C.R., Azzinnari, D., Spinelli, S., Seifritz, E., Tegethoff, M., and Meinlschmidt, G. (2011a). 
Helplessness: A systematic translational review of theory and evidence for its relevance to 
understanding and treating depression. Pharmacology & therapeutics 132, 242-267. 
128 
 
Pryce, C.R., Azzinnari, D., Spinelli, S., Seifritz, E., Tegethoff, M., and Meinlschmidt, G. (2011b). 
Helplessness: a systematic translational review of theory and evidence for its relevance to 
understanding and treating depression. Pharmacology & therapeutics 132, 242-267. 
Pryce, C.R., and Seifritz, E. (2011). A translational research framework for enhanced validity of mouse 
models of psychopathological states in depression. Psychoneuroendocrinology 36, 308-329. 
Pugh, C.R., Kumagawa, K., Fleshner, M., Watkins, L.R., Maier, S.F., and Rudy, J.W. (1998). Selective effects 
of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. 
Brain, behavior, and immunity 12, 212-229. 
Qin, L., Liu, Y., Hong, J.S., and Crews, F.T. (2013). NADPH oxidase and aging drive microglial activation, 
oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 
61, 855-868. 
Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.-S., Knapp, D.J., and Crews, F.T. (2007). Systemic 
LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453-462. 
Racagni, G., Riva, M.A., Molenti, R., Musazzi, L., Calabrese, F., Popoli, M., and Tardito, D. (2011). Mode of 
action of agomelatine: Synergy between melatonergic and 5-HT2C receptors. The World Journal of 
Biological Psychiatry 12, 574-587. 
Raineki, C., Hellemans, K.G., Bodnar, T., Lavigne, K.M., Ellis, L., Woodward, T.S., and Weinberg, J. (2014). 
Neurocircuitry underlying stress and emotional regulation in animals prenatally exposed to alcohol 
and subjected to chronic mild stress in adulthood. Frontiers in endocrinology 5, 5. 
Rainer, Q., Xia, L., Guilloux, J.-P., Gabriel, C., Mocaer, E., Hen, R., Enhamre, E., Gardier, A.M., and David, 
D.J. (2012). Beneficial behavioural and neurogenic effects of agomelatine in a model of 
depression/anxiety. International Journal of Neuropsychopharmacology 15, 321-335. 
Raison, C.L., Borisov, A.S., Majer, M., Drake, D.F., Pagnoni, G., Woolwine, B.J., Vogt, G.J., Massung, B., and 
Miller, A.H. (2009). Activation of Central Nervous System Inflammatory Pathways by Interferon-
Alpha: Relationship to Monoamines and Depression. Biological psychiatry 65, 296-303. 
Ransohoff, R.M., and Perry, V.H. (2009). Microglial physiology: unique stimuli, specialized responses. 
Annual review of immunology 27, 119-145. 
Rasouli, J., Lekhraj, R., Ozbalik, M., Lalezari, P., and Casper, D. (2011). Brain-Spleen Inflammatory 
Coupling: A Literature Review. Einstein J Biol Med 27, 74-77. 
Reader, B.F., Jarrett, B.L., McKim, D.B., Wohleb, E.S., Godbout, J.P., and Sheridan, J.F. (2015). Peripheral 
and central effects of repeated social defeat stress: monocyte trafficking, microglial activation, and 
anxiety. Neuroscience 289, 429-442. 
Reading, P.J., and Dunnett, S.B. (1991). The effects of excitotoxic lesions of the nucleus accumbens on a 
matching to position task. Behavioural brain research 46, 17-29. 
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., and Pollmächer, T. (2001). 
Cytokine-Associated Emotional and Cognitive Disturbances in Humans. Archives of general psychiatry 
58, 445. 
Rice, M.W., Roberts, R.C., Melendez-Ferro, M., and Perez-Costas, E. (2014). Mapping dopaminergic 
deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Structure and 
Function. 
Rios, C., and Santamaria, A. (1991). Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. 
Neurochemical research 16, 1139-1143. 
Roane, H.S. (2008). On the applied use of progressive-ratio schedules of reinforcement. Journal of applied 
behavior analysis 41, 155-161. 
Roy, A., Pickar, D., Linnoila, M., Doran, A.R., Ninan, P., and Paul, S.M. (1985). Cerebrospinal fluid 
monoamine and monoamine metabolite concentrations in melancholia. Psychiatry research 15, 281-
292. 
Russo, S.J., and Nestler, E.J. (2013). The brain reward circuitry in mood disorders. Nature Reviews 
Neuroscience 14, 609-625. 
Sakurai, K., Zou, J.P., Tschetter, J.R., Ward, J.M., and Shearer, G.M. (2002). Effect of indoleamine 2,3-
dioxygenase on induction of experimental autoimmune encephalomyelitis. Journal of 
neuroimmunology 129, 186-196. 
129 
 
Salamone, J.D., and Correa, M. (2012). The mysterious motivational functions of mesolimbic dopamine. 
Neuron 76, 470-485. 
Salamone, J.D., Correa, M., Farrar, A., and Mingote, S.M. (2007). Effort-related functions of nucleus 
accumbens dopamine and associated forebrain circuits. Psychopharmacology 191, 461-482. 
Savitz, J., Dantzer, R., Meier, T.B., Wurfel, B.E., Victor, T.A., McIntosh, S.A., Ford, B.N., Morris, H.M., 
Bodurka, J., Teague, T.K., et al. (2015a). Activation of the kynurenine pathway is associated with 
striatal volume in major depressive disorder. Psychoneuroendocrinology 62, 54-58. 
Savitz, J., Drevets, W.C., Smith, C.M., Victor, T.A., Wurfel, B.E., Bellgowan, P.S., Bodurka, J., Teague, T.K., 
and Dantzer, R. (2015b). Putative neuroprotective and neurotoxic kynurenine pathway metabolites 
are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 40, 463-471. 
Savitz, J., Drevets, W.C., Wurfel, B.E., Ford, B.N., Bellgowan, P.S., Victor, T.A., Bodurka, J., Teague, T.K., 
and Dantzer, R. (2015c). Reduction of kynurenic acid to quinolinic acid ratio in both the depressed 
and remitted phases of major depressive disorder. Brain, behavior, and immunity 46, 55-59. 
Schaefer, M., Engelbrechta, M.A., Gut, O., Fiebich, B.L., Bauer, J., Schmidt, F., Grunze, H., and Lieb, K. 
(2002). Interferon alpha (IFNα) and psychiatric syndromes. Progress in Neuro-Psychopharmacology 
and Biological Psychiatry 26, 731-746. 
Schiavone, S., Jaquet, V., Sorce, S., Dubois-Dauphin, M., Hultqvist, M., Backdahl, L., Holmdahl, R., 
Colaianna, M., Cuomo, V., Trabace, L., et al. (2012). NADPH oxidase elevations in pyramidal neurons 
drive psychosocial stress-induced neuropathology. Translational psychiatry 2, e111. 
Schmidt, D., Reber, S.O., Botteron, C., Barth, T., Peterlik, D., Uschold, N., Mannel, D.N., and Lechner, A. 
(2010). Chronic psychosocial stress promotes systemic immune activation and the development of 
inflammatory Th cell responses. Brain, behavior, and immunity 24, 1097-1104. 
Schultz, W. (1998). The Phasic Reward Signal of Primate Dopamine Neurons. In Advances in 
pharmacology (Elsevier BV), pp. 686-690. 
Schwarcz, R., Bruno, J.P., Muchowski, P.J., and Wu, H.Q. (2012). Kynurenines in the mammalian brain: 
when physiology meets pathology. Nature reviews Neuroscience 13, 465-477. 
Schwarcz, R., and Pellicciari, R. (2002). Manipulation of brain kynurenines: glial targets, neuronal effects, 
and clinical opportunities. The Journal of pharmacology and experimental therapeutics 303, 1-10. 
Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., and Kirchner, H. (1996). Increased CD56+ natural 
killer cells and related cytokines in major depression. Clin Immunol Immunopathol 78, 83-85. 
Sesack, S.R., and Grace, A.A. (2010). Cortico-Basal Ganglia reward network: microcircuitry. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 35, 27-47. 
Setiawan, E., Wilson, A.A., Mizrahi, R., Rusjan, P.M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J.L., 
Rekkas, P.V., Houle, S., et al. (2015). Role of translocator protein density, a marker of 
neuroinflammation, in the brain during major depressive episodes. JAMA psychiatry 72, 268-275. 
Shelton, R.C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D.A., and Mirnics, K. 
(2011). Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major 
depression. Molecular psychiatry 16, 751-762. 
Sheng, W., Zong, Y., Mohammad, A., Ajit, D., Cui, J., Han, D., Hamilton, J.L., Simonyi, A., Sun, A.Y., Gu, Z., 
et al. (2011). Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, 
and upregulation of ERK1/2, iNOS and sPLA(2)-IIA expression in astrocytes and microglia. Journal of 
neuroinflammation 8, 121. 
Sherdell, L., Waugh, C.E., and Gotlib, I.H. (2012). Anticipatory pleasure predicts motivation for reward in 
major depression. Journal of Abnormal Psychology 121, 51-60. 
Shiratori, A.P., Iop Rda, R., Borges Junior, N.G., Domenech, S.C., and Gevaerd Mda, S. (2014). Evaluation 
protocols of hand grip strength in individuals with rheumatoid arthritis: a systematic review. Rev Bras 
Reumatol 54, 140-147. 
130 
 
Siffrin, V., Radbruch, H., Glumm, R., Niesner, R., Paterka, M., Herz, J., Leuenberger, T., Lehmann, S.M., 
Luenstedt, S., Rinnenthal, J.L., et al. (2010). In vivo imaging of partially reversible th17 cell-induced 
neuronal dysfunction in the course of encephalomyelitis. Immunity 33, 424-436. 
Singh, A.B., Bousman, C.A., Ng, C.H., Byron, K., and Berk, M. (2013). Psychomotor depressive symptoms 
may differentially respond to venlafaxine. International clinical psychopharmacology 28, 121-126. 
Slavich, G.M., and Irwin, M.R. (2014). From stress to inflammation and major depressive disorder: a social 
signal transduction theory of depression. Psychological bulletin 140, 774-815. 
Slavich, G.M., Thornton, T., Torres, L.D., Monroe, S.M., and Gotlib, I.H. (2009). Targeted Rejection Predicts 
Hastened Onset of Major Depression. J Soc Clin Psychol 28, 223-243. 
Smith, K.S., Berridge, K.C., and Aldridge, J.W. (2011). Disentangling pleasure from incentive salience and 
learning signals in brain reward circuitry. Proceedings of the National Academy of Sciences of the 
United States of America 108, E255-264. 
Soczynska, J.K., Mansur, R.B., Brietzke, E., Swardfager, W., Kennedy, S.H., Woldeyohannes, H.O., Powell, 
A.M., Manierka, M.S., and McIntyre, R.S. (2012). Novel therapeutic targets in depression: minocycline 
as a candidate treatment. Behavioural brain research 235, 302-317. 
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.G., and Bogerts, B. (2008). 
Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia 
and depression is associated with suicide. Journal of psychiatric research 42, 151-157. 
Steiner, J., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H.G., and Myint, A.M. (2012). Bridging 
the gap between the immune and glutamate hypotheses of schizophrenia and major depression: 
Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. The 
world journal of biological psychiatry : the official journal of the World Federation of Societies of 
Biological Psychiatry 13, 482-492. 
Steiner, J., Walter, M., Gos, T., Guillemin, G.J., Bernstein, H.G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, 
H., Meyer zu Schwabedissen, L., et al. (2011). Severe depression is associated with increased 
microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-
modulated glutamatergic neurotransmission? Journal of neuroinflammation 8, 94. 
Stone, E.A., Lehmann, M.L., Lin, Y., and Quartermain, D. (2007). Reduced evoked fos expression in 
activity-related brain regions in animal models of behavioral depression. Progress in neuro-
psychopharmacology & biological psychiatry 31, 1196-1207. 
Stott, S.R., and Barker, R.A. (2014). Time course of dopamine neuron loss and glial response in the 6-
OHDA striatal mouse model of Parkinson's disease. The European journal of neuroscience 39, 1042-
1056. 
Strigo, I.A., Simmons, A.N., Matthews, S.C., Craig, A.D., and Paulus, M.P. (2008). Association of major 
depressive disorder with altered functional brain response during anticipation and processing of heat 
pain. Archives of general psychiatry 65, 1275-1284. 
Stuber, G.D., and Mason, A.O. (2013). Integrating optogenetic and pharmacological approaches to study 
neural circuit function: current applications and future directions. Pharmacol Rev 65, 156-170. 
Sublette, M.E., Galfalvy, H.C., Fuchs, D., Lapidus, M., Grunebaum, M.F., Oquendo, M.A., Mann, J.J., and 
Postolache, T.T. (2011). Plasma kynurenine levels are elevated in suicide attempters with major 
depressive disorder. Brain, behavior, and immunity 25, 1272-1278. 
Sundaram, G., Brew, B.J., Jones, S.P., Adams, S., Lim, C.K., and Guillemin, G.J. (2014). Quinolinic acid 
toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. Journal 
of neuroinflammation 11, 204. 
Suter, T., Biollaz, G., Gatto, D., Bernasconi, L., Herren, T., Reith, W., and Fontana, A. (2003). The brain as 
an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. 
European journal of immunology 33, 2998-3006. 
Svenningsson, P., Nishi, A., Fisone, G., Girault, J.A., Nairn, A.C., and Greengard, P. (2004). DARPP-32: an 
integrator of neurotransmission. Annual review of pharmacology and toxicology 44, 269-296. 
Tait, D.S., and Brown, V.J. (2007). Difficulty overcoming learned non-reward during reversal learning in 
rats with ibotenic acid lesions of orbital prefrontal cortex. Annals of the New York Academy of 
Sciences 1121, 407-420. 
131 
 
Tanaka, K., Furuyashiki, T., Kitaoka, S., Senzai, Y., Imoto, Y., Segi-Nishida, E., Deguchi, Y., Breyer, R.M., 
Breyer, M.D., and Narumiya, S. (2012). Prostaglandin E2-mediated attenuation of mesocortical 
dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 32, 4319-4329. 
Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., and Souza, D.O. (2002). 
Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into 
astrocytes. Neurochemistry international 40, 621-627. 
Taylor Tavares, J.V., Clark, L., Furey, M.L., Williams, G.B., Sahakian, B., and Drevets, W.C. (2008). Neural 
basis of abnormal response to negative feedback in unmedicated mood disorders. NeuroImage 42, 
1118-1126. 
Torres-Platas, S.G., Cruceanu, C., Chen, G.G., Turecki, G., and Mechawar, N. (2014). Evidence for 
increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white 
matter of depressed suicides. Brain, behavior, and immunity 42, 50-59. 
Treadway, M.T. (2015). The Neurobiology of Motivational Deficits in Depression-An Update on Candidate 
Pathomechanisms. Current topics in behavioral neurosciences. 
Treadway, M.T., Bossaller, N.A., Shelton, R.C., and Zald, D.H. (2012). Effort-based decision-making in 
major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 121, 
553-558. 
Treadway, M.T., and Zald, D.H. (2011). Reconsidering anhedonia in depression: lessons from translational 
neuroscience. Neuroscience and biobehavioral reviews 35, 537-555. 
Tremblay, L.K., Naranjo, C.A., Graham, S.J., Herrmann, N., Mayberg, H.S., Hevenor, S., and Busto, U.E. 
(2005). Functional Neuroanatomical Substrates of Altered Reward Processing in Major Depressive 
Disorder Revealed by a Dopaminergic Probe. Archives of general psychiatry 62, 1228. 
Tretter, F., and Gebicke-Haerter, P.J. (2012). Systems biology in psychiatric research: from complex data 
sets over wiring diagrams to computer simulations. Methods in molecular biology 829, 567-592. 
Ungless, M.A., Singh, V., Crowder, T.L., Yaka, R., Ron, D., and Bonci, A. (2003). Corticotropin-releasing 
factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine 
neurons. Neuron 39, 401-407. 
Urata, Y., Koga, K., Hirota, Y., Akiyama, I., Izumi, G., Takamura, M., Nagai, M., Harada, M., Hirata, T., 
Yoshino, O., et al. (2014). IL-1β Increases Expression of Tryptophan 2,3-dioxygenase and Stimulates 
Tryptophan Catabolism in Endometrioma Stromal Cells. American journal of reproductive 
immunology 72, 496-503. 
van der Plasse, G., and Feenstra, M.G.P. (2008). Serial reversal learning and acute tryptophan depletion. 
Behavioural brain research 186, 23-31. 
van Heesch, F., Prins, J., Konsman, J.P., Korte-Bouws, G.A., Westphal, K.G., Rybka, J., Olivier, B., Kraneveld, 
A.D., and Korte, S.M. (2014). Lipopolysaccharide increases degradation of central monoamines: an in 
vivo microdialysis study in the nucleus accumbens and medial prefrontal cortex of mice. Eur J 
Pharmacol 725, 55-63. 
van Heesch, F., Prins, J., Korte-Bouws, G.A., Westphal, K.G., Lemstra, S., Olivier, B., Kraneveld, A.D., and 
Korte, S.M. (2013). Systemic tumor necrosis factor-alpha decreases brain stimulation reward and 
increases metabolites of serotonin and dopamine in the nucleus accumbens of mice. Behavioural 
brain research 253, 191-195. 
van Schouwenburg, M., Aarts, E., and Cools, R. (2010). Dopaminergic Modulation of Cognitive Control: 
Distinct Roles for the Prefrontal Cortex and the Basal Ganglia. CPD 16, 2026-2032. 
Vandresen-Filho, S., Martins, W.C., Bertoldo, D.B., Mancini, G., De Bem, A.F., and Tasca, C.I. (2015). 
Cerebral cortex, hippocampus, striatum and cerebellum show differential susceptibility to quinolinic 
acid-induced oxidative stress. Neurological sciences : official journal of the Italian Neurological 
Society and of the Italian Society of Clinical Neurophysiology 36, 1449-1456. 
Ventura, R., Coccurello, R., Andolina, D., Latagliata, E.C., Zanettini, C., Lampis, V., Battaglia, M., D'Amato, 
F.R., and Moles, A. (2013). Postnatal aversive experience impairs sensitivity to natural rewards and 
increases susceptibility to negative events in adult life. Cerebral cortex 23, 1606-1617. 
132 
 
Vialou, V., Robison, A.J., Laplant, Q.C., Covington, H.E., 3rd, Dietz, D.M., Ohnishi, Y.N., Mouzon, E., Rush, 
A.J., 3rd, Watts, E.L., Wallace, D.L., et al. (2010). DeltaFosB in brain reward circuits mediates 
resilience to stress and antidepressant responses. Nature neuroscience 13, 745-752. 
Vichaya, E.G., Hunt, S.C., and Dantzer, R. (2014). Lipopolysaccharide reduces incentive motivation while 
boosting preference for high reward in mice. Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 39, 2884-2890. 
Walker, A.K., Budac, D.P., Bisulco, S., Lee, A.W., Smith, R.A., Beenders, B., Kelley, K.W., and Dantzer, R. 
(2013). NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like 
behavior in C57BL/6J mice. Neuropsychopharmacology : official publication of the American College 
of Neuropsychopharmacology 38, 1609-1616. 
Walker, F.R., Beynon, S.B., Jones, K.A., Zhao, Z., Kongsui, R., Cairns, M., and Nilsson, M. (2014). Dynamic 
structural remodelling of microglia in health and disease: A review of the models, the signals and the 
mechanisms. Brain, behavior, and immunity 37, 1-14. 
Wallace, D.L., Han, M.H., Graham, D.L., Green, T.A., Vialou, V., Iniguez, S.D., Cao, J.L., Kirk, A., Chakravarty, 
S., Kumar, A., et al. (2009). CREB regulation of nucleus accumbens excitability mediates social 
isolation-induced behavioral deficits. Nature neuroscience 12, 200-209. 
Wang, D., An, S.C., and Zhang, X. (2008). Prevention of chronic stress-induced depression-like behavior by 
inducible nitric oxide inhibitor. Neuroscience letters 433, 59-64. 
Wang, J., Huang, J., Yang, X.-h., Lui, S.S.Y., Cheung, E.F.C., and Chan, R.C.K. (2015). Anhedonia in 
schizophrenia: Deficits in both motivation and hedonic capacity. Schizophrenia research 168, 465-
474. 
Watkins, P.C., Mathews, A., Williamson, D.A., and Fuller, R.D. (1992). Mood-congruent memory in 
depression: emotional priming or elaboration? J Abnorm Psychol 101, 581-586. 
Webb, C.A., Dillon, D.G., Pechtel, P., Goer, F., Murray, L., Huys, Q.J., Fava, M., McGrath, P.J., Weissman, 
M., Parsey, R., et al. (2015). Neural Correlates of Three Promising Endophenotypes of Depression: 
Evidence from the EMBARC Study. Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology. 
Wenzel, J.M., Rauscher, N.A., Cheer, J.F., and Oleson, E.B. (2015). A role for phasic dopamine release 
within the nucleus accumbens in encoding aversion: a review of the neurochemical literature. ACS 
chemical neuroscience 6, 16-26. 
Whitton, A.E., Treadway, M.T., and Pizzagalli, D.A. (2015). Reward processing dysfunction in major 
depression, bipolar disorder and schizophrenia. Current opinion in psychiatry 28, 7-12. 
Wichmann, T., and DeLong, M.R. (2003). Pathophysiology of Parkinson's disease: the MPTP primate 
model of the human disorder. Annals of the New York Academy of Sciences 991, 199-213. 
Wilkinson, L.S., Humby, T., Killcross, A.S., Torres, E.M., Everitt, B.J., and Robbins, T.W. (1998). 
Dissociations in dopamine release in medial prefrontal cortex and ventral striatum during the 
acquisition and extinction of classical aversive conditioning in the rat. European Journal of 
Neuroscience 10, 1019-1026. 
Wilkinson, M.B., Dias, C., Magida, J., Mazei-Robison, M., Lobo, M., Kennedy, P., Dietz, D., Covington, H., 
3rd, Russo, S., Neve, R., et al. (2011). A novel role of the WNT-dishevelled-GSK3beta signaling 
cascade in the mouse nucleus accumbens in a social defeat model of depression. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 31, 9084-9092. 
Winter, C., von Rumohr, A., Mundt, A., Petrus, D., Klein, J., Lee, T., Morgenstern, R., Kupsch, A., and 
Juckel, G. (2007). Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the 
ventral tegmental area enhance depressive-like behavior in rats. Behavioural brain research 184, 
133-141. 
Wise, R.A. (2004). Dopamine, learning and motivation. Nature reviews Neuroscience 5, 483-494. 
Wittmann, B.C., and D’Esposito, M. (2015). Levodopa administration modulates striatal processing of 
punishment-associated items in healthy participants. Psychopharmacology 232, 135-144. 
Wohleb, E.S., Fenn, A.M., Pacenta, A.M., Powell, N.D., Sheridan, J.F., and Godbout, J.P. (2012). Peripheral 
innate immune challenge exaggerated microglia activation, increased the number of inflammatory 
133 
 
CNS macrophages, and prolonged social withdrawal in socially defeated mice. 
Psychoneuroendocrinology 37, 1491-1505. 
Wohleb, E.S., Hanke, M.L., Corona, A.W., Powell, N.D., Stiner, L.M., Bailey, M.T., Nelson, R.J., Godbout, 
J.P., and Sheridan, J.F. (2011). beta-Adrenergic receptor antagonism prevents anxiety-like behavior 
and microglial reactivity induced by repeated social defeat. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 31, 6277-6288. 
Wohleb, E.S., McKim, D.B., Shea, D.T., Powell, N.D., Tarr, A.J., Sheridan, J.F., and Godbout, J.P. (2014a). 
Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the 
spleen to the brain. Biological psychiatry 75, 970-981. 
Wohleb, E.S., Patterson, J.M., Sharma, V., Quan, N., Godbout, J.P., and Sheridan, J.F. (2014b). Knockdown 
of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation 
and prevented anxiety-like behavior. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 34, 2583-2591. 
Wohleb, E.S., Powell, N.D., Godbout, J.P., and Sheridan, J.F. (2013). Stress-induced recruitment of bone 
marrow-derived monocytes to the brain promotes anxiety-like behavior. The Journal of neuroscience 
: the official journal of the Society for Neuroscience 33, 13820-13833. 
Wong, E.H., Yocca, F., Smith, M.A., and Lee, C.M. (2010). Challenges and opportunities for drug discovery 
in psychiatric disorders: the drug hunters' perspective. The international journal of 
neuropsychopharmacology / official scientific journal of the Collegium Internationale 
Neuropsychopharmacologicum 13, 1269-1284. 
Woody, M.L., and Gibb, B.E. (2015). Integrating NIMH Research Domain Criteria (RDoC) into Depression 
Research. Current opinion in psychology 4, 6-12. 
Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Yao, W., Ma, M., Dong, C., and Hashimoto, K. (2015). R-
ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. 
Translational psychiatry 5, e632. 
Young, A.M.J., Joseph, M.H., and Gray, J.A. (1993). Latent inhibition of conditioned dopamine release in 
rat nucleus accumbens. Neuroscience 54, 5-9. 
Yu, T., Guo, M., Garza, J., Rendon, S., Sun, X.L., Zhang, W., and Lu, X.Y. (2011). Cognitive and neural 
correlates of depression-like behaviour in socially defeated mice: an animal model of depression with 
cognitive dysfunction. The international journal of neuropsychopharmacology / official scientific 
journal of the Collegium Internationale Neuropsychopharmacologicum 14, 303-317. 
Zachariou, V., Sgambato-Faure, V., Sasaki, T., Svenningsson, P., Berton, O., Fienberg, A.A., Nairn, A.C., 
Greengard, P., and Nestler, E.J. (2006). Phosphorylation of DARPP-32 at Threonine-34 is required for 
cocaine action. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 31, 555-562. 
Zarate, C.A., Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., and 
Manji, H.K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant 
major depression. Archives of general psychiatry 63, 856-864. 
Zucker, M., Aviv, A., Shelef, A., Weizman, A., and Rehavi, M. (2002). Elevated platelet vesicular 
monoamine transporter density in untreated patients diagnosed with major depression. Psychiatry 
research 112, 251-256. 
Zucker, M., Weizman, A., and Rehavi, M. (2001). Characterization of high-affinity [3H]TBZOH binding to 
the human platelet vesicular monoamine transporter. Life Sci 69, 2311-2317. 
Zunszain, P.A., Anacker, C., Cattaneo, A., Carvalho, L.A., and Pariante, C.M. (2011). Glucocorticoids, 
cytokines and brain abnormalities in depression. Progress in neuro-psychopharmacology & biological 
psychiatry 35, 722-729. 
Zweifel, L.S., Fadok, J.P., Argilli, E., Garelick, M.G., Jones, G.L., Dickerson, T.M., Allen, J.M., Mizumori, S.J., 
Bonci, A., and Palmiter, R.D. (2011). Activation of dopamine neurons is critical for aversive 
conditioning and prevention of generalized anxiety. Nature neuroscience 14, 620-626. 
 
  
